

CITATION REPORT

List of articles citing

The 2016 World Health Organization Classification of Tumors of the Central Nervous System: a summary

DOI: 10.1007/s00401-016-1545-1

Acta Neuropathologica, 2016, 131, 803-20.

Source: <https://exaly.com/paper-pdf/64155989/citation-report.pdf>

Version: 2024-04-20

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
2234	Gene expression profiling in glioblastoma and immunohistochemical evaluation of IGFBP-2 and CDC20. 2008 , 453, 599-609		53
2233	Polysomy for chromosomes 1 and 19 predicts earlier recurrence in anaplastic oligodendrogliomas with concurrent 1p/19q loss. 2009 , 15, 6430-7		72
2232	Age-incidence patterns of primary CNS tumors in children, adolescents, and adults in England. 2009 , 11, 403-13		111
2231	Expression of mutant p53 proteins implicates a lineage relationship between neural stem cells and malignant astrocytic glioma in a murine model. 2009 , 15, 514-26		199
2230	Cytogenetic findings in a rare pediatric mixed glioneuronal tumor and review of the literature. 2009 , 25, 1485-90		1
2229	Cerebral astroblastoma: analysis of six cases and critical review of treatment options. 2009 , 93, 369-78		51
2228	Brain angiogenesis in developmental and pathological processes: mechanism and therapeutic intervention in brain tumors. 2009 , 276, 4653-64		47
2227	Discrimination of human astrocytoma subtypes by lipid analysis using desorption electrospray ionization imaging mass spectrometry. 2010 , 49, 5953-6		107
2226	Bevacizumab salvage therapy following progression in high-grade glioma patients treated with VEGF receptor tyrosine kinase inhibitors. 2010 , 12, 603-7		43
2225	Activating mutations in BRAF characterize a spectrum of pediatric low-grade gliomas. 2010 , 12, 621-30		228
2224	Quantitative detection of multiple gene promoter hypermethylation in tumor tissue, serum, and cerebrospinal fluid predicts prognosis of malignant gliomas. 2010 , 12, 540-8		48
2223	A compressive sensing approach for glioma margin delineation using mass spectrometry. 2011 , 2011, 5682-5		5
2222	Diffusion differences between pilocytic astrocytomas and grade II ependymomas. 2011 , 45, 97-101		8
2221	A new metric for detecting change in slowly evolving brain tumors: validation in meningioma patients. 2011 , 68, 225-33		11
2220	Gone FISHing: clinical lessons learned in brain tumor molecular diagnostics over the last decade. 2011 , 21, 57-73		76
2219	Common molecular cytogenetic pathway in papillary tumors of the pineal region (PTPR). 2011 , 21, 672-7		21
2218	Phase II study of sunitinib malate in patients with recurrent high-grade glioma. 2011 , 103, 491-501		99

2217	The effect of WHO reclassification of necrotic anaplastic oligoastrocytomas on incidence and survival in glioblastoma. 2011 , 104, 621-2	6
2216	Assessment of MGMT promoter methylation status in pleomorphic xanthoastrocytoma. 2011 , 105, 397-400	19
2215	[Update from the soft tissue tumour registry in Jena]. 2011 , 32, 40-6	5
2214	Measurements of diagnostic examination performance and correlation analysis using microvascular leakage, cerebral blood volume, and blood flow derived from 3T dynamic susceptibility-weighted contrast-enhanced perfusion MR imaging in glial tumor grading. 2011 , 53, 435-47	31
2213	Management of childhood brain tumors: consensus report by the Pediatric Hematology Oncology (PHO) Chapter of Indian Academy of Pediatrics (IAP). 2011 , 78, 1510-9	5
2212	Thalamic high-grade gliomas in children: a distinct clinical subset?. 2011 , 13, 680-9	48
2211	Glioblastoma recurrence after cediranib therapy in patients: lack of "rebound" revascularization as mode of escape. 2011 , 71, 19-28	163
2210	Recurrent meningeal hemangiopericytoma with multiple metastasis and hypoglycemia: a case report. 2012 , 2012, 628756	10
2209	Moving toward molecular classification of diffuse gliomas in adults. 2012 , 79, 1917-26	54
2208	Successful treatment with a low-dose cisplatin--etoposide regimen for patients with diencephalic syndrome. 2012 , 109, 375-83	7
2207	A case for reclassifying infiltrating gliomas in adults. 2012 , 109, 587-91	4
2206	miR-335 promotes cell proliferation by directly targeting Rb1 in meningiomas. 2012 , 110, 155-62	48
2205	Something old and something new about molecular diagnostics in gliomas. 2012 , 5, 919-939	11
2204	Expression of proto-oncogene KIT is up-regulated in subset of human meningiomas. 2012 , 12, 212	5
2203	Complement activation in astrocytomas: deposition of C4d and patient outcome. 2012 , 12, 565	8
2202	Tumor-derived hepatocyte growth factor is associated with poor prognosis of patients with glioma and influences the chemosensitivity of glioma cell line to cisplatin in vitro. 2012 , 10, 128	8
2201	Biomarkers classification and therapeutic decision-making for malignant gliomas. 2012 , 13, 417-36	22
2200	Patterns of care and survival for glioblastoma patients in the Veterans population. 2012 , 106, 627-35	20

2199	Primary brain tumour epidemiology in Georgia: first-year results of a population-based study. 2013 , 112, 241-6	17
2198	Expression pattern of id proteins in medulloblastoma. 2013 , 19, 437-46	5
2197	Re-evaluation of nondiagnostic biopsies of suspected low-grade glioma using isocitrate dehydrogenase 1 mutation immunohistochemistry. 2013 , 15, 811-3	4
2196	Insights into the prognostic value of DJ-1 and MIB-1 in astrocytic tumors. 2013 , 8, 126	8
2195	Molecular fingerprinting reflects different histotypes and brain region in low grade gliomas. 2013 , 13, 387	9
2194	Ambient mass spectrometry for the intraoperative molecular diagnosis of human brain tumors. 2013 , 110, 1611-6	201
2193	Targeting placental growth factor/neuropilin 1 pathway inhibits growth and spread of medulloblastoma. 2013 , 152, 1065-76	174
2192	Secondary hematological malignancies associated with temozolomide in patients with glioma. 2013 , 15, 1445-50	33
2191	Brain tumor classification using AFM in combination with data mining techniques. 2013 , 2013, 176519	6
2190	Accumulation of 2-hydroxyglutarate is not a biomarker for malignant progression in IDH-mutated low-grade gliomas. 2013 , 15, 682-90	19
2189	1p/19q testing has no significance in the workup of glioblastomas. 2013 , 39, 706-17	41
2188	Prognostic significance of the aggregative perivascular growth pattern of tumor cells in primary central nervous system diffuse large B-cell lymphoma. 2013 , 15, 727-34	19
2187	TTF-1 expressing sellar neoplasm with ependymal rosettes and oncocytic change: mixed ependymal and oncocytic variant pituitaryoma. 2014 , 25, 436-8	20
2186	Genetic changes observed in a case of adult pilocytic astrocytoma revealed by array CGH analysis. 2014 , 7, 95	6
2185	Incidence rates of the primary brain tumours in Georgia--a population-based study. 2014 , 14, 29	9
2184	Paediatric and adult glioblastoma: multiform (epi)genomic culprits emerge. 2014 , 14, 92-107	383
2183	Mutant BRAF in low-grade epilepsy-associated tumors and focal cortical dysplasia. 2014 , 1, 130-4	28
2182	New concepts in the management of diffuse low-grade glioma: Proposal of a multistage and individualized therapeutic approach. 2015 , 17, 332-42	107

2181	Adult pilocytic astrocytomas: clinical features and molecular analysis. 2014 , 16, 841-7	42
2180	Global expression profile in low grade meningiomas and schwannomas shows upregulation of PDGFD, CDH1 and SLIT2 compared to their healthy tissue. 2014 , 32, 2327-34	10
2179	Socio-economic characteristics of patients with glioblastoma multiforme. 2015 , 125, 325-9	8
2178	An infant with hyperalertness, hyperkinesis, and failure to thrive: a rare diencephalic syndrome due to hypothalamic anaplastic astrocytoma. 2015 , 15, 616	5
2177	Screening for Psychological Distress in Adult Primary Brain Tumor Patients and Caregivers: Considerations for Cancer Care Coordination. 2015 , 5, 203	34
2176	Emerging role of linker histone variant H1x as a biomarker with prognostic value in astrocytic gliomas. A multivariate analysis including trimethylation of H3K9 and H4K20. 2015 , 10, e0115101	21
2175	Distinguishing grade I meningioma from higher grade meningiomas without biopsy. 2015 , 6, 38421-8	13
2174	Atypical extraventricular neurocytoma in a 3-year-old girl: case report with radiological-pathological correlation. 2015 , 31, 1189-93	7
2173	Targeted BRAF and CTNNB1 next-generation sequencing allows proper classification of nonadenomatous lesions of the sellar region in samples with limiting amounts of lesional cells. 2015 , 18, 905-11	27
2172	Advances in the treatment of newly diagnosed glioblastoma. 2015 , 13, 293	31
2171	Microfoci of malignant progression in diffuse low-grade gliomas: towards the creation of an intermediate grade in glioma classification?. 2015 , 466, 433-44	31
2170	Tissue thioredoxin reductase-1 expression in astrocytomas of different grades. 2015 , 121, 451-8	22
2169	Clinical presentation and long-term outcome of primary spinal peripheral primitive neuroectodermal tumors. 2015 , 124, 455-63	14
2168	IDH mutation status and role of WHO grade and mitotic index in overall survival in grade II-III diffuse gliomas. <i>Acta Neuropathologica</i> , 2015 , 129, 585-96	14.3 211
2167	Disseminated oligodendroglial-like leptomeningeal tumors: preliminary diagnostic and therapeutic results for a novel tumor entity [corrected]. 2015 , 124, 65-74	34
2166	Molecular Markers in Low-Grade Glioma-Toward Tumor Reclassification. 2015 , 25, 155-63	41
2165	Genetic analysis of a case of glioblastoma with oligodendroglial component arising during the progression of diffuse astrocytoma. 2015 , 21, 839-43	1
2164	Prognostic factors for patients with atypical or malignant meningiomas treated at a single center. 2015 , 38, 101-7; discussion 107	50

2163	The Molecular Pathogenesis of Glioblastoma. 2016 , 21-31	2
2162	The 2016 World Health Organization Classification of tumours of the Central Nervous System: what the paediatric neuroradiologist needs to know. 2016 , 6, 486-489	37
2161	Clinical, pathological, and molecular data on desmoplastic/nodular medulloblastoma: case studies and a review of the literature. 2016 , 35, 106-13	4
2160	Not all 1p/19q non-codeleted oligodendroglial tumors are astrocytic. 2016 , 7, 64615-64630	17
2159	Gliosarcoma with Primary Skull Base Invasion. 2016 , 2016, 1762195	5
2158	Hallmarks of glioblastoma: a systematic review. 2016 , 1, e000144	77
2157	Disseminated Cerebrospinal Embryonal Tumor in the Adult. 2016 , 2016, 6785459	3
2156	Molecular Genetics of Intracranial Meningiomas with Emphasis on Canonical Wnt Signalling. 2016 , 8,	26
2155	Advance Care Planning in Glioblastoma Patients. 2016 , 8,	31
2154	Non-invasive detection of 2-hydroxyglutarate in IDH-mutated gliomas using two-dimensional localized correlation spectroscopy (2D L-COSY) at 7 Tesla. 2016 , 14, 274	28
2153	Angiomatous pleomorphic xanthoastrocytoma: a case report and literature review. 2016 , 11, 73	5
2152	Contribution of 1p, 19q, 9p and 10q Automated Analysis by FISH to the Diagnosis and Prognosis of Oligodendroglial Tumors According to WHO 2016 Guidelines. 2016 , 11, e0168728	4
2151	MicroRNA-101 reverses temozolomide resistance by inhibition of GSK3 β in glioblastoma. 2016 , 7, 79584-79595	43
2150	Genetic mutations in high grade gliomas of the adult spinal cord. 2016 , 33, 267-269	22
2149	Posterior Fossa Tumors. 2016 , 05, 089-110	0
2148	AACR Cancer Progress Report 2016. 2016 , 22 Suppl 19, S1-S137	27
2147	TP53 and Histone H3.3 Mutations in Triple-Negative Lower-Grade Gliomas. 2016 , 375, 2206-2208	12
2146	Treatment Strategies for Low-Grade Glioma in Adults. 2016 , 12, 1235-1241	36

2145 Evolution of Low-Grade Glioma Therapy. **2016**, 12, 1242-1243

2144 Pilocytic astrocytoma and glioneuronal tumor with histone H3 K27M mutation. **2016**, 4, 84 64

2143 Integrating precision cancer medicine into healthcare-policy, practice, and research challenges. **2016**, 8, 108 33

2142 The impact of body mass index and height on the risk for glioblastoma and other glioma subgroups: a large prospective cohort study. **2017**, 19, 976-985 26

2141 A novel brain tumour model in zebrafish reveals the role of YAP activation in MAPK- and PI3K-induced malignant growth. **2017**, 10, 15-28 35

2140 Case 38-2016. A 52-Year-Old Woman with Recurrent Oligodendroglioma. **2016**, 375, 2381-2389 3

2139 Long-term neurologic health and psychosocial function of adult survivors of childhood medulloblastoma/PNET: a report from the Childhood Cancer Survivor Study. **2017**, 19, 689-698 39

2138 Current management of low-grade gliomas. **2016**, 29, 782-788 19

2137 Virtual special issue - neuroradiology. **2016**, 71, 1223-1225

2136 Management of Medulloblastoma in the Pediatric Population. **2016**, 38, 1-7

2135 Progress in neuro-imaging of brain tumors. **2016**, 28, 484-493 23

2134 [Adolescent and Young Adults (AYAS) brain tumor national Web conference. On behalf of ANOCEF, GO-AJA and SFCE societies]. **2016**, 103, 1050-1056 7

2133 SHOX2 is a Potent Independent Biomarker to Predict Survival of WHO Grade II-III Diffuse Gliomas. **2016**, 13, 80-89 21

2132 Metastatic meningioma presenting as a malignant soft tissue tumour. **2016**, 6, 23 5

2131 Prognostic value of diffusion tensor imaging parameters for Gamma Knife radiosurgery in meningiomas. **2016**, 125, 83-88 6

2130 Human glioblastoma stem-like cells accumulate protoporphyrin IX when subjected to exogenous 5-aminolaevulinic acid, rendering them sensitive to photodynamic treatment. **2016**, 163, 203-10 17

2129 EANO guidelines for the diagnosis and treatment of meningiomas. **2016**, 17, e383-91 414

2128 Immunological effects of chemotherapy and radiotherapy against brain tumors. **2016**, 16, 1087-94 26

2127	Inhibition of fatty acid synthase suppresses neovascularization via regulating the expression of VEGF-A in glioma. 2016 , 142, 2447-2459	16
2126	Pretreatment Evaluation of Glioma. 2016 , 26, 567-580	8
2125	The analysis of correlative factors affecting long-term outcomes in patients with Solid Cerebellar Hemangioblastomas. 2016 , 150, 59-66	10
2124	Repeat surgery for recurrent low-grade gliomas should be standard of care. 2016 , 151, 18-23	22
2123	Shedding Light on the 2016 World Health Organization Classification of Tumors of the Central Nervous System in the Era of Radiomics and Radiogenomics. 2016 , 24, 741-749	10
2122	Inhibitor of apoptosis protein expression in glioblastomas and their in vitro and in vivo targeting by SMAC mimetic GDC-0152. 2016 , 7, e2325	25
2121	Actionable molecular biomarkers in primary brain tumors. 2016 , 2, 338-349	29
2120	An integrative molecular and genomic analysis of pediatric hemispheric low-grade gliomas: an update. 2016 , 32, 1789-97	22
2119	MRI-guided laser interstitial thermal therapy for the treatment of low-grade gliomas in children: a case-series review, description of the current technologies and perspectives. 2016 , 32, 1947-56	27
2118	Pediatric low-grade gliomas: implications of the biologic era. 2017 , 19, 750-761	47
2117	Integrating molecular markers into the World Health Organization classification of CNS tumors: a survey of the neuro-oncology community. 2017 , 19, 336-344	15
2116	Adult Brain Tumors and Pseudotumors: Interesting (Bizarre) Cases. 2016 , 26, 667-689	4
2115	A combination of TERT promoter mutation and MGMT methylation status predicts clinically relevant subgroups of newly diagnosed glioblastomas. 2016 , 4, 79	137
2114	Secretory Meningiomas: Peritumoral Edema and Seizures. 2016 , 94, 573	2
2113	Posttreatment Evaluation of Brain Gliomas. 2016 , 26, 581-599	14
2112	Chromosome 1q gain and tenascin-C expression are candidate markers to define different risk groups in pediatric posterior fossa ependymoma. 2016 , 4, 88	31
2111	Targeted detection of genetic alterations reveal the prognostic impact of H3K27M and MAPK pathway aberrations in paediatric thalamic glioma. 2016 , 4, 93	77
2110	Epilepsy-associated tumours: what epileptologists should know about neuropathology, terminology, and classification systems. 2016 , 18, 240-51	24

2109	Prospective Longitudinal Analysis of 2-Hydroxyglutarate Magnetic Resonance Spectroscopy Identifies Broad Clinical Utility for the Management of Patients With IDH-Mutant Glioma. 2016 , 34, 4030-4039	124
2108	Epilepsy surgery for pediatric low-grade gliomas of the cerebral hemispheres: neurosurgical considerations and outcomes. 2016 , 32, 1923-30	4
2107	Incidence of pseudoprogression in low-grade gliomas treated with radiotherapy. 2017 , 19, 719-725	26
2106	Mutant IDH1 and thrombosis in gliomas. <i>Acta Neuropathologica</i> , 2016 , 132, 917-930	14.3 94
2105	Detecting tumor progression in glioma: current standards and new techniques. 2016 , 16, 1177-1188	14
2104	Precision medicine in glioblastoma therapy. 2016 , 1, 451-468	
2103	Gliomatosis cerebri: A consensus summary report from the First International Gliomatosis cerebri Group Meeting, March 26-27, 2015, Paris, France. 2016 , 63, 2072-2077	14
2102	2016 World Health Organization Classification of Central Nervous System Tumors: An Era of Molecular Biology. 2016 , 94, 561-562	23
2101	WHO's arrived in 2016! An updated weather forecast for integrated brain tumor diagnosis. 2016 , 33, 157-60	11
2100	Challenges in epilepsy-associated tumors. 2016 , 130, 239-240	3
2099	The Role of Molecular Diagnostics in the Management of Patients with Gliomas. 2016 , 17, 51	25
2098	Cystic meningioma: radiological, histological, and surgical particularities in 43 patients. 2016 , 158, 1955-64	27
2097	Prognostic impact of the 2016 WHO classification of diffuse gliomas in the French POLA cohort. <i>Acta Neuropathologica</i> , 2016 , 132, 625-34	14.3 72
2096	Cancers of the brain and CNS: global patterns and trends in incidence. 2017 , 19, 270-280	51
2095	Natural course and prognosis of anaplastic gangliogliomas: a multicenter retrospective study of 43 cases from the French Brain Tumor Database. 2017 , 19, 678-688	17
2094	BRAF Mutations Open Doors for N-Ethyl-N-Nitrosourea-Induced Gliomagenesis. 2016 , 186, 2551-4	2
2093	Unexpected and sudden death due to undiagnosed medulloblastoma in twin pregnancy: A case report. 2016 , 266, e14-e17	3
2092	The impact of MGMT methylation and IDH-1 mutation on long-term outcome for glioblastoma treated with chemoradiotherapy. 2016 , 158, 1943-53	29

2091	In search of a target: PD-1 and PD-L1 profiling across glioma types. 2016 , 18, 1331-2	11
2090	Clinical, Imaging, Histopathological and Molecular Characterization of Anaplastic Ganglioglioma. 2016 , 75, 971-980	40
2089	Lowered H3K27me3 and DNA hypomethylation define poorly prognostic pediatric posterior fossa ependymomas. 2016 , 8, 366ra161	109
2088	Early detection of human glioma sphere xenografts in mouse brain using diffusion MRI at 14.1 T. 2016 , 29, 1577-1589	7
2087	Brain invasion in otherwise benign meningiomas does not predict tumor recurrence. <i>Acta Neuropathologica</i> , 2016 , 132, 479-81	14-3 34
2086	Novel fusion genes and chimeric transcripts in ependymal tumors. 2016 , 55, 944-953	4
2085	Completeness of required site-specific factors for brain and CNS tumors in the Surveillance, Epidemiology and End Results (SEER) 18 database (2004-2012, varying). 2016 , 130, 31-42	29
2084	Non-invasive metabolic imaging of brain tumours in the era of precision medicine. 2016 , 13, 725-739	64
2083	[Pediatric ependymomas: Current diagnosis and therapy]. 2016 , 103, 869-879	
2082	¿Hacia dónde vamos con la patologí moderna? La patologí personalizada. 2016 , 49, 205-207	2
2081	A review of molecular alterations with clinical impact in adult and paediatric gliomas. 2016 , 22, 439-446	
2080	Low-grade epilepsy-associated neuroepithelial tumours - the 2016 WHO classification. 2016 , 12, 732-740	58
2079	GLI1, a master regulator of the hallmark of pancreatic cancer. 2016 , 66, 653-660	12
2078	Freiburg Neuropathology Case Conference : A Pituitary Mass Lesion. 2016 , 26, 493-497	
2077	The prognostic value of MGMT promoter status by pyrosequencing assay for glioblastoma patients' survival: a meta-analysis. 2016 , 14, 261	39
2076	Freiburg neuropathology case conference : Brainstem tumor in a child. 2016 , 26, 377-83	
2075	Surgical resection of fourth ventricular ependymomas: case series and technical nuances. 2016 , 130, 341-349	15
2074	Glioblastoma, hypoxia and autophagy: a survival-prone 'mãage-trois'. 2016 , 7, e2434	77

2073	Atypical meningioma-is it time to standardize surgical sampling techniques?. 2017 , 19, 453-454	11
2072	Establishment of Anti-Human ATRX Monoclonal Antibody AMab-6. 2016 , 35, 254-258	4
2071	Moving the needle: Optimizing classification for glioma. 2016 , 8, 350fs14	19
2070	Single-cell RNA-seq supports a developmental hierarchy in human oligodendroglioma. 2016 , 539, 309-313	561
2069	Endothelial Cell Hypertrophy and Microvascular Proliferation in Meningiomas Are Correlated with Higher Histological Grade and Shorter Progression-Free Survival. 2016 , 75, 1160-1170	11
2068	Compliance with reporting guidelines by Australian pathologists: an audit of the quality of histopathology reporting in high-grade glioma. 2016 , 3, 97-104	
2067	Das Tumorepigenom Von der Genregulation Über die Tumorklassifikation zum Therapietarget. 2016 , 28, 424-434	
2066	Practical implications of integrated glioma classification according to the World Health Organization classification of tumors of the central nervous system 2016. 2016 , 28, 494-501	53
2065	Hirntumoren im Kindes- und Jugendalter. 2016 , 22, 908-922	
2064	Management of Medulloblastoma in the Pediatric Population. 2016 , 38, 8-8	
2063	Adult anaplastic pilocytic astrocytoma - a diagnostic challenge? A case series and literature review. 2016 , 147, 98-104	5
2062	Clinicopathological differences between variants of the NAB2-STAT6 fusion gene in solitary fibrous tumors of the meninges and extra-central nervous system. 2016 , 33, 169-74	27
2061	ATRX immunostaining predicts IDH and H3F3A status in gliomas. 2016 , 4, 60	76
2060	New Brain Tumor Entities Emerge from Molecular Classification of CNS-PNETs. 2016 , 164, 1060-1072	483
2059	The McGill Interactive Pediatric OncoGenetic Guidelines: An approach to identifying pediatric oncology patients most likely to benefit from a genetic evaluation. 2017 , 64, e26441	19
2058	Neuro-oncology in 2016: Advances in brain tumour classification and therapy. 2017 , 13, 71-72	11
2057	Clinical targeted exome-based sequencing in combination with genome-wide copy number profiling: precision medicine analysis of 203 pediatric brain tumors. 2017 , 19, 986-996	39
2056	Prognostic value of molecular and imaging biomarkers in patients with supratentorial glioma. 2017 , 44, 1155-1164	58

2055	Early postoperative tumor progression predicts clinical outcome in glioblastoma-implication for clinical trials. 2017 , 132, 249-254	16
2054	Development of the SIOPE DIPG network, registry and imaging repository: a collaborative effort to optimize research into a rare and lethal disease. 2017 , 132, 255-266	34
2053	New classification of epilepsy-related neoplasms: The clinical perspective. 2017 , 67, 91-97	17
2052	Cerebral Cortex Regions Selectively Vulnerable to Radiation Dose-Dependent Atrophy. 2017 , 97, 910-918	45
2051	Potential mechanisms of microRNA-129-5p in inhibiting cell processes including viability, proliferation, migration and invasiveness of glioblastoma cells U87 through targeting FNDC3B. 2017 , 87, 405-411	34
2050	WHO 2016: Open questions and practical implications. 2017 , 159, 419-422	2
2049	Genetically Defined Oligodendroglioma Is Characterized by Indistinct Tumor Borders at MRI. 2017 , 38, 678-684	45
2048	Risk assessment in paediatric glioma-Time to move on from the binary classification. 2017 , 111, 52-59	3
2047	Podoplanin expression in primary brain tumors induces platelet aggregation and increases risk of venous thromboembolism. 2017 , 129, 1831-1839	109
2046	Glioma: experimental models and reality. <i>Acta Neuropathologica</i> , 2017 , 133, 263-282	14.3 165
2045	Effects of the functional HOTAIR rs920778 and rs12826786 genetic variants in glioma susceptibility and patient prognosis. 2017 , 132, 27-34	28
2044	Molecular Neuropathology and the Ontogeny of Malignant Gliomas. 2017 , 15-29	
2043	Utility of neurological smears for intrasurgical brain cancer diagnostics and tumour cell percentage by DESI-MS. 2017 , 142, 449-454	19
2042	Low preoperative prognostic nutritional index predicts poor survival in patients with newly diagnosed high-grade gliomas. 2017 , 132, 239-247	26
2041	Expression and prognostic value of microRNAs in lower-grade glioma depends on IDH1/2 status. 2017 , 132, 207-218	12
2040	Molecular mechanisms involved in gliomagenesis. 2017 , 34, 1-7	11
2039	Prognostic value of survivin and DNA topoisomerase II α in diffuse and anaplastic astrocytomas. 2017 , 213, 339-347	1
2038	Molecular markers in glioma. 2017 , 134, 505-512	156

2037	Visceral and bone metastases of a WHO grade 2 meningioma: A case report and review of the literature. 2017 , 21, 55-59	11
2036	Imaging Characteristics of Pediatric Diffuse Midline Gliomas with Histone H3 K27M Mutation. 2017 , 38, 795-800	90
2035	Atypical Meningioma: Referral Patterns, Treatment and Adherence to Guidelines. 2017 , 44, 283-287	6
2034	Reliability of noncontrast-enhancing tumor as a biomarker of IDH1 mutation status in glioblastoma. 2017 , 39, 170-175	24
2033	New Molecular Considerations for Glioma: IDH, ATRX, BRAF, TERT, H3 K27M. 2017 , 17, 19	66
2032	IDH mutation assessment of glioma using texture features of multimodal MR images. 2017 ,	4
2031	Glioma Subclassifications and Their Clinical Significance. 2017 , 14, 284-297	247
2030	Glutamine Addiction In Gliomas. 2017 , 42, 1735-1746	41
2029	Targeting Epigenetic Pathways in the Treatment of Pediatric Diffuse (High Grade) Gliomas. 2017 , 14, 274-283	16
2028	Tissue thioredoxin-interacting protein expression predicted recurrence in patients with meningiomas. 2017 , 22, 660-666	6
2027	Immune checkpoint blockade for glioma. 2017 ,	78
2026	Volumetric growth rates of meningioma and its correlation with histological diagnosis and clinical outcome: a systematic review. 2017 , 159, 435-445	32
2025	Quantitative multi-modal MR imaging as a non-invasive prognostic tool for patients with recurrent low-grade glioma. 2017 , 132, 171-179	12
2024	Stochastic modelling of slow-progressing tumors: Analysis and applications to the cell interplay and control of low grade gliomas. 2017 , 49, 63-80	6
2023	High expression of RAB43 predicts poor prognosis and is associated with epithelial-mesenchymal transition in gliomas. 2017 , 37, 903-912	14
2022	Adult infiltrating gliomas with WHO 2016 integrated diagnosis: additional prognostic roles of ATRX and TERT. <i>Acta Neuropathologica</i> , 2017 , 133, 1001-1016	143 185
2021	ATRX status correlates with 11 C-methionine uptake in WHO grade II and III gliomas with IDH1 mutations. 2017 , 34, 20-27	3
2020	Diffuse low-grade glioma: a review on the new molecular classification, natural history and current management strategies. 2017 , 19, 931-944	64

2019	Quantitative glioma grading using transformed gray-scale invariant textures of MRI. 2017 , 83, 102-108	40
2018	A Distinctive Pathologic Meningioma Completely without Enhancement and Dural Tail Sign on Imaging Findings. 2017 , 101, 815.e9-815.e12	3
2017	Secondary Glioblastoma: Molecular and Clinical Factors That Affect Outcome After Malignant Progression of a Lower Grade Tumor. 2017 , 102, 49-55	5
2016	A case of high-grade astrocytoma with BRAF and ATRX mutations following a long-standing course over two decades. 2017 , 37, 351-357	5
2015	Intraoperative photodynamic treatment for high-grade gliomas. 2017 ,	1
2014	Post-operative diffusion weighted imaging as a predictor of posterior fossa syndrome permanence in paediatric medulloblastoma. 2017 , 33, 457-465	11
2013	Intracranial Subependymoma: A SEER Analysis 2004-2013. 2017 , 101, 599-605	24
2012	Integrated genomic analyses of de novo pathways underlying atypical meningiomas. 2017 , 8, 14433	95
2011	Incidence and survival trends in oligodendrogliomas and anaplastic oligodendrogliomas in the United States from 2000 to 2013: a CBTRUS Report. 2017 , 133, 17-25	11
2010	The Survival Advantage of "Supratotal" Resection of Glioblastoma Using Selective Cortical Mapping and the Subpial Technique. 2017 , 81, 275-288	63
2009	DNA methylation signatures for 2016 WHO classification subtypes of diffuse gliomas. 2017 , 9, 32	18
2008	Catharanthus roseus. 2017 ,	7
2007	Novel GOPC(FIG)-ROS1 fusion in a pediatric high-grade glioma survivor. 2017 , 20, 51-55	16
2006	Autophagy and TrkC/NT-3 signaling joined forces boost the hypoxic glioblastoma cell survival. 2017 , 38, 592-603	17
2005	Genomic profiles of low-grade murine gliomas evolve during progression to glioblastoma. 2017 , 19, 1237-1247	9
2004	ALK Expression Is a Novel Marker for the WNT-activated Type of Pediatric Medulloblastoma and an Indicator of Good Prognosis for Patients. 2017 , 41, 781-787	10
2003	Genomic Analysis in the Practice of Surgical Neuropathology: The Emory Experience. 2017 , 141, 355-365	2
2002	Does early resection of presumed low-grade glioma improve survival? A clinical perspective. 2017 , 133, 137-146	21

2001	The role of tumor board conferences in neuro-oncology: a nationwide provider survey. 2017 , 133, 1-7	30
2000	Amino acid PET and MR perfusion imaging in brain tumours. 2017 , 5, 209-223	43
1999	Biotechnology and Production of Anti-Cancer Compounds. 2017 ,	5
1998	IDH mutation and 1p19q codeletion distinguish two radiological patterns of diffuse low-grade gliomas. 2017 , 133, 37-45	39
1997	Extent of Resection in Glioma-A Review of the Cutting Edge. 2017 , 103, 538-549	86
1996	5ALA in pediatric brain tumors is not routinely beneficial. 2017 , 33, 787-792	6
1995	Primary Gliosarcoma of the Optic Nerve: A Unique Adult Optic Pathway Glioma. 2017 , 33, e88-e92	5
1994	Isolated intracerebral Langerhans cell histiocytosis with multifocal lesions. 2017 , 64, e26546	
1993	Biopsy targeting with dynamic contrast-enhanced versus standard neuronavigation MRI in glioma: a prospective double-blinded evaluation of selection benefits. 2017 , 133, 155-163	4
1992	Survival trends of oligodendroglial tumor patients and associated clinical practice patterns: a SEER-based analysis. 2017 , 133, 173-181	11
1991	Rapid progression to glioblastoma in a subset of IDH-mutated astrocytomas: a genome-wide analysis. 2017 , 133, 183-192	25
1990	Therapeutic Options for Recurrent High-Grade Gliomas: A Perspective Statement. 2017 , 105, 985-987	3
1989	Dual-Genotype Diffuse Low-Grade Glioma: Is It Really Time to Abandon Oligoastrocytoma As a Distinct Entity?. 2017 , 76, 342-346	15
1988	Optic pathway glioma of childhood. 2017 , 28, 289-295	34
1987	Catharanthus roseus: The Cancer-Fighting Medicine. 2017 , 121-151	1
1986	Multimodal Magnetic Resonance Imaging of Treatment-Induced Changes to Diffuse Infiltrating Pontine Gliomas in Children and Correlation to Patient Progression-Free Survival. 2017 , 99, 476-485	17
1985	Radiogenomic analysis of lower grade glioma: a pilot multi-institutional study shows an association between quantitative image features and tumor genomics. 2017 ,	1
1984	Spinal Solitary Fibrous Tumor/Hemangiopericytoma: A Clinicopathologic and Radiologic Analysis of Eleven Cases. 2017 , 104, 318-329	23

1983	Unusual Occurrence of Multifocal Desmoplastic Infantile Astrocytoma: A Case Report and Review of the Literature. 2017 , 52, 173-180	3
1982	Accuracy of 1H magnetic resonance spectroscopy for quantification of 2-hydroxyglutarate using linear combination and J-difference editing at 9.4T. 2017 , 27, 300-309	2
1981	Surgical resection versus watchful waiting in low-grade gliomas. 2017 , 28, 1942-1948	151
1980	Pediatric Tumors. 2017 , 805-843	1
1979	Large cell/anaplastic medulloblastoma is associated with poor prognosis-a retrospective analysis at a single institute. 2017 , 33, 1285-1294	9
1978	Frequent AKT1E17K mutations in skull base meningiomas are associated with mTOR and ERK1/2 activation and reduced time to tumor recurrence. 2017 , 19, 1088-1096	49
1977	Tailoring Medulloblastoma Treatment Through Genomics: Making a Change, One Subgroup at a Time. 2017 , 18, 143-166	18
1976	Current Clinical Brain Tumor Imaging. 2017 , 81, 397-415	157
1975	Noninvasive Assessment of Mutational Status in World Health Organization Grade II and III Astrocytomas Using DWI and DSC-PWI Combined with Conventional MR Imaging. 2017 , 38, 1138-1144	59
1974	Is the information provided by amino acid PET radiopharmaceuticals clinically equivalent in gliomas?. 2017 , 44, 1408-1410	15
1973	Molecular alterations in pediatric gliomatosis cerebri are similar to those in less invasive forms of pediatric diffuse glioma. 2017 , 133, 217-219	1
1972	Simultaneous analysis of miRNA-mRNA in human meningiomas by integrating transcriptome: A relationship between PTX3 and miR-29c. 2017 , 17, 207	16
1971	Invasiveness is associated with metastasis and decreased survival in hemangiopericytoma of the central nervous system. 2017 , 133, 409-417	12
1970	Sensitization of glioblastoma tumor micro-environment to chemo- and immunotherapy by Galectin-1 intranasal knock-down strategy. 2017 , 7, 1217	75
1969	"The simplest explanation is usually the correct one" - Can Occam's razor be applied for diffuse astrocytoma and paradoxical amino acid metabolism?. 2017 , 44, 1411-1412	3
1968	Management of Glioblastoma Multiforme in Elderly Patients: A Review of the Literature. 2017 , 105, 53-62	13
1967	Meningiomas induced by low-dose radiation carry structural variants of NF2 and a distinct mutational signature. <i>Acta Neuropathologica</i> , 2017 , 134, 155-158	14.3 19
1966	European Association for Neuro-Oncology (EANO) guideline on the diagnosis and treatment of adult astrocytic and oligodendroglial gliomas. 2017 , 18, e315-e329	599

1965	Aptamer Functionalization of Nanosystems for Glioblastoma Targeting through the Blood-Brain Barrier. 2017 , 60, 4510-4516	71
1964	Structural and functional intratumor heterogeneities in glioblastoma: a spacetime odyssey at single-cell level. 2017 , 28, 1415-1417	3
1963	Multicenter phase II study of temozolomide and myeloablative chemotherapy with autologous stem cell transplant for newly diagnosed anaplastic oligodendroglioma. 2017 , 19, 1380-1390	20
1962	Immunohistochemical investigation of topolllH3K27me3 and JMJD3 expressions in medulloblastoma. 2017 , 213, 975-981	4
1961	Angiogenesis inhibitors in tackling recurrent glioblastoma. 2017 , 17, 507-515	21
1960	Prevalence and clinicopathological features of H3.3 G34-mutant high-grade gliomas: a retrospective study of 411 consecutive glioma cases in a single institution. 2017 , 34, 103-112	38
1959	Genomics and Artificial Intelligence Working Together in Drug Discovery and Repositioning: The Advent of Adaptive Pharmacogenomics in Glioblastoma and Chronic Arterial Inflammation Therapies. 2017 , 253-281	8
1958	Predictors of Morbidity and Cleavage Plane in Surgical Resection of Pure Convexity Meningiomas Using Cerebrospinal Fluid Sensitive Image Subtraction Magnetic Resonance Imaging. 2017 , 57, 35-43	8
1957	Rosette-Forming Glioneuronal Tumor Originating From the Spinal Cord: Report of 2 Cases and Literature Review. 2017 , 98, 875.e1-875.e7	15
1956	Dabrafenib in BRAFV600-mutated anaplastic pleomorphic xanthoastrocytoma. 2017 , 6, 5-9	30
1955	Bioinformatic Profiling Identifies a Glucose-Related Risk Signature for the Malignancy of Glioma and the Survival of Patients. 2017 , 54, 8203-8210	26
1954	Recent advances in subtyping tumors of the central nervous system using molecular data. 2017 , 17, 83-94	9
1953	miRNA Regulation in Gliomas: Usual Suspects in Glial Tumorigenesis and Evolving Clinical Applications. 2017 , 76, 246-254	19
1952	Glioma groups classified by IDH and TERT promoter mutations remain stable among primary and recurrent gliomas. 2017 , 19, 1008-1010	8
1951	Toward more informative biomarker-based clinical trials in glioblastoma. 2017 , 19, 880-881	2
1950	From K-space to Nucleotide: Insights Into the Radiogenomics of Brain Tumors. 2017 , 26, 33-41	1
1949	The Alkylating Chemotherapeutic Temozolomide Induces Metabolic Stress in -Mutant Cancers and Potentiates NAD Depletion-Mediated Cytotoxicity. 2017 , 77, 4102-4115	53
1948	Update on Radiotherapy for Central Nervous System Malignancies. 2017 , 26, 347-355	3

1947	Impact of induction chemotherapy, hyperfractionated accelerated radiotherapy and high-dose thiotepa on brain volume loss and functional status of children with primitive neuroectodermal tumour. 2017 , 64, e26619	5
1946	Genomic diagnostics leading to the identification of a TFG-ROS1 fusion in a child with possible atypical meningioma. 2017 , 212-213, 32-37	11
1945	Preclinical drug screen reveals topotecan, actinomycin D, and volasertib as potential new therapeutic candidates for ETMR brain tumor patients. 2017 , 19, 1607-1617	25
1944	Preparing pathology for precision medicine: challenges and opportunities. 2017 , 471, 141-146	6
1943	Embryonal tumors in Canadian children less than 36 months of age: results from the Canadian Pediatric Brain Tumor Consortium (CPBTC). 2017 , 133, 581-587	2
1942	Discrimination between Glioma Grades II and III Using Dynamic Susceptibility Perfusion MRI: A Meta-Analysis. 2017 , 38, 1348-1355	26
1941	An Update on the Approach to the Imaging of Brain Tumors. 2017 , 17, 53	10
1940	Glioblastoma-derived cells unveil the spectrum of drug resistance capability - comparative study of tumour chemosensitivity in different culture systems. 2017 , 37,	6
1939	Novel molecular subgroups for clinical classification and outcome prediction in childhood medulloblastoma: a cohort study. 2017 , 18, 958-971	248
1938	Post-fine-needle aspiration biopsy communication and the integrated and standardized cytopathology report. 2017 , 125, 486-493	5
1937	H3 K27M mutations are extremely rare in posterior fossa group A ependymoma. 2017 , 33, 1047-1051	29
1936	The Utility of Expert Diagnosis in Surgical Neuropathology: Analysis of Consultations Reviewed at 5 National Comprehensive Cancer Network Institutions. 2017 , 76, 189-194	1
1935	. 2017 ,	1
1934	Diagnostic accuracy of proton magnetic resonance spectroscopy and perfusion-weighted imaging in brain gliomas follow-up: a single institutional experience. 2017 , 30, 240-252	3
1933	IDH mutant and 1p/19q co-deleted oligodendrogliomas: tumor grade stratification using diffusion-, susceptibility-, and perfusion-weighted MRI. 2017 , 59, 555-562	22
1932	Recurrent Thromboembolic Events after Ischemic Stroke in Patients with Primary Brain Tumors. 2017 , 26, 2396-2403	9
1931	Same-day genomic and epigenomic diagnosis of brain tumors using real-time nanopore sequencing. <i>Acta Neuropathologica</i> , 2017 , 134, 691-703	14.3 78
1930	Differential diagnosis of oligodendroglial and astrocytic tumors using imaging results: the added value of perfusion MR imaging. 2017 , 59, 665-675	8

1929	Perfusion and diffusion MRI signatures in histologic and genetic subtypes of WHO grade II-III diffuse gliomas. 2017 , 134, 177-188	83
1928	Citation classics in neuro-oncology: assessment of historical trends and scientific progress. 2017 , 19, 1158-1172	16
1927	Correlation of immune phenotype with IDH mutation in diffuse glioma. 2017 , 19, 1460-1468	144
1926	Adult IDH wild-type lower-grade gliomas should be further stratified. 2017 , 19, 1327-1337	121
1925	Prognostic significance of preoperative neutrophilia on recurrence-free survival in meningioma. 2017 , 19, 1503-1510	7
1924	Clinical value of fluorine-18methyltyrosine PET in patients with gliomas: comparison with fluorine-18 fluorodeoxyglucose PET. 2017 , 7, 50	4
1923	Rexin-G, a tumor-targeted retrovector for malignant peripheral nerve sheath tumor: A case report. 2017 , 6, 861-865	14
1922	miR-599 inhibits proliferation and invasion of glioma by targeting periostin. 2017 , 39, 1325-1333	20
1921	Meningiomas Adjacent to Major Venous Sinuses-Clinical Outcome and Recurrence. 2017 , 104, 560-566	13
1920	Multidimensional scaling of diffuse gliomas: application to the 2016 World Health Organization classification system with prognostically relevant molecular subtype discovery. 2017 , 5, 39	65
1919	Molecular classification of adult diffuse gliomas: conflicting IDH1/IDH2, ATRX, and 1p/19q results. 2017 , 69, 15-22	20
1918	MELK and EZH2 Cooperate to Regulate Medulloblastoma Cancer Stem-like Cell Proliferation and Differentiation. 2017 , 15, 1275-1286	24
1917	Cell biology-metabolic crosstalk in glioma. 2017 , 89, 171-181	23
1916	Primary histiocytic sarcoma presenting as diffuse leptomeningeal disease: Case description and review of the literature. 2017 , 37, 517-525	14
1915	Betulinic acid derivative B10 inhibits glioma cell proliferation through suppression of SIRT1, acetylation of FOXO3a and upregulation of Bim/PUMA. 2017 , 92, 347-355	18
1914	Imaging of amino acid transport in brain tumours: Positron emission tomography with O-(2-[F]fluoroethyl)-L-tyrosine (FET). 2017 , 130, 124-134	55
1913	Microglia-glioblastoma interactions: New role for Wnt signaling. 2017 , 1868, 333-340	27
1912	CD147 and glioma: a meta-analysis. 2017 , 134, 145-156	14

1911	Treatment of Glioma in the 21st Century: An Exciting Decade of Postsurgical Treatment Advances in the Molecular Era. 2017 , 92, 995-1004	14
1910	CBF1 is clinically prognostic and serves as a target to block cellular invasion and chemoresistance of EMT-like glioblastoma cells. 2017 , 117, 102-112	18
1909	Feasibility, Risk Profile and Diagnostic Yield of Stereotactic Biopsy in Children and Young Adults with Brain Lesions. 2017 , 229, 133-141	10
1908	Our panel of experts highlights the most important research articles across the spectrum of topics relevant to the field of CNS oncology. 2017 , 6, 85-87	78
1907	Center-Focusing Multi-task CNN with Injected Features for Classification of Glioma Nuclear Images. 2017 , 2017, 834-841	18
1906	Precision Medicine in Pediatric Oncology: Translating Genomic Discoveries into Optimized Therapies. 2017 , 23, 5329-5338	16
1905	Intertumoral Heterogeneity within Medulloblastoma Subgroups. 2017 , 31, 737-754.e6	511
1904	From One to Many: Further Refinement of Medulloblastoma Subtypes Offers Promise for Personalized Therapy. 2017 , 31, 727-729	8
1903	Intraoperative assessment of tumor margins during glioma resection by desorption electrospray ionization-mass spectrometry. 2017 , 114, 6700-6705	106
1902	Study protocol of a phase IB/II clinical trial of metformin and chloroquine in patients with -mutated or -mutated solid tumours. 2017 , 7, e014961	55
1901	TUMORES CEREBRALES ASOCIADOS A EPILEPSIA. 2017 , 28, 420-428	
1900	Glioblastoma targeted therapy: updated approaches from recent biological insights. 2017 , 28, 1457-1472	230
1899	Retrospective Analysis of Molecular and Immunohistochemical Characterization of 381 Primary Brain Tumors. 2017 , 76, 179-188	19
1898	Diagnostic challenges in meningioma. 2017 , 19, 1588-1598	57
1897	PET imaging in patients with meningioma-report of the RANO/PET Group. 2017 , 19, 1576-1587	97
1896	Apport de l'imagerie métabolique dans la prise en charge des patients ayant une tumeur cérébrale primitive de l'adulte du point de vue du neuro-oncologue. 2017 , 41, 235-236	
1895	Management and Survival Patterns of Patients with Gliomatosis Cerebri: A SEER-Based Analysis. 2017 , 103, 186-193	13
1894	A clinical perspective on the 2016 WHO brain tumor classification and routine molecular diagnostics. 2017 , 19, 614-624	79

1893	Multigene signature for predicting prognosis of patients with 1p19q co-deletion diffuse glioma. 2017, 19, 786-795	57
1892	Treatment strategy and IDH status improve nomogram validity in newly diagnosed GBM patients. 2017, 19, 736-738	10
1891	Telomerase activation in posterior fossa group A ependymomas is associated with dismal prognosis and chromosome 1q gain. 2017, 19, 1183-1194	24
1890	Milestones of the last 10 years: CNS cancer. 2017, 10, 18-21	6
1889	Overall survival benefit associated with adjuvant radiotherapy in WHO grade II meningioma. 2017, 19, 1263-1270	57
1888	Diffuse intrinsic pontine gliomas-current management and new biologic insights. Is there a glimmer of hope?. 2017, 19, 1025-1034	58
1887	Replication stress, DNA damage signalling, and cytomegalovirus infection in human medulloblastomas. 2017, 11, 945-964	9
1886	Detection of small changes in medical and random-dot images comparing self-organizing map performance to human detection. 2017, 7, 39-45	10
1885	IDH1 mutant negative ganglioglioma progression to gliosarcoma. 2017, 9, 41-44	
1884	Connectomic profile and clinical phenotype in newly diagnosed glioma patients. 2017, 14, 87-96	40
1883	Impact of Resection on Survival of Isocitrate Dehydrogenase 1-Mutated World Health Organization Grade II Astrocytoma After Malignant Progression. 2017, 103, 180-185	7
1882	Management of Elderly Patients with Glioblastoma. 2017, 17, 35	5
1881	Positron emission tomography and magnetic resonance spectroscopy in cerebral gliomas. 2017, 5, 151-158	3
1880	Spindle cell oncocytoma: Report of two cases with massive bleeding and review of the literature. 2017, 39, 39-44	15
1879	Intraocular Ependymoma With Blood-Filled Spaces: Neoplasm or a Reactive Process With Ependymal Differentiation-A Dilemma. 2017, 25, 368-373	1
1878	Characteristics of H3 K27M-mutant gliomas in adults. 2017, 19, 1127-1134	150
1877	Reappraising the 2016 WHO classification for diffuse glioma. 2017, 19, 609-610	4
1876	Combination therapy with potent PI3K and MAPK inhibitors overcomes adaptive kinome resistance to single agents in preclinical models of glioblastoma. 2017, 19, 1469-1480	28

1875	Diffuse leptomeningeal glioneuronal tumor (DLGNT) mimicking Whipple's disease: a case report and literature review. 2017 , 33, 1411-1414	14
1874	Medulloblastoma: Molecular Classification-Based Personal Therapeutics. 2017 , 14, 265-273	47
1873	Advances in neuro-oncology imaging. 2017 , 13, 279-289	185
1872	Finding of IDH1 R132H mutation in histologically non-neoplastic glial tissue changes surgical strategies, a case report. 2017 , 33, 1217-1220	2
1871	Central nervous system gliomas. 2017 , 113, 213-234	84
1870	A comprehensive review of paediatric low-grade diffuse glioma: pathology, molecular genetics and treatment. 2017 , 34, 51-61	33
1869	Pediatric high-grade glioma: current molecular landscape and therapeutic approaches. 2017 , 134, 541-549	68
1868	Incidence of CNS tumors in Appalachian children. 2017 , 132, 507-512	5
1867	miR-181d/MALT1 regulatory axis attenuates mesenchymal phenotype through NF- κ B pathways in glioblastoma. 2017 , 396, 1-9	40
1866	Novel recursive partitioning analysis classification for newly diagnosed glioblastoma: A multi-institutional study highlighting the MGMT promoter methylation and IDH1 gene mutation status. 2017 , 123, 106-111	26
1865	Single vs. combination immunotherapeutic strategies for glioma. 2017 , 17, 543-554	11
1864	Atypical and Malignant Meningiomas. 2017 , 856-870	
1863	Diffuse Low-Grade Gliomas. 2017 , 888-898	
1862	Overexpression of SMC4 activates TGF β /Smad signaling and promotes aggressive phenotype in glioma cells. 2017 , 6, e301	37
1861	Endoplasmic reticulum proteostasis in glioblastoma-From molecular mechanisms to therapeutic perspectives. 2017 , 10,	74
1860	Aberrant ganglioside composition in glioblastoma multiforme and peritumoral tissue: A mass spectrometry characterization. 2017 , 137, 56-68	14
1859	Evaluation of the applicability of territorial arterial spin labeling in meningiomas for presurgical assessments compared with 3-dimensional time-of-flight magnetic resonance angiography. 2017 , 27, 4072-4081	7
1858	IDH mutation is paradoxically associated with higher F-FDOPA PET uptake in diffuse grade II and grade III gliomas. 2017 , 44, 1306-1311	47

1857	Does Pretreatment Tumor Growth Hold Prognostic Information for Patients with Glioblastoma?. 2017 , 101, 686-694.e4	11
1856	The Effect of Molecular Diagnostics on the Treatment of Glioma. 2017 , 19, 26	28
1855	Lymph node metastasis of presacral ependymblastoma in a young child. 2017 , 40, 64-66	1
1854	Contemporary management of low--grade glioma: a paradigm shift in neuro-oncology. 2017 , 17, 183-190	10
1853	DNA methylation-based classification and grading system for meningioma: a multicentre, retrospective analysis. 2017 , 18, 682-694	336
1852	Development of induced glioblastoma by implantation of a human xenograft in Yucatan minipig as a large animal model. 2017 , 282, 61-68	18
1851	The involvement of thrombin in the pathogenesis of glioblastoma. 2017 , 95, 2080-2085	16
1850	Primary intracranial germ cell tumor with five distinct histologic components and bilateral pulmonary metastasis-a rare case report. 2017 , 33, 21-23	1
1849	Perfusion imaging of brain gliomas using arterial spin labeling: correlation with histopathological vascular density in MRI-guided biopsies. 2017 , 59, 51-59	16
1848	The transcription factor PPAR β s overexpressed and is associated with a favourable prognosis in IDH-wildtype primary glioblastoma. 2017 , 70, 1030-1043	12
1847	Metabolic Reprogramming in Brain Tumors. 2017 , 12, 515-545	56
1846	Wnt5a Drives an Invasive Phenotype in Human Glioblastoma Stem-like Cells. 2017 , 77, 996-1007	54
1845	Epilepsy-related brain tumors. 2017 , 44, 93-97	42
1844	Magnetic Resonance-Guided Laser Ablation: A Viable Treatment Alternative for Recurrent Meningioma?. 2017 , 99, 779-781	
1843	Advances in the molecular genetics of gliomas - implications for classification and therapy. 2017 , 14, 434-452	320
1842	Comparison between perfusion computed tomography and dynamic contrast-enhanced magnetic resonance imaging in assessing glioblastoma microvasculature. 2017 , 87, 120-124	12
1841	'Low grade glioma': an update for radiologists. 2017 , 90, 20160600	13
1840	Seizures caused by brain tumors in children. 2017 , 44, 98-107	21

1839	Prognostic relevance of gemistocytic grade II astrocytoma: gemistocytic component and MR imaging features compared to non-gemistocytic grade II astrocytoma. 2017 , 27, 3022-3032		7
1838	Use of an anti-viral drug, Ribavirin, as an anti-glioblastoma therapeutic. 2017 , 36, 3037-3047		32
1837	Hypervascular Lesions of the Cerebellopontine Angle: The Relevance of Angiography as a Diagnostic and Therapeutic Tool and the Role of Stereotactic Radiosurgery in Management. A Comprehensive Review. 2017 , 100, 100-117		8
1836	Tissue mechanics regulate brain development, homeostasis and disease. 2017 , 130, 71-82		160
1835	Clinicoradiologic Features and Surgical Outcomes of Sellar Xanthogranulomas: A Single-Center 10-Year Experience. 2017 , 99, 439-447		13
1834	Gain of 12p encompassing CCND2 is associated with gemistocytic histology in IDH mutant astrocytomas. <i>Acta Neuropathologica</i> , 2017 , 133, 325-327	14-3	10
1833	Announcing cIMPACT-NOW: the Consortium to Inform Molecular and Practical Approaches to CNS Tumor Taxonomy. <i>Acta Neuropathologica</i> , 2017 , 133, 1-3	14-3	77
1832	Overexpression of TEAD4 in atypical teratoid/rhabdoid tumor: New insight to the pathophysiology of an aggressive brain tumor. 2017 , 64, e26398		9
1831	Dabrafenib and trametinib in BRAFV600E mutated glioma. 2017 , 6, 291-296		39
1830	Does intensification of chemotherapy in anaplastic oligodendrogliomas still have a role?. 2017 , 19, 1292-1293		
1829	ASA404, a vascular disrupting agent, as an experimental treatment approach for brain tumors. 2017 , 14, 5443-5451		2
1828	CATNON interim results: another triumph of upfront chemotherapy in glioma. 2017 , 19, 1287-1288		1
1827	H3.3 Cooperates with Trp53 Loss and PDGFRA Gain in Mouse Embryonic Neural Progenitor Cells to Induce Invasive High-Grade Gliomas. 2017 , 32, 684-700.e9		121
1826	Treatment of Glioblastoma in Older Adults. 2017 , 19, 81		29
1825	Prognostic factors in atypical meningioma. 2017 , 31, 165-171		
1824	A glycolysis-based ten-gene signature correlates with the clinical outcome, molecular subtype and IDH1 mutation in glioblastoma. 2017 , 44, 519-530		17
1823	Management of supratentorial recurrent low-grade glioma: A multidisciplinary experience in 35 adult patients. 2017 , 14, 2789-2795		5
1822	Giant Cell Ependymoma of Lateral Ventricle: Case Report, Literature Review, and Analysis of Prognostic Factors and Genetic Profile. 2017 , 108, 997.e9-997.e14		3

1821	Extent of surgical resection and tumor size predicts prognosis in granular cell tumor of the sellar region. 2017 , 159, 2209-2216	5
1820	Management of raised intracranial pressure in aneurysmal subarachnoid hemorrhage: time for a consensus?. 2017 , 43, E13	18
1819	Central neurocytoma of the third ventricle: Case report and treatment review?? Source(s) of support in the form of grants, equipment, drugs, or all of these: None.View all notes. 2017 , 4, 361-365	1
1818	Medulloblastoma in children and adolescents: a systematic review of contemporary phase I and II clinical trials and biology update. 2017 , 6, 2606-2624	28
1817	Assessing inhibitors of mutant isocitrate dehydrogenase using a suite of pre-clinical discovery assays. 2017 , 7, 12758	41
1816	Recent Advances for Targeted Therapies in Glioblastoma. 2017 , 91-115	
1815	Spatially graded hydrogels for preclinical testing of glioblastoma anticancer therapeutics. 2017 , 7, 442-449	17
1814	Primary Pediatric Brain Tumors of the Posterior Fossa Part II: A Comprehensive Overview of Medulloblastoma. 2017 , 327-351	
1813	Comparison of Cellular Transforming Activity of OCT4, NANOG, and SOX2 in Immortalized Astrocytes. 2017 , 36, 1000-1009	6
1812	Cystic supratentorial mass in a middle-aged patient: MR imaging findings with histopathologic correlation. 2017 , 117, 909-913	1
1811	Analysis of human gliomas by swab touch spray-mass spectrometry: applications to intraoperative assessment of surgical margins and presence of oncometabolites. 2017 , 142, 4058-4066	27
1810	[Tumors of the inner ear and adjacent structures]. 2017 , 38, 521-528	
1809	Integrated Molecular Meta-Analysis of 1,000 Pediatric High-Grade and Diffuse Intrinsic Pontine Glioma. 2017 , 32, 520-537.e5	423
1808	TERT promoter mutation and its interaction with IDH mutations in glioma: Combined TERT promoter and IDH mutations stratifies lower-grade glioma into distinct survival subgroups-A meta-analysis of aggregate data. 2017 , 120, 1-9	34
1807	2016 Updates to the WHO Brain Tumor Classification System: What the Radiologist Needs to Know. 2017 , 37, 2164-2180	72
1806	Primary Astrocytic Tumours and Paired Recurrences have Similar Biological Features in IDH1, TP53 and TERTp Mutation and MGMT, ATRX Loss. 2017 , 7, 13038	4
1805	Patterns of care and outcomes for use of concurrent chemoradiotherapy over radiotherapy alone for anaplastic gliomas. 2017 , 125, 258-265	1
1804	Diffusion tensor image features predict IDH genotype in newly diagnosed WHO grade II/III gliomas. 2017 , 7, 13396	50

1803	Molecular and clinical heterogeneity of adult diffuse low-grade IDH wild-type gliomas: assessment of TERT promoter mutation and chromosome 7 and 10 copy number status allows superior prognostic stratification. <i>Acta Neuropathologica</i> , 2017 , 134, 957-959	14.3	61
1802	Current trends in mouse models of glioblastoma. 2017 , 135, 423-432		57
1801	Migfilin promotes migration and invasion in glioma by driving EGFR and MMP-2 signalings: A positive feedback loop regulation. 2017 , 44, 557-565		6
1800	Induction of synthetic lethality in IDH1-mutated gliomas through inhibition of Bcl-xL. 2017 , 8, 1067		73
1799	Altered metabolic landscape in IDH-mutant gliomas affects phospholipid, energy, and oxidative stress pathways. 2017 , 9, 1681-1695		71
1798	Paroxysmal dysphasia in a 68 year-old man: Enhancing the MRI spectrum!. 2017 , 8, 96-99		
1797	Usefulness of Reintervention in Recurrent Glioblastoma: An Indispensable Weapon for Increasing Survival. 2017 , 108, 610-617		16
1796	Immunotherapy with subcutaneous immunogenic autologous tumor lysate increases murine glioblastoma survival. 2017 , 7, 13902		12
1795	Comparison of F-FET PET and perfusion-weighted MRI for glioma grading: a hybrid PET/MR study. 2017 , 44, 2257-2265		41
1794	Incidence and survival trends for medulloblastomas in the United States from 2001 to 2013. 2017 , 135, 433-441		43
1793	miR-217-casein kinase-2 cross talk regulates ERK activation in ganglioglioma. 2017 , 95, 1215-1226		7
1792	Pharmacometabolomics Informs Quantitative Radiomics for Glioblastoma Diagnostic Innovation. 2017 , 21, 429-439		8
1791	Radiogenomics and Histomics in Glioblastoma: The Promise of Linking Image-Derived Phenotype with Genomic Information. 2017 , 143-159		2
1790	Updated 2016 WHO classification of tumors of the CNS: turning the corner where molecule meets pathology. 2017 , 34, 139-140		10
1789	Injectable nanomedicine hydrogel for local chemotherapy of glioblastoma after surgical resection. 2017 , 264, 45-54		76
1788	Ewing Sarcoma of the Cervical Epidural Space Presenting with Tetraplegia: Case Report and Review of Literature. 2017 , 107, 1046.e9-1046.e15		6
1787	Vasculogenesis and angiogenesis initiation under normoxic conditions through Wnt/ β catenin pathway in gliomas. 2018 , 29, 71-91		66
1786	Freiburg Neuropathology Case Conference : Cystic Posterior Fossa Tumor. 2017 , 27, 393-398		1

1785	Effect of Surgery, Adjuvant Therapy, and Other Prognostic Factors on Choroid Plexus Carcinoma: A Systematic Review and Individual Patient Data Analysis. 2017 , 99, 1199-1206	16
1784	Surgical Resection and Cellular Proliferation Index Predict Prognosis for Patients with Papillary Glioneuronal Tumor: Systematic Review and Pooled Analysis. 2017 , 107, 534-541	11
1783	Functional MRI for Surgery of Gliomas. 2017 , 19, 34	51
1782	High Expression of Glypican-1 Predicts Dissemination and Poor Prognosis in Glioblastomas. 2017 , 105, 282-288	38
1781	Modified rapid immunohistochemical staining for intraoperative diagnosis of malignant brain tumors. 2017 , 34, 141-148	2
1780	Histogram analysis of diffusion kurtosis imaging estimates for in vivo assessment of 2016 WHO glioma grades: A cross-sectional observational study. 2017 , 95, 202-211	17
1779	Clinical Application of Whole Genome Array Improves the Diagnosis of Pediatric Brain Tumors. 2017 , 25, 688-695	2
1778	Frequency and clinical significance of chromosome 7 and 10 aneuploidies, amplification of the EGFR gene, deletion of PTEN and TP53 genes, and 1p/19q deficiency in a sample of adult patients diagnosed with glioblastoma from Southern Brazil. 2017 , 135, 465-472	5
1777	Oncogenic role of cytomegalovirus in medulloblastoma?. 2017 , 408, 55-59	4
1776	Clinical, radiological, pathological and prognostic aspects of intraventricular oligodendroglioma: comparison with central neurocytoma. 2017 , 135, 57-65	2
1775	IDH mutation status trumps the Pignatti risk score as a prognostic marker in low-grade gliomas. 2017 , 135, 273-284	14
1774	Predicting clinical outcomes from large scale cancer genomic profiles with deep survival models. 2017 , 7, 11707	104
1773	GBM skin metastasis: a case report and review of the literature. 2017 ,	13
1772	Gene expression meta-analysis in diffuse low-grade glioma and the corresponding histological subtypes. 2017 , 7, 11741	16
1771	Spinal Cord Astrocytoma with Isocitrate Dehydrogenase 1 Gene Mutation. 2017 , 108, 991.e13-991.e16	14
1770	The 2016 WHO classification of central nervous system tumors: what neurologists need to know. 2017 , 30, 643-649	42
1769	Genetic Evolution of Glioblastoma Stem-Like Cells From Primary to Recurrent Tumor. 2017 , 35, 2218-2228	30
1768	Recursive partitioning analysis for disease progression in adult intracranial ependymoma patients. 2017 , 46, 72-78	2

1767	Atypical meningioma. A study on recurrence and disease-specific survival. 2017 , 63, 273-281	30
1766	Progression-Free Survival and Factors Associated with Postoperative Recurrence in 126 Patients with Atypical Intracranial Meningioma. 2017 , 107, 698-705	15
1765	Angiomatous Meningiomas Have a Very Benign Outcome Despite Frequent Peritumoral Edema at Onset. 2017 , 108, 465-473	12
1764	Anaplastic gliomas in adults: an update. 2017 , 29, 434-442	7
1763	Applications of high-resolution magic angle spinning MRS in biomedical studies II-Human diseases. 2017 , 30, e3784	23
1762	Epigenetics and Precision Oncology. 2017 , 23, 262-269	40
1761	Primary central nervous system lymphoma: time for diagnostic biomarkers and biotherapies?. 2017 , 30, 669-676	10
1760	New prognostic factor telomerase reverse transcriptase promotor mutation presents without MR imaging biomarkers in primary glioblastoma. 2017 , 59, 1223-1231	9
1759	Identification and targeting of an FGFR fusion in a pediatric thalamic "central oligodendroglioma". 2017 , 1, 29	5
1758	Molecular Pathology of Glioblastoma- An Update. 2017 , 19-55	
1757	Epidemiology of glioma: clinical characteristics, symptoms, and predictors of glioma patients grade I-IV in the the Danish Neuro-Oncology Registry. 2017 , 135, 571-579	121
1756	Rapid and accurate intraoperative pathological diagnosis by artificial intelligence with deep learning technology. 2017 , 107, 98-99	11
1755	An Unusual Combination of Mirror-Image Dextrocardia with Familial Medulloblastoma: Is There a Histogenetic Relationship?. 2017 , 107, 860-867	
1754	Pseudoprogression after glioma therapy: an update. 2017 , 17, 1109-1115	32
1753	Imaging correlates for the 2016 update on WHO classification of grade II/III gliomas: implications for IDH, 1p/19q and ATRX status. 2017 , 135, 601-609	54
1752	[Critical consideration of the European Association for Neuro-Oncology (EANO) guideline on the diagnosis and treatment of adult astrocytic and oligodendroglial gliomas]. 2017 , 193, 984-988	1
1751	Predicting IDH mutation status in grade II gliomas using amide proton transfer-weighted (APT _w) MRI. 2017 , 78, 1100-1109	81
1750	The whole-genome landscape of medulloblastoma subtypes. 2017 , 547, 311-317	472

1749	Imaging Correlates of Adult Glioma Genotypes. 2017 , 284, 316-331	93
1748	Inhibition of Heparanase in Pediatric Brain Tumor Cells Attenuates their Proliferation, Invasive Capacity, and Tumor Growth. 2017 , 16, 1705-1716	28
1747	Rethinking childhood ependymoma: a retrospective, multi-center analysis reveals poor long-term overall survival. 2017 , 135, 201-211	54
1746	Glioblastoma cellular cross-talk converges on NF- κ B to attenuate EGFR inhibitor sensitivity. 2017 , 31, 1212-1227	38
1745	MicroRNAs as Multifaceted Players in Glioblastoma Multiforme. 2017 , 333, 269-323	16
1744	HGNET-BCOR Tumors of the Cerebellum: Clinicopathologic and Molecular Characterization of 3 Cases. 2017 , 41, 1254-1260	29
1743	A PML/Slit Axis Controls Physiological Cell Migration and Cancer Invasion in the CNS. 2017 , 20, 411-426	27
1742	Assessment of molecular markers demonstrates concordance between samples acquired via stereotactic biopsy and open craniotomy in both anaplastic astrocytomas and glioblastomas. 2017 , 133, 399-407	5
1741	Descriptive epidemiology of primary malignant and non-malignant central nervous tumors in Spain: Results from the Girona Cancer Registry (1994-2013). 2017 , 50, 1-8	19
1740	Letter: A Role for Wild-Type Isocitrate Dehydrogenase 1 in Gliomagenesis. 2017 , 81, E56-E57	
1739	Genetic changes of MLH1 and MSH2 genes could explain constant findings on microsatellite instability in intracranial meningioma. 2017 , 39, 1010428317705791	5
1738	Immunohistochemical analysis of H3K27me3 demonstrates global reduction in group-A childhood posterior fossa ependymoma and is a powerful predictor of outcome. <i>Acta Neuropathologica</i> , 2017 , 134, 705-714	14.3 114
1737	Animal Models in Glioblastoma: Use in Biology and Developing Therapeutic Strategies. 2017 , 219-240	4
1736	Diffusion tensor tractography in the preoperative precise identification of the course of facial nerve in a meningioma of the cerebellopontine angle □ Technical implications. 2017 , 9, 58-60	1
1735	EVALUACI3N DE GLIOMAS POR T3CNICAS AVANZADAS DE RESONANCIA MAGN3TICA. 2017 , 28, 360-377	
1734	Meningeal haemangiopericytoma and solitary fibrous tumour: a retrospective bi centre study for outcome and prognostic factor assessment. 2017 , 134, 387-395	6
1733	Imaging features of intracranial psammomatous meningioma. 2017 , 44, 395-399	5
1732	Characterization of PD-1 upregulation on tumor-infiltrating lymphocytes in human and murine gliomas and preclinical therapeutic blockade. 2017 , 141, 1891-1900	20

1731	[Recommendations for the organ donation from patients with brain or medullary primitive tumors on behalf of the Association of the Neuro-oncologists of French Expression (ANOCEF) and the Club of Neuro-oncology of the French Society of Neurosurgery]. 2017 , 104, 771-788	
1730	[Anterior skull-base schwannoma]. 2017 , 28, 298-305	3
1729	CLINICAL RELEVANCE OF MOLECULAR MARKERS IN GLIOMAS. 2017 , 28, 343-351	5
1728	Recurrent Pituicytoma with Pseudoaneurysm: Report of a Challenging Case. 2017 , 105, 1043.e1-1043.e5	7
1727	Procarbazine, lomustine and vincristine for recurrent high-grade glioma. 2017 , 7, CD011773	16
1726	Tumor Purity as an Underlying Key Factor in Glioma. 2017 , 23, 6279-6291	170
1725	Pathophysiology of Meningioma Growth in Pregnancy. 2017 , 12, 195-200	25
1724	Pseudoprogression in pediatric low-grade glioma after irradiation. 2017 , 135, 371-379	14
1723	Volumetric quantification of glioblastoma: experiences with different measurement techniques and impact on survival. 2017 , 135, 391-402	29
1722	T2-FLAIR Mismatch, an Imaging Biomarker for IDH and 1p/19q Status in Lower-grade Gliomas: A TCGA/TCIA Project. 2017 , 23, 6078-6085	157
1721	Detection of the alternative lengthening of telomeres pathway in malignant gliomas for improved molecular diagnosis. 2017 , 135, 381-390	14
1720	Molecular Basis of Pediatric Brain Tumors. 2017 , 19, 256-270	9
1719	Hypomethylation of CNTFRs associated with proliferation and poor prognosis in lower grade gliomas. 2017 , 7, 7079	7
1718	Early changes in glioblastoma metabolism measured by MR spectroscopic imaging during combination of anti-angiogenic cediranib and chemoradiation therapy are associated with survival. 2017 , 1,	8
1717	Management of glioblastoma in elderly patients. 2017 , 380, 250-255	29
1716	Phosphorylated mTOR and YAP serve as prognostic markers and therapeutic targets in gliomas. 2017 , 97, 1354-1363	23
1715	Natural history of lesions with the MR imaging appearance of multinodular and vacuolating neuronal tumor. 2017 , 59, 873-883	27
1714	Non-canonical IDH1 and IDH2 mutations: a clonal and relevant event in an Italian cohort of gliomas classified according to the 2016 World Health Organization (WHO) criteria. 2017 , 135, 245-254	16

1713	Evaluating the potential of circulating hTERT levels in glioma: can plasma levels serve as an independent prognostic marker?. 2017 , 135, 255-261	4
1712	Outcomes and patterns of care in a nationwide cohort of pediatric medulloblastoma: Factors affecting proton therapy utilization. 2017 , 2, 588-596	9
1711	Putting the new ILAE classification of focal cortical dysplasia into practice in western China. 2017 , 51, 133-138	1
1710	Methods for molecular imaging of brain tumours in a hybrid MR-PET context: Water content, T ₂ diffusion indices and FET-PET. 2017 , 130, 135-151	7
1709	Grading and outcome prediction of pediatric diffuse astrocytic tumors with diffusion and arterial spin labeling perfusion MRI in comparison with 18F-DOPA PET. 2017 , 44, 2084-2093	37
1708	The Prognostic Impact of Ventricular Opening in Glioblastoma Surgery: A Retrospective Single Center Analysis. 2017 , 106, 615-624	13
1707	Probing the phosphatidylinositol 3-kinase/mammalian target of rapamycin pathway in gliomas: A phase 2 study of everolimus for recurrent adult low-grade gliomas. 2017 , 123, 4631-4639	24
1706	[Bilateral hippocampal primary CNS lymphoma: unusual differential diagnosis of rapid progressive dementia]. 2017 , 85, 410-413	
1705	[Pediatric brain tumors]. 2017 , 57, 728-739	1
1704	Stereotactic biopsy in elderly patients: risk assessment and impact on treatment decision. 2017 , 134, 303-307	9
1703	Long-term outcomes of concomitant chemoradiotherapy with temozolomide for newly diagnosed glioblastoma patients: A single-center analysis. 2017 , 96, e7422	32
1702	Loss of CDKN1C in a Recurrent Atypical Teratoid/Rhabdoid Tumor. 2017 , 39, e466-e469	0
1701	Cell Signaling Pathways in Brain Tumors. 2017 , 26, 15-26	3
1700	Gliosarcomas with the V600E mutation: a report of two cases and review of the literature. 2017 , 70, 1079-1083	10
1699	Topotecan is a potent inhibitor of SUMOylation in glioblastoma multiforme and alters both cellular replication and metabolic programming. 2017 , 7, 7425	18
1698	Correlation of volumetric growth and histological grade in 50 meningiomas. 2017 , 159, 2169-2177	16
1697	Positron emission tomography imaging in gliomas: applications in clinical diagnosis, for assessment of prognosis and of treatment effects, and for detection of recurrences. 2017 , 24, 1255-e70	6
1696	miR-216b inhibits glioma cell migration and invasion through suppression of FoxM1. 2017 , 38, 1751-1759	15

1695	Seeding of Abdomen with Primary Intracranial Hemangiopericytoma by Ventriculoperitoneal Shunt: Case Report. 2017 , 107, 1048.e7-1048.e14	4
1694	CRAF gene fusions in pediatric low-grade gliomas define a distinct drug response based on dimerization profiles. 2017 , 36, 6348-6358	39
1693	Neural Precursor-Derived Pleiotrophin Mediates Subventricular Zone Invasion by Glioma. 2017 , 170, 845-859.e19	98
1692	Imaging Biomarkers for Adult Medulloblastomas: Genetic Entities May Be Identified by Their MR Imaging Radiophenotype. 2017 , 38, 1892-1898	17
1691	Analysis of health-related quality of life in patients with brain tumors prior and subsequent to radiotherapy. 2017 , 14, 1841-1846	16
1690	Radiation-induced gliomas: a report of four cases and analysis of molecular biomarkers. 2017 , 34, 149-154	9
1689	Recent Advances in the Classification and Treatment of Ependymomas. 2017 , 18, 55	16
1688	Immunohistochemical Characterization and Sensitivity to Human Adenovirus Serotypes 3, 5, and 11p of New Cell Lines Derived from Human Diffuse Grade II to IV Gliomas. 2017 , 10, 772-779	4
1687	A new diagnostic marker for differentiating multicentric gliomas from multiple intracranial diffuse large B-cell lymphomas on 18F-FDG PET images. 2017 , 96, e7756	5
1686	Time-sequenced drug delivery approaches towards effective chemotherapeutic treatment of glioma. 2017 , 4, 977-996	11
1685	Phosphatases and solid tumors: focus on glioblastoma initiation, progression and recurrences. 2017 , 474, 2903-2924	8
1684	[Alterations in the WHO classification of brain tumors from 2016]. 2017 , 57, 701-706	2
1683	Grading of diffuse astrocytic gliomas: Broders, Kernohan, Zlitch, the WHO and Shakespeare. <i>Acta Neuropathologica</i> , 2017 , 134, 517-520	14-3 9
1682	Glioblastoma entities express subtle differences in molecular composition and response to treatment. 2017 , 38, 1341-1352	14
1681	miR-29a/b/c function as invasion suppressors for gliomas by targeting CDC42 and predict the prognosis of patients. 2017 , 117, 1036-1047	36
1680	Prognostic and predictive factors in high-grade gliomas. Experience at our institution. 2017 , 28, 276-283	1
1679	In Reply to the Letter to the Editor "Circumventricular Organ Origin of Hemangioblastoma; Hypothesis for Pathogenesis of Disease". 2017 , 108, 983-984	
1678	The Updated World Health Organization Glioma Classification: Cellular and Molecular Origins of Adult Infiltrating Gliomas. 2017 , 141, 1633-1645	24

1677	Strategy for automated metabolic profiling of glioma subtypes from ex-vivo HRMAS spectra. 2017 , 13, 1	3
1676	From Prognostication to Personalized Medicine: Classification of Tumors of the Central Nervous System (CNS) Using Chromosomal Microarrays. 2017 , 5, 117-124	2
1675	GPR56/ADGRG1 Inhibits Mesenchymal Differentiation and Radioresistance in Glioblastoma. 2017 , 21, 2183-2197	41
1674	Impact on Radiation Dose and Volume V57 Gy of the Brain on Recurrence and Survival of Patients with Glioblastoma Multiformae. 2017 , 51, 463-468	
1673	Rare Brain Tumor in a Neonate. 2017 , 25, 240-243	2
1672	5-Aminolevulinic Acid Guided Sampling of Glioblastoma Microenvironments Identifies Pro-Survival Signaling at Infiltrative Margins. 2017 , 7, 15593	12
1671	Developing chemotherapy for diffuse pontine intrinsic gliomas (DIPG). 2017 , 120, 111-119	25
1670	Fine-Needle Aspiration of Metastatic Central Type Primitive Neuroectodermal Tumors in Patients with a Germ Cell Tumor. 2017 , 61, 409-417	
1669	The biology and mathematical modelling of glioma invasion: a review. 2017 , 14,	98
1668	NCCN Guidelines Insights: Central Nervous System Cancers, Version 1.2017. 2017 , 15, 1331-1345	106
1667	From bench to clinical trials the EORTC experience in biology-based clinical cancer research. 2017 , 29, 171-176	
1666	PDGF Family Expression in Glioblastoma Multiforme: Data Compilation from Ivy Glioblastoma Atlas Project Database. 2017 , 7, 15271	34
1665	Overexpression of cytosolic, plasma membrane bound and extracellular heat shock protein 70 (Hsp70) in primary glioblastomas. 2017 , 135, 443-452	21
1664	Neuronal activity in the glioma microenvironment. 2017 , 47, 156-161	24
1663	Effects of syndecan-1 on the expression of syntenin and the migration of U251 glioma cells. 2017 , 14, 7217-7224	7
1662	Survival and complications of stereotactic radiosurgery: A systematic review of stereotactic radiosurgery for newly diagnosed and recurrent high-grade gliomas. 2017 , 96, e8293	27
1661	Intraoperative imaging technology to maximise extent of resection for glioma. 2017 ,	6
1660	[Prognostic and predictive factors in high-grade gliomas. Experience at our institution]. 2017 , 28, 276-283	5

1659	Chronic subdural hematoma in aging population - How the age influence the outcome after surgical treatment:. 2017 , 2, 239-240	
1658	The frequency of MINS (Myocardial Injury after Noncardiac Surgery) and others postoperative complications in different age groups of elderly patients who underwent endovascular aortic repair because of abdominal aortic aneurysm:. 2017 , 2, 240	0
1657	Evaluation of clinical characteristics as indicators for shunt procedure in patients with medulloblastoma:. 2017 , 2, 240-241	0
1656	Comparative assessment of three methods to analyze MGMT methylation status in a series of 350 gliomas and gangliogliomas. 2017 , 213, 1489-1493	16
1655	Characterization of Metabolic, Diffusion, and Perfusion Properties in GBM: Contrast-Enhancing versus Non-Enhancing Tumor. 2017 , 10, 895-903	9
1654	HIF-1 β Targeting Acriflavine Provides Long Term Survival and Radiological Tumor Response in Brain Cancer Therapy. 2017 , 7, 14978	38
1653	Neonates with cancer and causes of death; lessons from 615 cases in the SEER databases. 2017 , 6, 1817-1826	19
1652	Association between epidermal growth factor receptor amplification and ADP-ribosylation factor 1 methylation in human glioblastoma. 2017 , 40, 389-399	8
1651	Medulloblastoma with tri-vergent melanocytic, myogenic and cartiligious elements. 2017 , 41, 100-103	1
1650	The role of prophylactic antiepileptic drugs for seizure prophylaxis in meningioma surgery: A systematic review. 2017 , 43, 47-53	13
1649	Fluorescence Lifetime Imaging Microscopy, a Novel Diagnostic Tool for Metastatic Cell Detection in the Cerebrospinal Fluid of Children with Medulloblastoma. 2017 , 7, 3648	15
1648	Detailed magnetic resonance imaging features of a case series of primary gliosarcoma. 2017 , 30, 546-553	13
1647	The clinical features and surgical outcomes of intracranial tanycytic ependymomas: a single-institutional experience. 2017 , 134, 339-347	3
1646	The Expression of Connexins and SOX2 Reflects the Plasticity of Glioma Stem-Like Cells. 2017 , 10, 555-569	13
1645	Medical laboratory scientist: a new partner in biomarker research. 2017 , 14, 285-291	0
1644	Players of 'hypoxia orchestra' - what is the role of FMISO?. 2017 , 44, 1679-1681	5
1643	Epilepsieassoziierte Tumoren im Kontext der aktualisierten WHO-Klassifikation für Tumoren des Zentralnervensystems 2016. 2017 , 30, 192-199	
1642	Correlation of higher levels of soluble TNF-R1 with a shorter survival, independent of age, in recurrent glioblastoma. 2017 , 131, 449-458	5

1641	Evaluation of human glioma using in-vivo proton magnetic resonance spectroscopy combined with expression of cyclooxygenase-2: a preliminary clinical trial. 2017 , 28, 414-420	1
1640	Multinodular and Vacuolating Neuronal Tumor of the Cerebrum: A New "Leave Me Alone" Lesion with a Characteristic Imaging Pattern. 2017 , 38, 1899-1904	50
1639	Expression of CD70 (CD27L) Is Associated With Epithelioid and Sarcomatous Features in IDH-Wild-Type Glioblastoma. 2017 , 76, 697-708	11
1638	Characterization of gliomas: from morphology to molecules. 2017 , 471, 257-269	57
1637	Relationship among clinical, pathological and bio-molecular features in low-grade epilepsy-associated neuroepithelial tumors. 2017 , 44, 158-163	6
1636	Postoperative neoadjuvant temozolomide before radiotherapy versus standard radiotherapy in patients 60 years or younger with anaplastic astrocytoma or glioblastoma: a randomized trial. 2017 , 56, 1776-1785	11
1635	Cancer Screening Recommendations and Clinical Management of Inherited Gastrointestinal Cancer Syndromes in Childhood. 2017 , 23, e107-e114	62
1634	Clinical, Radiologic, and Pathologic Features of 56 Cases of Intracranial Lymphoplasmacyte-Rich Meningioma. 2017 , 106, 152-164	7
1633	Effects of anticancer drugs on glioma brain tumor model characterized by acoustic impedance microscopy. 2017 , 56, 07JF15	10
1632	Surgical Considerations in the Optimal Management of Patients with Malignant Brain Tumors. 2017 , 18, 46	4
1631	Pharmacotherapy of Glioblastoma: Established Treatments and Emerging Concepts. 2017 , 31, 675-684	19
1630	Chemotherapy for Diffuse Low Grade Gliomas. 2017 , 535-577	
1629	Radiation Therapy in the Treatment of Low Grade Gliomas. 2017 , 579-594	
1628	Pediatric High Grade Glioma. 2017 , 241-266	1
1627	Next-Generation Sequencing in Glioblastoma Personalized Therapy. 2017 , 161-190	1
1626	Atypical choroid plexus papilloma: spontaneous resolution of diffuse leptomeningeal contrast enhancement after primary tumor removal in 2 pediatric cases. 2017 , 20, 284-288	6
1625	Gliomklassifikation: Genetik schließt Histologie. 2017 , 19, 50-50	
1624	Pediatric Medulloblastoma: a Case of Recurrent Disease and Resiliency. 2017 , 3, 136-155	

1623	Analysis of Prognostic Factors, Survival Rates, and Treatment in Anaplastic Hemangiopericytoma. 2017 , 104, 795-801	6
1622	Neue WHO-Klassifikation der Hirntumoren und Folgen für die neurologische Therapie. 2017 , 19, 46-54	
1621	KLF4 is a tumor suppressor in anaplastic meningioma stem-like cells and human meningiomas. 2017 , 9, 315-324	23
1620	Durable Control of Metastatic AKT1-Mutant WHO Grade 1 Meningothelial Meningioma by the AKT Inhibitor, AZD5363. 2017 , 109, 1-4	31
1619	Cost-effectiveness of IDH testing in diffuse gliomas according to the 2016 WHO classification of tumors of the central nervous system recommendations. 2017 , 19, 1640-1650	36
1618	The allosteric AKT inhibitor MK2206 shows a synergistic interaction with chemotherapy and radiotherapy in glioblastoma spheroid cultures. 2017 , 17, 204	35
1617	Cerebellar ependymoma with overlapping features of clear-cell and tanycytic variants mimicking hemangioblastoma: a case report and literature review. 2017 , 12, 28	5
1616	Helical tomotherapy of spinal chordomas: French Multicentric, retrospective study of a cohort of 30 cases. 2017 , 12, 32	1
1615	The 150 most important questions in cancer research and clinical oncology series: questions 31-39 : Edited by Chinese Journal of Cancer. 2017 , 36, 48	3
1614	Advances in Biology and Treatment of Glioblastoma. 2017 ,	
1613	[Intra-axial brain tumors in adults : On the basis of the 2016 WHO classification]. 2017 , 57, 707-714	
1612	Positive influence of partial resection on overall survival of patients with overlapping glioblastomas. 2017 , 161, 22-28	1
1611	Early experience with formalin-fixed paraffin-embedded (FFPE) based commercial clinical genomic profiling of gliomas-robust and informative with caveats. 2017 , 103, 87-93	7
1610	Computer-aided grading of gliomas based on local and global MRI features. 2017 , 139, 31-38	51
1609	Classification of adult diffuse gliomas by molecular markers-a short review with historical footnote. 2017 , 47, 2-6	5
1608	Imaging and Diagnosis in Pediatric Brain Tumor Studies. 2017 ,	5
1607	Prediction of genetic subgroups in adult supra tentorial gliomas by pre- and intraoperative parameters. 2017 , 131, 403-412	15
1606	Angiocentric Glioma in an Elderly Patient: Case Report and Review of the Literature. 2017 , 97, 755.e5-755.e10	8

1605	cIMPACT-NOW (the consortium to inform molecular and practical approaches to CNS tumor taxonomy): a new initiative in advancing nervous system tumor classification. 2017 , 27, 851-852	36
1604	The current consensus on the clinical management of intracranial ependymoma and its distinct molecular variants. <i>Acta Neuropathologica</i> , 2017 , 133, 5-12	14.3 202
1603	Epidemiology for primary brain tumors: a nationwide population-based study. 2017 , 131, 525-546	56
1602	Longitudinal experience with WHO Grade III (anaplastic) meningiomas at a single institution. 2017 , 131, 555-563	24
1601	The effects of CD147 on the cell proliferation, apoptosis, invasion, and angiogenesis in glioma. 2017 , 38, 129-136	14
1600	Quantitative Diffusion Tensor Imaging Analysis of Low-Grade Gliomas: From Preclinical Application to Patient Care. 2017 , 97, 333-343	11
1599	Cranial Pilocytic Astrocytoma With Spinal Drop Metastasis in an Adult: Case Report and Literature Review. 2017 , 98, 883.e7-883.e12	5
1598	The Unexpected Roles of Aurora A Kinase in Glioblastoma Recurrences. 2017 , 12, 11-18	9
1597	Genetic alterations related to BRAF-FGFR genes and dysregulated MAPK/ERK/mTOR signaling in adult pilocytic astrocytoma. 2017 , 27, 580-589	19
1596	Role of STAT3 in Genesis and Progression of Human Malignant Gliomas. 2017 , 54, 5780-5797	35
1595	Intracranial Clear Cell Meningiomas: Study on Clinical Features and Predictors of Recurrence. 2017 , 97, 693-700.e11	12
1594	HSP47 Promotes Glioblastoma Stemlike Cell Survival by Modulating Tumor Microenvironment Extracellular Matrix through TGF- β Pathway. 2017 , 8, 128-134	26
1593	Molecular pathology of paediatric central nervous system tumours. 2017 , 241, 159-172	45
1592	Perioperative Risk Assessment of Patients with Gliomatosis Cerebri. 2017 , 98, 334-338	5
1591	Evaluation parameters between intra-voxel incoherent motion and diffusion-weighted imaging in grading and differentiating histological subtypes of meningioma: A prospective pilot study. 2017 , 372, 60-69	18
1590	Posterior Fossa Tumors. 2017 , 27, 1-37	51
1589	Supratentorial Tumors in Pediatric Patients. 2017 , 27, 39-67	16
1588	Brain Tumors in the Neonate. 2017 , 27, 69-83	7

1587	Current therapy and the evolving molecular landscape of paediatric ependymoma. 2017 , 70, 34-41	50
1586	Agents for fluorescence-guided glioma surgery: a systematic review of preclinical and clinical results. 2017 , 159, 151-167	76
1585	Survey on current practice within the European Low-Grade Glioma Network: where do we stand and what is the next step?. 2017 , 4, 241-247	11
1584	Chordoid Glioma of the Third Ventricle, a Rare Tumor with an Unexpected Outcome. 2017 , 36, 32-37	
1583	Meningiomas with different histological grade in the same patient: Case report. 2017 , 96, e9086	3
1582	IDH1 Mutation and World Health Organization 2016 Diagnostic Criteria for Adult Diffuse Gliomas: Advances in Surgical Strategy. 2017 , 64, 134-138	20
1581	IDH mutation testing in gliomas-where do we draw the line?. 2017 , 19, 1568-1569	1
1580	P4HB and PDIA3 are associated with tumor progression and therapeutic outcome of diffuse gliomas. 2018 , 39, 501-510	34
1579	Primary intramedullary primitive neuroectodermal tumor: A case report and review of the literature. 2017 , 96, e9001	4
1578	Expression profile and clinical significance of Wnt signaling in human gliomas. 2018 , 15, 610-617	10
1577	Circumventricular Organ Origin of Hemangioblastoma; Hypothesis for Pathogenesis of Disease. 2017 , 108, 980	
1576	SIOP PODC Adapted treatment guidelines for low grade gliomas in low and middle income settings. 2017 , 64 Suppl 5, e26737	14
1575	A high F-FDOPA uptake is associated with a slow growth rate in diffuse Grade II-III gliomas. 2018 , 91, 20170803	14
1574	BCAT1 is a New MR Imaging-related Biomarker for Prognosis Prediction in IDH1-wildtype Glioblastoma Patients. 2017 , 7, 17740	13
1573	Daam1 activates RhoA to regulate Wnt5a-induced glioblastoma cell invasion. 2018 , 39, 465-472	17
1572	Friday 20 October 2017. 2017 , 61, 29-71	1
1571	Tumeurs cérébrales Session 4. 2017 , 41, 358-361	
1570	Seltene Tumordispositionssyndrome mit Manifestation im Kindesalter. 2017 , 29, 283-295	2

1569	Rare case of subependymal giant cell astrocytoma without clinical features of tuberous sclerosis: Case report and literature review. 2017 , 1, 108-112	5
1568	The 2016 WHO Classification of Tumours of the Central Nervous System: The Major Points of Revision. 2017 , 57, 301-311	134
1567	A sophisticated convolutional neural network model for brain tumor classification. 2017 ,	15
1566	Single-Agent Carboplatin for a Rare Case of Pilomyxoid Astrocytoma of the Spinal Cord in an Adult with Neurofibromatosis Type 1. 2016 , 9, 568-573	3
1565	1q/19p co-polysomy predicts longer survival in patients with astrocytic gliomas. 2017 , 8, 67104-67116	1
1564	Subependymal giant cell astrocytomas in Tuberous Sclerosis Complex have consistent biallelic inactivation, and no mutations. 2017 , 8, 95516-95529	34
1563	A Simplified Overview of World Health Organization Classification Update of Central Nervous System Tumors 2016. 2017 , 8, 629-641	65
1562	Aging and Neurological Diseases. 2017 ,	7
1561	Butterfly Tumor of the Corpus Callosum: Clinical Characteristics, Diagnosis, and Survival Analysis. 2017 , 8, S57-S65	8
1560	Epigenetic silencing of XAF1 in high-grade gliomas is associated with IDH1 status and improved clinical outcome. 2017 , 8, 15071-15084	10
1559	Circulating microRNAs as emerging non-invasive biomarkers for gliomas. 2017 , 5, 277	26
1558	Correlation between molecular features and genetic subtypes of Glioblastoma: critical analysis in 109 cases. 2017 , 4,	4
1557	Assessment of Anti-Proliferative Activities of Selected Medicinal Plant Extracts Used for Management of Diseases around Lake Victoria Basin. 2017 , 08,	2
1556	Beyond Alkylating Agents for Gliomas: Quo Vadimus?. 2017 , 37, 175-186	6
1555	Practice-Changing Abstracts From the 2016 Society for Neuro-Oncology Annual Scientific Meeting. 2017 , 37, 187-191	1
1554	Sellar and Suprasellar Granular Cell Tumor of Neurohypophysis. 2017 , 130, 741-743	10
1553	Atypical Suprasellar Neurocytoma in a 31-Month-Old Child: A Case Report. 2017 , 15, 080-083	
1552	Giant meningioma in skull radiograph. 2017 , 2017,	1

1551	Metastatic meningioma: a rare cause of mediastinal lymphadenopathy. 2017 , 2017,	1
1550	DNA sequences within glioma-derived extracellular vesicles can cross the intact blood-brain barrier and be detected in peripheral blood of patients. 2017 , 8, 1416-1428	119
1549	Targeted Nanotechnology in Glioblastoma Multiforme. 2017 , 8, 166	79
1548	Expression of Cathepsins B, D, and G in Isocitrate Dehydrogenase-Wildtype Glioblastoma. 2017 , 4, 28	28
1547	Computed Tomography and Magnetic Resonance Imaging Are Equivalent in Mensuration and Similarly Inaccurate in Grade and Type Predictability of Canine Intracranial Gliomas. 2017 , 4, 157	10
1546	Atypical bilateral cerebellopontine angle medulloblastoma: differential diagnosis, immunohistochemical features and radiological presentation. 2017 , 21, 249-253	
1545	Targeting immune checkpoints in malignant glioma. 2017 , 8, 7157-7174	36
1544	Nanotechnologies for brain tumor therapy. 2017 , 171-190	1
1543	Long non-coding RNA PAR5 inhibits the proliferation and progression of glioma through interaction with EZH2. 2017 , 38, 3177-3186	16
1542	Overexpression of mitochondrial serine hydroxyl-methyltransferase 2 is associated with poor prognosis and promotes cell proliferation and invasion in gliomas. 2017 , 10, 3781-3788	17
1541	Metabotropic glutamate receptors as a new therapeutic target for malignant gliomas. 2017 , 8, 22279-22298	28
1540	Aptamers and Glioblastoma: Their Potential Use for Imaging and Therapeutic Applications. 2017 , 18,	23
1539	Molecular and Genetic Determinants of Glioma Cell Invasion. 2017 , 18,	20
1538	Major Challenges and Potential Microenvironment-Targeted Therapies in Glioblastoma. 2017 , 18,	21
1537	Magnetic Resonance Spectroscopy for Detection of 2-Hydroxyglutarate as a Biomarker for IDH Mutation in Gliomas. 2017 , 7,	34
1536	Neuro-Coagulopathy: Blood Coagulation Factors in Central Nervous System Diseases. 2017 , 18,	48
1535	Zebrafish in Translational Cancer Research: Insight into Leukemia, Melanoma, Glioma and Endocrine Tumor Biology. 2017 , 8,	29
1534	Clinical Applications of Contrast-Enhanced Perfusion MRI Techniques in Gliomas: Recent Advances and Current Challenges. 2017 , 2017, 7064120	56

1533	Adjuvant treatments for ependymomas. 2018 , 62, 71-77	4
1532	Generation and Performance of R132H Mutant IDH1 Rabbit Monoclonal Antibody. 2017 , 6,	7
1531	Towards Targeting PI3K-Dependent Regulation of Gene Expression in Brain Cancer. 2017 , 9,	20
1530	The Role of miRNAs in Angiogenesis, Invasion and Metabolism and Their Therapeutic Implications in Gliomas. 2017 , 9,	37
1529	Role and Therapeutic Targeting of the HGF/MET Pathway in Glioblastoma. 2017 , 9,	38
1528	The Role of Hypoxia in Glioblastoma Invasion. 2017 , 6,	132
1527	Modeling and Targeting MYC Genes in Childhood Brain Tumors. 2017 , 8,	15
1526	Epigenetic Regulation of Telomere Maintenance for Therapeutic Interventions in Gliomas. 2017 , 8,	19
1525	RECQ1 Helicase Silencing Decreases the Tumour Growth Rate of U87 Glioblastoma Cell Xenografts in Zebrafish Embryos. 2017 , 8,	10
1524	EGFR and EGFRvIII Promote Angiogenesis and Cell Invasion in Glioblastoma: Combination Therapies for an Effective Treatment. 2017 , 18,	66
1523	Molecular Markers of Gliomas. 2017 , 32, 180-190	1
1522	Downregulation of mitochondrial UQCRB inhibits cancer stem cell-like properties in glioblastoma. 2018 , 52, 241-251	8
1521	[Central neurocytomas: clinical and radiopathological correlations: about 12 cases]. 2017 , 27, 222	
1520	Novel Therapy for Glioblastoma Multiforme by Restoring LRR4 in Tumor Cells: LRR4 Inhibits Tumor-Infiltrating Regulatory T Cells by Cytokine and Programmed Cell Death 1-Containing Exosomes. 2017 , 8, 1748	20
1519	Biomimetic Strategies for the Glioblastoma Microenvironment. 2017 , 4,	14
1518	Analysis of DTI-Derived Tensor Metrics in Differential Diagnosis between Low-grade and High-grade Gliomas. 2017 , 9, 271	10
1517	Improved Pathologic Diagnosis-Forecasting the Future in Glioblastoma. 2017 , 8, 707	3
1516	Redox-Related Epigenetic Mechanisms in Glioblastoma: Nuclear Factor (Erythroid-Derived 2)-Like 2, Cobalamin, and Dopamine Receptor Subtype 4. 2017 , 7, 46	7

1515	Genomic Insights into Diffuse Intrinsic Pontine Glioma. 2017 , 7, 57	40
1514	Gliomatosis Cerebri: Current Understanding and Controversies. 2017 , 7, 165	20
1513	The Role of ATRX in Glioma Biology. 2017 , 7, 236	44
1512	Lipomatous/Extensively Vacuolated Ependymoma with Signet-Ring Cell-Like Appearance: Analysis of a Case with Extensive Literature Review. 2017 , 2017, 8617050	0
1511	Expression Levels and Localizations of DVL3 and sFRP3 in Glioblastoma. 2017 , 2017, 9253495	9
1510	The Temporal Pattern of a Lesion Modulates the Functional Network Topology of Remote Brain Regions. 2017 , 2017, 3530723	8
1509	MicroRNA in Glioblastoma: An Overview. 2017 , 2017, 7639084	83
1508	Amplification and Mutations in Glioblastoma Patients of the Northeast of Morocco. 2017 , 2017, 8045859	9
1507	Proliferative and Invasive Effects of Progesterone-Induced Blocking Factor in Human Glioblastoma Cells. 2017 , 2017, 1295087	15
1506	MRI in Glioma Immunotherapy: Evidence, Pitfalls, and Perspectives. 2017 , 2017, 5813951	42
1505	The Identification of Key Genes and Pathways in Glioma by Bioinformatics Analysis. 2017 , 2017, 1278081	24
1504	Diagnostic and Therapeutic Biomarkers in Glioblastoma: Current Status and Future Perspectives. 2017 , 2017, 8013575	159
1503	Study on the Role of Doubling Time Heterogeneity among Primary Glioblastoma Cell Lines. 2017 , 2017, 8569328	20
1502	Brain Tumors. 2017 , 319-344	
1501	Synergistic regulatory effects of microRNAs on brain glioma cells. 2017 , 16, 1409-1416	5
1500	IDH1 R132H Mutation Is Accompanied with Malignant Progression of Paired Primary-Recurrent Astrocytic Tumours. 2017 , 8, 2704-2712	8
1499	Advances in Genomics Explain Medulloblastoma Behavior at the Bedside. 2017 , 64, 21-26	5
1498	Human menstrual blood-derived mesenchymal stem cells as a cellular vehicle for malignant glioma gene therapy. 2017 , 8, 58309-58321	15

1497	Diffuse Midline Gliomas Harboring the H3 K27M-Mutation in the Bilateral Thalamus and Midbrain: A Case Report and a Review of the Literature. 2017 , 77, 416	2
1496	Radiologic characteristics of ependymomas: a case-based approach. 2018 , 62, 38-45	1
1495	Advances in Molecular Imaging of Locally Delivered Targeted Therapeutics for Central Nervous System Tumors. 2017 , 18,	14
1494	Effect of a computer-aided diagnosis system on radiologists' performance in grading gliomas with MRI. 2017 , 12, e0171342	10
1493	Integrating Tenascin-C protein expression and 1q25 copy number status in pediatric intracranial ependymoma prognostication: A new model for risk stratification. 2017 , 12, e0178351	10
1492	A mathematical model describes the malignant transformation of low grade gliomas: Prognostic implications. 2017 , 12, e0179999	18
1491	The anti-apoptotic protein survivin can improve the prognostication of meningioma patients. 2017 , 12, e0185217	2
1490	Neuroonkologische Zentren (NOZ). 2017 , 44, 8-14	2
1489	Cellular heterogeneity contributes to subtype-specific expression of ZEB1 in human glioblastoma. 2017 , 12, e0185376	7
1488	Prognostic markers for survival in patients with oligodendroglial tumors; a single-institution review of 214 cases. 2017 , 12, e0188419	5
1487	Erythropoietin Promotes Glioblastoma via miR-451 Suppression. 2017 , 105, 249-271	10
1486	Anatomic mapping of molecular subtypes in diffuse glioma. 2017 , 17, 183	11
1485	Prognostic significance of E-cadherin and N-cadherin expression in Gliomas. 2017 , 17, 583	41
1484	O-(2-[F]fluoroethyl)-L-tyrosine PET in gliomas: influence of data processing in different centres. 2017 , 7, 64	11
1483	The frequency and prognostic effect of TERT promoter mutation in diffuse gliomas. 2017 , 5, 62	50
1482	Role of regenerating gene IA expression on local invasion and survival in nasopharyngeal carcinoma. 2017 , 50, 37	4
1481	Radiotherapy plus temozolomide in elderly patients with glioblastoma: a "real-life" report. 2017 , 12, 197	13
1480	Ketogenic diets as an adjuvant therapy in glioblastoma (the KEATING trial): study protocol for a randomised pilot study. 2017 , 3, 67	9

1479	Anaplastic pleomorphic xanthoastrocytoma with disseminated growth pattern at the time of diagnosis as well as after treatment: case report and review of literature. 2017 , 3,	2
1478	Case-based review: pediatric medulloblastoma. 2017 , 4, 138-150	13
1477	Neue WHO-Klassifikation der Hirntumoren. 2017 , 20, 40-47	1
1476	High ATP2A2 expression correlates with better prognosis of diffuse astrocytic tumor patients. 2017 , 37, 2865-2874	7
1475	Gliomatosis Cerebri Mimicking Viral Encephalitis – A Case Report. 2017 , 08,	
1474	Vascular Endothelial Growth Factor as an Angiogenic Marker in Malignant Astrocytoma and Oligodendroglioma: An Indian Scenario. 2017 , 11, EC05-EC07	1
1473	EZH2 and Sonic Hedgehog Inhibition Reduce Proliferation, Migration, In Vitro Tumorigenesis, and CD133 Expression in Desmoplastic Medulloblastoma Cells. 2017 , 02,	
1472	Individual Prediction of Brain Tumor Histological Grading Using Radiomics on Structural MRI. 2017 ,	0
1471	You're the Flight Surgeon. 2017 , 88, 794-796	
1470	Expression levels of Eatenin and galectin-3 in meningioma and their effect on brain invasion and recurrence: a tissue microarray study. 2017 , 14, 319-326	7
1469	Treatment Recommendations for Adult Patients with Diffuse Gliomas of Grades II and III According to the New WHO Classification in 2016. 2017 , 57, 658-666	7
1468	Cerium Oxide Nanoparticles as Novel Tool in Glioma Treatment: An In vitro Study. 2017 , 08,	5
1467	Study of mutations in IDH1 and IDH2 genes in a sample of gliomas from Colombian population. 2018 , 38, 86-92	3
1466	Histopathological Analysis of Brain Tumours- A Seven Year Study from a Tertiary Care Centre in South India. 2017 , 11, EC05-EC08	4
1465	Imaging Characteristics, Pathologic Features, and Prognoses of the Molecular Subgroups of Medulloblastoma. 2017 , 7, 455-460	1
1464	PATZ1 is a new prognostic marker of glioblastoma associated with the stem-like phenotype and enriched in the proneural subtype. 2017 , 8, 59282-59300	20
1463	Response of Leptomeningeal Dissemination of Anaplastic Glioma to Temozolomide: Experience of Two Cases. 2017 , 5, 99-104	2
1462	AHNAK as a Prognosis Factor Suppresses the Tumor Progression in Glioma. 2017 , 8, 2924-2932	23

1461	Obstacles to Brain Tumor Therapy: Key ABC Transporters. 2017 , 18,	50
1460	The Clinical Outcome of Hydroxyurea Chemotherapy after Incomplete Resection of Atypical Meningiomas. 2017 , 5, 77-86	11
1459	High expression of XIAP and Bcl-2 may inhibit programmed cell death in glioblastomas. 2017 , 75, 875-880	23
1458	Disparities in Brain Cancer in the United States: A Literature Review of Gliomas. 2017 , 5,	10
1457	D11-Mediated Inhibition of Protein Kinase CK2 Impairs HIF-1 β -Mediated Signaling in Human Glioblastoma Cells. 2017 , 10,	1
1456	High expression of anti-apoptotic genes in grade I and II meningiomas. 2017 , 75, 209-215	2
1455	Anti-GD2-ch14.18/CHO coated nanoparticles mediate glioblastoma (GBM)-specific delivery of the aromatase inhibitor, Letrozole, reducing proliferation, migration and chemoresistance in patient-derived GBM tumor cells. 2017 , 8, 16605-16620	25
1454	Molecular Testing of Brain Tumor. 2017 , 51, 205-223	44
1453	Association between depression and brain tumor: a systematic review and meta-analysis. 2017 , 8, 94932-94943	50
1452	Pineal Tumors. 2017 , 25-28	
1451	Correlation Between Ki-67 Index, World Health Organization Grade and Patient Survival in Glial Tumors With Astrocytic Differentiation. 2017 , 9, e1396	10
1450	The integrative metabolomic-transcriptomic landscape of glioblastome multiforme. 2017 , 8, 49178-49190	16
1449	Diffuse Infiltrating Oligodendroglioma and Astrocytoma. 2017 , 35, 2394-2401	103
1448	Adult Glioblastoma. 2017 , 35, 2402-2409	320
1447	Medulloblastoma: From Myth to Molecular. 2017 , 35, 2355-2363	90
1446	Genomic Analysis of Childhood Brain Tumors: Methods for Genome-Wide Discovery and Precision Medicine Become Mainstream. 2017 , 35, 2346-2354	21
1445	Novel Considerations in the Approach to Glioblastoma. 2017 , 13, 639-640	
1444	Histopathological, molecular, clinical and radiological characterization of rosette-forming glioneuronal tumor in the central nervous system. 2017 , 8, 109175-109190	33

1443	Differential expression of folate receptor 1 in medulloblastoma and the correlation with clinicopathological characters and target therapeutic potential. 2017 , 8, 23048-23060	7
1442	Brain Tumors: Challenges and Opportunities to Cure. 2017 , 35, 2343-2345	17
1441	Evaluation of autoantibody signatures in meningioma patients using human proteome arrays. 2017 , 8, 58443-58456	12
1440	Impact of epidemiological characteristics of supratentorial gliomas in adults brought about by the 2016 world health organization classification of tumors of the central nervous system. 2017 , 8, 20354-20361	32
1439	Diffuse glioblastoma resembling acute hemorrhagic leukoencephalitis. 2017 , 7, 592-597	3
1438	Interest of integrins targeting in glioblastoma according to tumor heterogeneity and cancer stem cell paradigm: an update. 2017 , 8, 86947-86968	49
1437	Comparison of chemoradiotherapy with radiotherapy alone for "biopsy only" anaplastic astrocytoma. 2017 , 8, 69038-69046	3
1436	Blocking interleukin-6 signaling inhibits cell viability/proliferation, glycolysis, and colony forming activity of human medulloblastoma cells. 2018 , 52, 571-578	8
1435	Spinal metastases of two different grade oligodendrogliomas: a case report and review of literature. 2017 , 3, 468-474	0
1434	Unusual cauda equina syndrome due to multifocal ependymoma infiltrated by lymphoma. 2017 , 3, 697-701	1
1433	Multifocal intradural extramedullary anaplastic ependymoma of the spine. 2017 , 3, 727-731	9
1432	Genetic and immune features of resectable malignant brainstem gliomas. 2017 , 8, 82571-82582	8
1431	Glioma infiltration and extracellular matrix: key players and modulators. 2018 , 66, 1542-1565	88
1430	Diffuse gliomas classified by 1p/19q co-deletion, TERT promoter and IDH mutation status are associated with specific genetic risk loci. <i>Acta Neuropathologica</i> , 2018 , 135, 743-755	14.3 28
1429	A novel high-sensitivity assay to detect a small fraction of mutant IDH1 using droplet digital PCR. 2018 , 35, 97-105	10
1428	[Introduction to multidisciplinary in neuro-oncology in Lebanon: First Annual Day of Neuro-Oncology]. 2018 , 105, 327-328	0
1427	Functional variants of p21 gene alter susceptibility to meningioma. 2018 , 75, 92-94	1
1426	Ensembles of Multiple Models and Architectures for Robust Brain Tumour Segmentation. 2018 , 450-462	164

1425	Semi-automatic Method for Low-Grade Gliomas Segmentation in Magnetic Resonance Imaging. 2018 , 39, 116-128	6
1424	Solitary fibrous tumours and haemangiopericytoma of the meninges. A retrospective study for outcome and prognostic factor assessment. 2018 , 64, 37-43	7
1423	IDH2 mutations are commonly associated with 1p/19q codeletion in diffuse adult gliomas. 2018 , 20, 716-718	6
1422	Quality improvement in neurology: Neuro-Oncology Quality Measurement Set. 2018 , 20, 531-537	3
1421	Embryonal tumor with multilayered rosettes: Diagnosis on intra-operative squash smear. 2018 , 38, 387	3
1420	Clinical significance of the 2016 WHO classification in Japanese patients with gliomas. 2018 , 35, 71-80	13
1419	SNCA, a novel biomarker for Group 4 medulloblastomas, can inhibit tumor invasion and induce apoptosis. 2018 , 109, 1263-1275	14
1418	Capillary morphogenesis protein 2 is a novel prognostic biomarker and plays oncogenic roles in glioma. 2018 , 245, 160-171	12
1417	Evaluation of DNA ploidy with intraoperative flow cytometry may predict long-term survival of patients with supratentorial low-grade gliomas: Analysis of 102 cases. 2018 , 168, 46-53	1
1416	Combining Clinical and Molecular Data to Predict the Benefits of Carmustine Wafers in Newly Diagnosed High-Grade Gliomas. 2018 , 20, 3	8
1415	A Review on Tumor-Treating Fields (TTFields): Clinical Implications Inferred From Computational Modeling. 2018 , 11, 195-207	40
1414	Glioma Grade Discrimination with MR Diffusion Kurtosis Imaging: A Meta-Analysis of Diagnostic Accuracy. 2018 , 287, 119-127	41
1413	Salvage therapy outcomes for atypical meningioma. 2018 , 138, 425-433	19
1412	Supratentorial intracerebral cerebellar liponeurocytoma: A case report and literature review. 2018 , 97, e9556	10
1411	Imaging in neuro-oncology. 2018 , 11, 1756286418759865	30
1410	MRI Features Can Predict 1p/19q Status in Intracranial Gliomas. 2018 , 39, 687-692	47
1409	Targeting metabotropic glutamate receptors in the treatment of primary brain tumors. 2018 , 38, 59-64	1
1408	Scalp blocks for brain tumor craniotomies: A retrospective survival analysis of a propensity match cohort of patients. 2018 , 51, 46-51	13

1407	Development of Molecularly Targeted Agents and Immunotherapies in Glioblastoma: A Personalized Approach. 2018 , 12, 1179554918759079		4
1406	Liquid Biopsy in Primary Brain Tumors: Looking for Stardust!. 2018 , 18, 13		25
1405	Incorporating Advances in Molecular Pathology Into Brain Tumor Diagnostics. 2018 , 25, 143-171		23
1404	The miR-139-5p regulates proliferation of supratentorial paediatric low-grade gliomas by targeting the PI3K/AKT/mTORC1 signalling. 2018 , 44, 687-706		24
1403	Biological tumour volumes of gliomas in early and standard 20-40´min F-FET PET images differ according to IDH mutation status. 2018 , 45, 1242-1249		15
1402	cIMPACT-NOW update 2: diagnostic clarifications for diffuse midline glioma, H3 K27M-mutant and diffuse astrocytoma/anaplastic astrocytoma, IDH-mutant. <i>Acta Neuropathologica</i> , 2018 , 135, 639-642	14.3	186
1401	Clinical and imaging features of granular cell tumor of the neurohypophysis: A retrospective analysis. 2018 , 97, e9745		10
1400	MR Elastography Analysis of Glioma Stiffness and -Mutation Status. 2018 , 39, 31-36		42
1399	Amide proton transfer imaging seems to provide higher diagnostic performance in post-treatment high-grade gliomas than methionine positron emission tomography. 2018 , 28, 3285-3295		17
1398	Quality improvement in neurology: Neuro-oncology quality measurement set. 2018 , 90, 652-658		5
1397	Integrated neurodegenerative disease autopsy diagnosis. <i>Acta Neuropathologica</i> , 2018 , 135, 643-646	14.3	7
1396	Primary management of atypical meningioma: treatment patterns and survival outcomes by patient age. 2018 , 144, 969-978		14
1395	Multiplexed immunofluorescence reveals potential PD-1/PD-L1 pathway vulnerabilities in craniopharyngioma. 2018 , 20, 1101-1112		36
1394	Prediction of Overall Survival Based on Isocitrate Dehydrogenase 1 Mutation and 18F-FDG Uptake on PET/CT in Patients With Cerebral Gliomas. 2018 , 43, 311-316		8
1393	Analysis of pseudoprogression after proton or photon therapy of 99 patients with low grade and anaplastic glioma. 2018 , 9, 30-34		24
1392	Molecular Diagnostics in Pathology: Time for a Next-Generation Pathologist?. 2018 , 142, 313-320		25
1391	Whole-Genome Expression Microarray Combined with Machine Learning to Identify Prognostic Biomarkers for High-Grade Glioma. 2018 , 64, 491-500		11
1390	Advantages of high b-value diffusion-weighted imaging for preoperative differential diagnosis between embryonal and ependymal tumors at 3 T MRI. 2018 , 101, 136-143		6

1389	Novel TLE4-NTRK2 fusion in a ganglioglioma identified by array-CGH and confirmed by NGS: Potential for a gene targeted therapy. 2018 , 38, 380		14
1388	On the Concepts and History of Glioblastoma Multiforme - Morphology, Genetics and Epigenetics. 2018 , 60, 48-66		23
1387	Distinct response to GDF15 knockdown in pediatric and adult glioblastoma cell lines. 2018 , 139, 51-60		3
1386	PHAP1 promotes glioma cell proliferation by regulating the Akt/p27/stathmin pathway. 2018 , 22, 3595-3604		15
1385	Silencing LncRNA LOXL1-AS1 attenuates mesenchymal characteristics of glioblastoma via NF- κ B pathway. 2018 , 500, 518-524		40
1384	Texture analysis- and support vector machine-assisted diffusional kurtosis imaging may allow in vivo gliomas grading and IDH-mutation status prediction: a preliminary study. 2018 , 8, 6108		34
1383	[Basic principles of diagnosis and treatment of gliomas]. 2018 , 89, 692-698		4
1382	Fitting the epigenome into the picture: methylation classification for paediatric brain tumours. 2018 , 44, 543-547		
1381	Novel, improved grading system(s) for IDH-mutant astrocytic gliomas. <i>Acta Neuropathologica</i> , 2018 , 136, 153-166	14.3	162
1380	Prognostic value of Ki-67 index in adult medulloblastoma after accounting for molecular subgroup: a retrospective clinical and molecular analysis. 2018 , 139, 333-340		7
1379	Towards tailored management of malignant brain tumors with nanotheranostics. 2018 , 73, 52-63		10
1378	A Comparative Analysis of the Usefulness of Survival Prediction Models for Patients with Glioblastoma in the Temozolomide Era: The Importance of Methylguanine Methyltransferase Promoter Methylation, Extent of Resection, and Subventricular Zone Location. 2018 , 115, e375-e385		14
1377	Spontaneous development of intratumoral heterogeneity in a transposon-induced mouse model of glioma. 2018 , 109, 1513-1523		6
1376	Glioma-related seizures in relation to histopathological subtypes: a report from the glioma international case-control study. 2018 , 265, 1432-1442		19
1375	Investigation of cis-4-[F]Fluoro-D-Proline Uptake in Human Brain Tumors After Multimodal Treatment. 2018 , 20, 1035-1043		4
1374	Acceptance and compliance of TTFIELDS treatment among high grade glioma patients. 2018 , 139, 177-184		15
1373	Radiological evaluation of response to immunotherapy in brain tumors: Where are we now and where are we going?. 2018 , 126, 135-144		12
1372	Next generation neuro-oncology. 2018 , 96, 1-5		5

1371	targets SP1 and suppresses the growth of glioma cells. 2018 , 38,	14
1370	CDH2 expression is of prognostic significance in glioma and predicts the efficacy of temozolomide therapy in patients with glioblastoma. 2018 , 15, 7415-7422	10
1369	Differentiation between benign and atypical cranial Meningiomas. Can ADC measurement help? MRI findings with hystopathological correlation. 2018 , 49, 172-175	2
1368	Medulloblastoma with myogenic and/or melanotic differentiation does not align immunohistochemically with the genetically defined molecular subgroups. 2018 , 75, 26-33	4
1367	Potent antitumor efficacy of anti-GD2 CAR T cells in H3-K27M diffuse midline gliomas. 2018 , 24, 572-579	189
1366	Craniopharyngiomas in Adults: Part I Clinical Approach. 2018 , 40, 1-5	
1365	The clinicopathological and prognostic significance of TP53 alteration in K27M mutated gliomas: an individual-participant data meta-analysis. 2018 , 39, 1191-1201	7
1364	Quantitative analysis of neurite orientation dispersion and density imaging in grading gliomas and detecting gene mutation status. 2018 , 19, 174-181	14
1363	Prognostic relevance of mutations and copy number alterations assessed with targeted next generation sequencing in IDH mutant grade II glioma. 2018 , 139, 349-357	15
1362	Pharmacodynamics of mutant-IDH1 inhibitors in glioma patients probed by in vivo 3D MRS imaging of 2-hydroxyglutarate. 2018 , 9, 1474	75
1361	Sequencing the next generation of glioblastomas. 2018 , 55, 264-282	14
1360	Contrast enhancement predicting survival in integrated molecular subtypes of diffuse glioma: an observational cohort study. 2018 , 139, 373-381	9
1359	Comparison of 1p and 19q status of glioblastoma by whole exome sequencing, array-comparative genomic hybridization, and fluorescence in situ hybridization. 2018 , 35, 60	13
1358	Tumor Surface Regularity at MR Imaging Predicts Survival and Response to Surgery in Patients with Glioblastoma. 2018 , 171051	4
1357	Peritumoral Edema Affects the Prognosis in Adult Pleomorphic Xanthoastrocytoma: Retrospective Analysis of 25 Patients. 2018 , 114, e457-e467	6
1356	Burden of brain tumors in low- and middle-income countries: a systematic review protocol. 2018 , 16, 609-614	
1355	An Integrated TCGA Pan-Cancer Clinical Data Resource to Drive High-Quality Survival Outcome Analytics. 2018 , 173, 400-416.e11	1072
1354	Loss of histone H3K27me3 identifies a subset of meningiomas with increased risk of recurrence. <i>Acta Neuropathologica</i> , 2018 , 135, 955-963	14.3 61

1353	Actual Oncologic Impact of Radical Surgical Resection for Malignant Gliomas. 2018 , 112, 308-309	2
1352	An Unusual Case of Lhermitte-Duclos Disease Manifesting with Intratumoral Hemorrhage. 2018 , 114, 326-329	5
1351	Houdini Tumor: Case Report and Literature Review of Pregnancy-Associated Meningioma. 2018 , 114, e1261-e1265	13
1350	Adoptive Immunotherapy Using PRAME-Specific T Cells in Medulloblastoma. 2018 , 78, 3337-3349	41
1349	Data mining of pediatric medulloblastoma microarray expression reveals a novel potential subdivision of the Group 4 molecular subgroup. 2018 , 15, 6241-6250	4
1348	Impact of surgery, adjuvant treatment, and other prognostic factors in the management of anaplastic ganglioglioma. 2018 , 34, 1207-1213	9
1347	Tumor growth dynamics in serially-imaged low-grade glioma patients. 2018 , 139, 167-175	11
1346	Single-Cell RNA-Sequencing in Glioma. 2018 , 20, 42	11
1345	Current state of immunotherapy for glioblastoma. 2018 , 15, 422-442	466
1344	The association of NF2 (neurofibromin 2) gene polymorphism and the risk of medulloblastomas. 2018 , 39, 1175-1183	
1343	A Distinct DNA Methylation Shift in a Subset of Glioma CpG Island Methylator Phenotypes during Tumor Recurrence. 2018 , 23, 637-651	90
1342	Medulloblastoma: From Molecular Subgroups to Molecular Targeted Therapies. 2018 , 41, 207-232	55
1341	Circulating Micrnas Predict Survival of Patients with Tumors of Glial Origin. 2018 , 30, 105-112	13
1340	Surgical outcomes of spinal cord and cauda equina ependymoma: Postoperative motor status and recurrence for each WHO grade in a multicenter study. 2018 , 23, 614-621	13
1339	The Diagnostic Properties of Intraoperative Ultrasound in Glioma Surgery and Factors Associated with Gross Total Tumor Resection. 2018 , 115, e129-e136	24
1338	Histologic Features and Prognosis of Spinal Intradural Extramedullary Ewing Sarcoma: Case Report, Literature Review, and Analysis of Prognosis. 2018 , 115, 448-452.e2	5
1337	Clinical implications of TERT promoter mutation on IDH mutation and MGMT promoter methylation in diffuse gliomas. 2018 , 214, 881-888	20
1336	Role of radiotherapy in residual pineal parenchymal tumors. 2018 , 166, 91-98	10

1335	Pediatric astrocytic tumor grading: comparison between arterial spin labeling and dynamic susceptibility contrast MRI perfusion. 2018 , 60, 437-446	26
1334	Renin angiotensin system and its role in biomarkers and treatment in gliomas. 2018 , 138, 1-15	18
1333	Differential expression of the TWEAK receptor Fn14 in IDH1 wild-type and mutant gliomas. 2018 , 138, 241-250	7
1332	Pediatric high-grade glioma: a review of biology, prognosis, and treatment. 2018 , 7, 7-15	5
1331	Pediatric Cancers. 2018 , 683-727	
1330	Diffusion Profiling via a Histogram Approach Distinguishes Low-grade from High-grade Meningiomas, Can Reflect the Respective Proliferative Potential and Progesterone Receptor Status. 2018 , 20, 632-640	28
1329	Brain Tumors. 2018 , 131, 874-882	51
1328	Up-regulation of MSH6 is associated with temozolomide resistance in human glioblastoma. 2018 , 496, 1040-1046	13
1327	Pathology and Genetics of Gliomas. 2018 , 31, 1-37	12
1326	Biomarkers in Recurrent Grade III Glioma Patients Treated with Bevacizumab and Irinotecan. 2018 , 36, 165-174	3
1325	Genotype prediction of ATRX mutation in lower-grade gliomas using an MRI radiomics signature. 2018 , 28, 2960-2968	51
1324	Molecular and clinical characterization of IDH associated immune signature in lower-grade gliomas. 2018 , 7, e1434466	23
1323	Central Nervous System Germinomas Express Programmed Death Ligand 1. 2018 , 77, 312-316	5
1322	Meningioma assessment: Kinetic parameters in dynamic contrast-enhanced MRI appear independent from microvascular anatomy and VEGF expression. 2018 , 45, 242-248	5
1321	Narcolepsy and Hypothalamic Region Tumors: Presentation and Evolution. 2018 , 84, 27-31	12
1320	IDH1 mutation is associated with a higher preoperative seizure incidence in low-grade glioma: A systematic review and meta-analysis. 2018 , 55, 76-82	21
1319	MicroRNA-Based Drugs for Brain Tumors. 2018 , 4, 222-238	35
1318	Clinical Features, Treatment, and Prognostic Factors of 56 Intracranial and Intraspinal Clear Cell Meningiomas. 2018 , 111, e880-e887	16

1317	Functional-Based Resection Does Not Worsen Quality of Life in Patients with a Diffuse Low-Grade Glioma Involving Eloquent Brain Regions: A Prospective Cohort Study. 2018 , 113, e200-e212	22
1316	Cerebellar Peduncle Localized Oligodendroglioma: Case Report and Review of the Literature. 2018 , 113, 62-66	3
1315	Focal Cortical Dysplasia Type IIIb with Oligodendroglioma in a Seizure-Free Patient. 2018 , 45, 360-362	
1314	Neurosurgery self-assessment: questions and answers. 2017 , 1	
1313	Adult Brainstem Gliomas With H3K27M Mutation: Radiology, Pathology, and Prognosis. 2018 , 77, 302-311	41
1312	Temozolomide-associated hypermutation in gliomas. 2018 , 20, 1300-1309	69
1311	Glioma through the looking GLASS: molecular evolution of diffuse gliomas and the Glioma Longitudinal Analysis Consortium. 2018 , 20, 873-884	63
1310	Fully Automatic Lesion Localization and Characterization: Application to Brain Tumors Using Multiparametric Quantitative MRI Data. 2018 , 37, 1678-1689	15
1309	Current state and future prospects of immunotherapy for glioma. 2018 , 10, 317-339	38
1308	Genomic analysis of synchronous intracranial meningiomas with different histological grades. 2018 , 138, 41-48	2
1307	PD-1 (PDCD1) Promoter Methylation Is a Prognostic Factor in Patients With Diffuse Lower-Grade Gliomas Harboring Isocitrate Dehydrogenase (IDH) Mutations. 2018 , 28, 97-104	35
1306	Kinin-B1 Receptor Stimulation Promotes Invasion and is Involved in Cell-Cell Interaction of Co-Cultured Glioblastoma and Mesenchymal Stem Cells. 2018 , 8, 1299	25
1305	Clinical outcomes of intracranial solitary fibrous tumor and hemangiopericytoma: analysis according to the 2016 WHO classification of central nervous system tumors. 2018 , 129, 1384-1396	27
1304	The DNA methylome of DDR genes and benefit from RT or TMZ in IDH mutant low-grade glioma treated in EORTC 22033. <i>Acta Neuropathologica</i> , 2018 , 135, 601-615	14.3 54
1303	cIMPACT-NOW update 1: Not Otherwise Specified (NOS) and Not Elsewhere Classified (NEC). <i>Acta Neuropathologica</i> , 2018 , 135, 481-484	14.3 78
1302	p53 expression and subcellular survivin localization improve the diagnosis and prognosis of patients with diffuse astrocytic tumors. 2018 , 41, 141-157	9
1301	Extent of BOLD Vascular Dysregulation Is Greater in Diffuse Gliomas without Isocitrate Dehydrogenase 1 R132H Mutation. 2018 , 287, 965-972	9
1300	Cell biology of glioblastoma multiforme: from basic science to diagnosis and treatment. 2018 , 35, 27	37

1299	New Technologies for Analysis of Extracellular Vesicles. 2018 , 118, 1917-1950	581
1298	A new method using Raman spectroscopy for in vivo targeted brain cancer tissue biopsy. 2018 , 8, 1792	92
1297	Disruption of the ciliary GTPase Arl13b suppresses Sonic hedgehog overactivation and inhibits medulloblastoma formation. 2018 , 115, 1570-1575	25
1296	Blood-Brain Barrier Disruption, Sodium Fluorescein, And Fluorescence-Guided Surgery Of Gliomas. 2018 , 32, 141-148	15
1295	Radiomics Strategy for Molecular Subtype Stratification of Lower-Grade Glioma: Detecting IDH and TP53 Mutations Based on Multimodal MRI. 2018 , 48, 916-926	65
1294	Liponeurocytoma of the Cerebellopontine Angle. 2018 , 112, 18-24	4
1293	From imaging to biology of glioblastoma: new clinical oncology perspectives to the problem of local recurrence. 2018 , 20, 989-1003	7
1292	Current treatment options for meningioma. 2018 , 18, 241-249	71
1291	Nucleolar and spindle-associated protein 1 is a tumor grade correlated prognosis marker for glioma patients. 2018 , 24, 178-186	23
1290	Use of multicolor fluorescence in situ hybridization to detect deletions in clinical tissue sections. 2018 , 98, 403-413	6
1289	Delayed leptomeningeal metastasis of an adult anaplastic pilocytic astrocytoma. 2018 , 35, 123-126	1
1288	Combination Therapy with Sulfasalazine and Valproic Acid Promotes Human Glioblastoma Cell Death Through Imbalance of the Intracellular Oxidative Response. 2018 , 55, 6816-6833	13
1287	Mendelian randomisation study of the relationship between vitamin D and risk of glioma. 2018 , 8, 2339	12
1286	Genome-Wide Association Studies in Glioma. 2018 , 27, 418-428	21
1285	Characterization of active and infiltrative tumorous subregions from normal tissue in brain gliomas using multiparametric MRI. 2018 , 48, 938-950	21
1284	MicroRNAs as biomarkers for human glioblastoma: progress and potential. 2018 , 39, 1405-1413	46
1283	Clinical prognostic value of the isocitrate dehydrogenase 1 single-nucleotide polymorphism rs11554137 in glioblastoma. 2018 , 138, 307-313	9
1282	Current therapeutic approaches to diffuse grade II and III gliomas. 2018 , 11, 1756285617752039	16

1281	Kinome and phosphoproteome of high-grade meningiomas reveal AKAP12 as a central regulator of aggressiveness and its possible role in progression. 2018 , 8, 2098	18
1280	Solitary-fibrous tumor/hemangiopericytoma of the central nervous system: a population-based study. 2018 , 138, 173-182	32
1279	Prognostic factors for progression in atypical meningioma. 2018 , 129, 1240-1248	31
1278	A Novel Method for Rapid Molecular Subgrouping of Medulloblastoma. 2018 , 24, 1355-1363	15
1277	HDL nanoparticles targeting sonic hedgehog subtype medulloblastoma. 2018 , 8, 1211	23
1276	The ten-year evolutionary trajectory of a highly recurrent paediatric high grade neuroepithelial tumour with MN1:BEND2 fusion. 2018 , 8, 1032	9
1275	Recurrence patterns after maximal surgical resection and postoperative radiotherapy in anaplastic gliomas according to the new 2016 WHO classification. 2018 , 8, 777	17
1274	Magnetic resonance perfusion for differentiating low-grade from high-grade gliomas at first presentation. 2018 , 1, CD011551	18
1273	Intraoperative imaging technology to maximise extent of resection for glioma. 2018 , 1, CD012788	52
1272	PET/MRI in Brain Tumors. 2018 , 185-222	
1271	PET/MRI for Clinical Pediatric Oncologic Imaging. 2018 , 401-432	1
1270	Supplementary motor area syndrome after surgery for parasagittal meningiomas. 2018 , 160, 583-587	8
1269	Reactive Astrocytes in Glioblastoma Multiforme. 2018 , 55, 6927-6938	56
1268	Magnetic hyperthermia therapy for the treatment of glioblastoma: a review of the therapy's history, efficacy and application in humans. 2018 , 34, 1316-1328	165
1267	Brain Gliomas: Multicenter Standardized Assessment of Dynamic Contrast-enhanced and Dynamic Susceptibility Contrast MR Images. 2018 , 287, 933-943	44
1266	MRI radiomics analysis of molecular alterations in low-grade gliomas. 2018 , 13, 563-571	47
1265	Response in a child with a BRAF V600E mutated desmoplastic infantile astrocytoma upon retreatment with vemurafenib. 2018 , 65, e26893	14
1264	Clinical and molecular characteristics of gliosarcoma and modern prognostic significance relative to conventional glioblastoma. 2018 , 137, 303-311	29

1263	Oroxyloside inhibits human glioma progression by suppressing proliferation, metastasis and inducing apoptosis related pathways. 2018 , 97, 1564-1574	4
1262	Immunohistochemical comparative analysis of GFAP, MAP - 2, NOGO - A, OLIG - 2 and WT - 1 expression in WHO 2016 classified neuroepithelial tumours and their prognostic value. 2018 , 214, 15-24	4
1261	Subventricular zone involvement at recurrence is a strong predictive factor of outcome following high grade glioma reirradiation. 2018 , 136, 413-419	5
1260	Temporal stability of MGMT promoter methylation in glioblastoma patients undergoing STUPP protocol. 2018 , 137, 233-240	6
1259	High-grade thalamic gliomas: Microsurgical treatment and prognosis analysis. 2018 , 49, 56-61	15
1258	IDH1 and IDH2 mutations in postoperative diffuse glioma-associated epilepsy. 2018 , 78, 30-36	17
1257	Meningioma growth dynamics assessed by radiocarbon retrospective birth dating. 2018 , 27, 176-181	15
1256	Imaging Features of Common Pediatric Intracranial Tumours: A Primer for the Radiology Trainee. 2018 , 69, 105-117	4
1255	STAT3 Gene Silencing by Aptamer-siRNA Chimera as Selective Therapeutic for Glioblastoma. 2018 , 10, 398-411	53
1254	Survival of Ventricular and Periventricular High-Grade Gliomas: A Surveillance, Epidemiology, and End Results Program-Based Study. 2018 , 111, e323-e334	10
1253	Association Between IDH1 and IDH2 Mutations and Preoperative Seizures in Patients with Low-Grade Versus High-Grade Glioma: A Systematic Review and Meta-Analysis. 2018 , 111, e539-e545	20
1252	2-Hydroxyglutarate Detection by Short Echo Time Magnetic Resonance Spectroscopy in Routine Imaging Study of Brain Glioma at 3.0 T. 2018 , 42, 469-474	8
1251	[Bone banks : The state-of-the-art]. 2018 , 47, 3-9	1
1250	Pretransplantation: Indications and Timing. 2018 , 57-76	
1249	Quantitative texture analysis in the prediction of IDH status in low-grade gliomas. 2018 , 164, 114-120	42
1248	Supratentorial extraventricular ependymomas: A retrospective study focused on long-term outcomes and prognostic factors. 2018 , 165, 1-6	10
1247	Optical Analysis of Glioma: Fourier-Transform Infrared Spectroscopy Reveals the Mutation Status. 2018 , 24, 2530-2538	16
1246	Discrimination between primary low-grade and high-grade glioma with C-methionine PET: a bivariate diagnostic test accuracy meta-analysis. 2018 , 91, 20170426	18

1245	MRI Features and IDH Mutational Status of Grade II Diffuse Gliomas: Impact on Diagnosis and Prognosis. 2018 , 210, 621-628	52
1244	Dual IRE1 RNase functions dictate glioblastoma development. 2018 , 10,	86
1243	Seizure Outcome After Surgical Resection of Insular Glioma. 2018 , 83, 709-718	14
1242	Germline SUFU mutation carriers and medulloblastoma: clinical characteristics, cancer risk, and prognosis. 2018 , 20, 1122-1132	35
1241	Molecular Basis of Diseases of the Nervous System. 2018 , 651-690	1
1240	A comparison of 2-hydroxyglutarate detection at 3 and 7 T with long-TE semi-LASER. 2018 , 31, e3886	13
1239	Needs and preferences among patients with high-grade glioma and their caregivers - A longitudinal mixed methods study. 2018 , 27, e12806	23
1238	Rapid Clinical and Radiographic Response With Combined Dabrafenib and Trametinib in Adults With -Mutated High-Grade Glioma. 2018 , 16, 4-10	39
1237	Handedness and the risk of glioma. 2018 , 137, 639-644	0
1236	Diagnostic Performance of Increased Signal Intensity Within the Resection Cavity on Fluid-Attenuated Inversion Recovery Sequences for Detection of Progression in Patients with Glioma. 2018 , 110, 434-441	2
1235	Rationale and design of the 500-patient, 3-year, and prospective Vigilant Observation of Gliadel WAfer ImplANT registry. 2018 , 7, CNS08	7
1234	Intracranial Ewing sarcoma: four pediatric examples. 2018 , 34, 441-448	13
1233	Improved Differentiation of Low-Grade and High-Grade Gliomas and Detection of Tumor Proliferation Using APT Contrast Fitted from Z-Spectrum. 2018 , 20, 623-631	32
1232	Epidermal growth factor receptor and EGFRVIII in glioblastoma: signaling pathways and targeted therapies. 2018 , 37, 1561-1575	210
1231	Atypical teratoid/rhabdoid tumor with retained INI1 (SMARCB1) expression and loss of BRG1 (SMARCA4). 2018 , 38, 305-308	14
1230	Diagnostic Values of DCE-MRI and DSC-MRI for Differentiation Between High-grade and Low-grade Gliomas: A Comprehensive Meta-analysis. 2018 , 25, 338-348	23
1229	Progesterin-associated shift of meningioma mutational landscape. 2018 , 29, 681-686	37
1228	Necrosis is a consistent factor to recurrence of meningiomas: should it be a stand-alone grading criterion for grade II meningioma?. 2018 , 137, 331-336	11

1227	EANO guidelines for the diagnosis and treatment of ependymal tumors. 2018 , 20, 445-456	100
1226	Cerebral blood flow changes after radiation therapy identifies pseudoprogression in diffuse intrinsic pontine gliomas. 2018 , 20, 994-1002	13
1225	Recent advances in intradural spinal tumors. 2018 , 20, 729-742	21
1224	An NF- κ B signature predicts low-grade glioma prognosis: a precision medicine approach based on patient-derived stem cells. 2018 , 20, 776-787	28
1223	The FDA NIH Biomarkers, EndpointS, and other Tools (BEST) resource in neuro-oncology. 2018 , 20, 1162-1172	38
1222	Adult Spinal Ependymomas: An Epidemiologic Study. 2018 , 111, e53-e61	13
1221	Advances in meningioma genetics: novel therapeutic opportunities. 2018 , 14, 106-115	80
1220	Highly specific determination of IDH status using edited in vivo magnetic resonance spectroscopy. 2018 , 20, 907-916	48
1219	Desmoplastic nodular medulloblastoma in young children: a management dilemma. 2018 , 20, 1026-1033	6
1218	De novo and secondary anaplastic meningiomas: a study of clinical and histomolecular prognostic factors. 2018 , 20, 1113-1121	44
1217	Circumscribed/non-diffuse histology confers a better prognosis in H3K27M-mutant gliomas. <i>Acta Neuropathologica</i> , 2018 , 135, 299-301	14-3 34
1216	Analysis of immunobiologic markers in primary and recurrent glioblastoma. 2018 , 137, 249-257	23
1215	Relapse pathway of glioblastoma revealed by single-cell molecular analysis. 2018 , 39, 931-936	18
1214	Prognostic role of survivin in patients with glioma. 2018 , 97, e0571	20
1213	Inhibition of the PI3K but not the MEK/ERK pathway sensitizes human glioma cells to alkylating drugs. 2018 , 18, 69	21
1212	BRAF activating mutations involving the B- ζ loop in V600E-negative anaplastic pleomorphic xanthoastrocytoma. 2018 , 6, 24	9
1211	Correlation Between the Residual Tumor Volume, Extent of Tumor Resection, and O-Methylguanine DNA Methyltransferase Status in Patients with Glioblastoma. 2018 , 116, e147-e161	6
1210	Comparative analysis of histologically classified oligodendrogliomas reveals characteristic molecular differences between subgroups. 2018 , 18, 399	11

1209	Impact of atopy on risk of glioma: a Mendelian randomisation study. 2018 , 16, 42	27
1208	Clinical significance of polyglutamylation in primary central nervous system lymphoma. 2018 , 6, 15	1
1207	Surgical outcomes and predictors of complication in elderly patients with meningiomas. 2018 , 54, 3	6
1206	Diagnostic value of six MRI features for central neurocytoma. 2018 , 28, 4306-4313	4
1205	DNA methylation-based reclassification of olfactory neuroblastoma. <i>Acta Neuropathologica</i> , 2018 , 136, 255-271	14-3 35
1204	Assessing the predictability of IDH mutation and MGMT methylation status in glioma patients using relaxation-compensated multipool CEST MRI at 7.0 T. 2018 , 20, 1661-1671	68
1203	Radiogenomics correlation between MR imaging features and major genetic profiles in glioblastoma. 2018 , 28, 4350-4361	42
1202	Type 1 IGF Receptor Localization in Paediatric Gliomas: Significant Association with WHO Grading and Clinical Outcome. 2018 , 9, 205-214	5
1201	Repurposing drugs for glioblastoma: From bench to bedside. 2018 , 428, 173-183	38
1200	Metastatic cervical paravertebral solitary fibrous tumor detected by fluorodeoxyglucose positron emission tomography-computed tomography. 2018 , 13, 464-467	0
1199	Anticancer activity of flavonoids isolated from <i>Achyrocline satureioides</i> in gliomas cell lines. 2018 , 51, 23-33	27
1198	Inhibition of GPR158 by microRNA-449a suppresses neural lineage of glioma stem/progenitor cells and correlates with higher glioma grades. 2018 , 37, 4313-4333	17
1197	Pediatric Spinal Ependymomas: An Epidemiologic Study. 2018 , 115, e119-e128	10
1196	Pediatric Optic Pathway/Hypothalamic Glioma. 2018 , 58, 1-9	20
1195	Multiple extraspinal recurrences of ependymoma 13 years after spinal cordectomy: case report. 2018 , 29, 92-96	
1194	MR-spectroscopic imaging of glial tumors in the spotlight of the 2016 WHO classification. 2018 , 139, 431-440	7
1193	Comparative study of pulsed-continuous arterial spin labeling and dynamic susceptibility contrast imaging by histogram analysis in evaluation of glial tumors. 2018 , 60, 599-608	8
1192	Regimen of procarbazine, lomustine, and vincristine versus temozolomide for gliomas. 2018 , 124, 2674-2676	9

1191	Differential somatostatin, CXCR4 chemokine and endothelin A receptor expression in WHO grade I-IV astrocytic brain tumors. 2018 , 144, 1227-1237	7
1190	Prognostic factors and the management of anaplastic meningioma. 2018 , 170, 13-19	9
1189	Pediatric diffuse intrinsic anaplastic astrocytoma of the medulla oblongata. 2018 , 14, 63-66	
1188	Seizure characteristics and the use of anti-epileptic drugs in children and young people with brain tumours and epileptic seizures: Analysis of regional paediatric cancer service population. 2018 , 58, 17-21	2
1187	The Effectiveness of Salvage Treatments for Recurrent Lesions of Oligodendrogliomas Previously Treated with Upfront Chemotherapy. 2018 , 114, e735-e742	2
1186	Clinical importance of eflornithine (Eflufurornithine) for the treatment of malignant gliomas. 2018 , 7, CNS16	21
1185	Opposite Interplay Between the Canonical WNT/ β Catenin Pathway and PPAR Gamma: A Potential Therapeutic Target in Gliomas. 2018 , 34, 573-588	40
1184	Incidence and risk factor of deep venous thrombosis in patients undergoing craniotomy for brain tumors: A Japanese single-center, retrospective study. 2018 , 165, 95-100	8
1183	Historadiological correlations in high-grade glioma with the histone 3.3 G34R mutation. 2018 , 45, 316-322	13
1182	Influence of obesity-related risk factors in the aetiology of glioma. 2018 , 118, 1020-1027	22
1181	In-Vitro Use of 5-ALA for Photodynamic Therapy in Pediatric Brain Tumors. 2018 , 83, 1328-1337	11
1180	Embryonal Tumors of the Central Nervous System: From the Radiologic Pathology Archives. 2018 , 38, 525-541	19
1179	Multi-institutional study of treatment patterns in Korean patients with WHO grade II gliomas: KNOG 15-02 and KROG 16-04 intergroup study. 2018 , 138, 667-677	1
1178	Gene Fusion in Malignant Glioma: An Emerging Target for Next-Generation Personalized Treatment. 2018 , 11, 609-618	31
1177	The T2-FLAIR mismatch sign as an imaging marker for non-enhancing IDH-mutant, 1p/19q-intact lower-grade glioma: a validation study. 2018 , 20, 1393-1399	88
1176	Highlights from the Literature. 2018 , 20, 441-444	78
1175	A PRDX1-p38 β heterodimer amplifies MET-driven invasion of IDH-wildtype and IDH-mutant gliomas. 2018 , 143, 1176-1187	10
1174	Medulloblastoma, WNT-activated/SHH-activated: clinical impact of molecular analysis and histogenetic evaluation. 2018 , 34, 809-815	16

1173	Comprehensive Molecular Profiling Identifies FOXM1 as a Key Transcription Factor for Meningioma Proliferation. 2018 , 22, 3672-3683	56
1172	Immunohistochemical and molecular genetic study on epithelioid glioblastoma: Series of seven cases with review of literature. 2018 , 214, 679-685	15
1171	Immunohistochemical ATRX expression is not a surrogate for 1p19q codeletion. 2018 , 35, 106-113	12
1170	Surveillance for metastatic hemangiopericytoma-solitary fibrous tumors-systematic literature review on incidence, predictors and diagnosis of extra-cranial disease. 2018 , 138, 447-467	23
1169	Supratentorial Cortical Ependymomas: A Retrospective Series of 13 Cases at a Single Center. 2018 , 112, e772-e777	7
1168	Anthropometrics and Body Composition in Adults with High-Grade Gliomas: Effects of Disease-Related Variables. 2018 , 70, 431-440	2
1167	Identification of Two Protein-Signaling States Delineating Transcriptionally Heterogeneous Human Medulloblastoma. 2018 , 22, 3206-3216	10
1166	Identification of CRKII, CFL1, CNTN1, NME2, and TKT as Novel and Frequent T-Cell Targets in Human IDH-Mutant Glioma. 2018 , 24, 2951-2962	21
1165	Reclassification of 400 consecutive glioma cases based on the revised 2016WHO classification. 2018 , 35, 81-89	12
1164	XRCC3 contributes to temozolomide resistance of glioblastoma cells by promoting DNA double-strand break repair. 2018 , 424, 119-126	19
1163	Current Clinical State of Advanced Magnetic Resonance Imaging for Brain Tumor Diagnosis and Follow Up. 2018 , 53, 45-61	7
1162	Effects of the Green Tea Polyphenol Epigallocatechin-3-Gallate on Glioma: A Critical Evaluation of the Literature. 2018 , 70, 317-333	18
1161	Radiomics strategy for glioma grading using texture features from multiparametric MRI. 2018 , 48, 1518-1528	101
1160	Expression-based intrinsic glioma subtypes are prognostic in low-grade gliomas of the EORTC22033-26033 clinical trial. 2018 , 94, 168-178	19
1159	Phosphorylated Hsp27 is mutually exclusive with ATRX loss and the IDH1 mutation and may predict better prognosis among glioblastomas without the IDH1 mutation and ATRX loss. 2018 , 71, 702-707	12
1158	Prevalence of the single-nucleotide polymorphism rs11554137 (IDH1) in brain tumors of a cohort of Italian patients. 2018 , 8, 4459	5
1157	Radiomics, Metabolic, and Molecular MRI for Brain Tumors. 2018 , 38, 32-40	15
1156	New Directions in the Treatment of Glioblastoma. 2018 , 38, 50-61	23

1155	Primary Central Nervous System Malignant Melanoma in Children: A Case Series and Review of the Literature. 2018 , 40, 616-619	0
1154	Practical Implications of the Updated WHO Classification of Brain Tumors. 2018 , 38, 11-18	3
1153	Drug discovery in neuro-oncology: challenges in the path forward. 2018 , 20, 435-436	3
1152	Intramedullary central neurocytoma of the thoracic spinal cord: A case report and literature review. 2018 , 8, 539-543	4
1151	Correlation and clinical significance of LC3, CD68+ microglia, CD4+ T lymphocytes, and CD8+ T lymphocytes in gliomas. 2018 , 168, 167-174	8
1150	Prognostic role of mitochondrial pyruvate carrier in isocitrate dehydrogenase-mutant glioma. 2018 , 130, 56-66	8
1149	Whole-Tumor Histogram and Texture Analyses of DTI for Evaluation of -Mutation and 1p/19q-Codeletion Status in World Health Organization Grade II Gliomas. 2018 , 39, 693-698	42
1148	The roles of C-acetate PET/CT in predicting tumor differentiation and survival in patients with cerebral glioma. 2018 , 45, 1012-1020	16
1147	Central nervous system (CNS) neuroblastoma. A case-based update. 2018 , 34, 817-823	11
1146	Timing of re-irradiation in recurrent high-grade gliomas: a single institution study. 2018 , 138, 571-579	7
1145	Intradural spinal tumors: 10 - years surgical experience in a single institution. 2018 , 169, 98-102	6
1144	Improving surgical outcome for gliomas with intraoperative mapping. 2018 , 18, 333-341	17
1143	Positron emission tomography of sodium glucose cotransport activity in high grade astrocytomas. 2018 , 138, 557-569	19
1142	Results of Biopsy-Proven Sellar Germ Cell Tumors: Nine Years' Experience in a Single Center. 2018 , 112, e229-e239	1
1141	Lateral cerebellum is preferentially sensitive to high sonic hedgehog signaling and medulloblastoma formation. 2018 , 115, 3392-3397	20
1140	Literature Review of Spinal Cord Glioblastoma. 2018 , 41, 1281-1287	20
1139	Tumors of the Optic Nerve and its Sheath. 2018 , 58, 237-260	0
1138	Response assessment in medulloblastoma and leptomeningeal seeding tumors: recommendations from the Response Assessment in Pediatric Neuro-Oncology committee. 2018 , 20, 13-23	43

1137	Exploration of Involved Key Genes and Signaling Diversity in Brain Tumors. 2018 , 38, 393-419	13
1136	Oligodendroglioma resection: a Surveillance, Epidemiology, and End Results (SEER) analysis. 2018 , 128, 1076-1083	26
1135	Surgical treatment of neuronal-glioma of mesial-basal part of temporal lobe: Long term outcome and control of epilepsy in pediatric patients. 2018 , 52, 2-8	4
1134	Glioma Grading and Determination of IDH Mutation Status and ATRX loss by DCE and ASL Perfusion. 2018 , 28, 421-428	34
1133	Loss of SMARCE1 expression is a specific diagnostic marker of clear cell meningioma: a comprehensive immunophenotypical and molecular analysis. 2018 , 28, 466-474	30
1132	Preclinical transgenic and patient-derived xenograft models recapitulate the radiological features of human adamantinomatous craniopharyngioma. 2018 , 28, 475-483	12
1131	MDM2 Degrades Deacetylated Nucleolin Through Ubiquitination to Promote Glioma Stem-Like Cell Enrichment for Chemotherapeutic Resistance. 2018 , 55, 3211-3223	11
1130	Noninvasive assessment of isocitrate dehydrogenase mutation status in cerebral gliomas by magnetic resonance spectroscopy in a clinical setting. 2018 , 128, 391-398	45
1129	A brief review of potent anti-CNS tumourics from marine sponges: covering the period from 1994 to 2014. 2018 , 32, 375-384	10
1128	Atypical pituitary adenoma: a clinicopathologic case series. 2018 , 128, 1058-1065	15
1127	Histopathological prognostic factors of recurrence following definitive therapy for atypical and malignant meningiomas. 2018 , 128, 1123-1132	25
1126	CRISPR-engineered genome editing for the next generation neurological disease modeling. 2018 , 81, 459-467	8
1125	CHD4 as a Potential Biomarker in Differentiating Between Cellular Schwannoma and Malignant Peripheral Nerve Sheath Tumor. 2018 , 26, 775-780	3
1124	Exosomes as a biomarker platform for detecting epidermal growth factor receptor-positive high-grade gliomas. 2018 , 128, 1091-1101	52
1123	Developments in neuro-oncology. 2018 , 11, 161-162	
1122	miR miR on the wall, who's the most malignant medulloblastoma miR of them all?. 2018 , 20, 313-323	12
1121	Clinical, radiological, and histological features and treatment outcomes of supratentorial extraventricular ependymoma: 14 cases from a single center. 2018 , 128, 1396-1402	18
1120	Amide proton transfer imaging for differentiation of benign and atypical meningiomas. 2018 , 28, 331-339	28

1119	Intracranial solitary fibrous tumors/hemangiopericytomas: first report of malignant progression. 2018 , 128, 1719-1724	16
1118	Application of intravoxel incoherent motion (IVIM) magnetic resonance imaging in the evaluation of primitive brain tumours. 2018 , 31, 4-9	14
1117	Posttreatment DSC-MRI is Predictive of Early Treatment Failure in Children with Supratentorial High-Grade Glioma Treated with Erlotinib. 2018 , 28, 393-400	4
1116	Dissecting human gliomas by single-cell RNA sequencing. 2018 , 20, 37-43	37
1115	A recombinant lentiviral PDGF-driven mouse model of proneural glioblastoma. 2018 , 20, 332-342	10
1114	Effect of Perfusion on Diffusion Kurtosis Imaging Estimates for In Vivo Assessment of Integrated 2016 WHO Glioma Grades : A Cross-Sectional Observational Study. 2018 , 28, 481-491	5
1113	Clinical characteristics associated with postoperative seizure control in adult low-grade gliomas: a systematic review and meta-analysis. 2018 , 20, 324-331	17
1112	The Role of Extent of Resection in IDH1 Wild-Type or Mutant Low-Grade Gliomas. 2018 , 82, 808-814	35
1111	Noninvasive electrical conductivity measurement by MRI: a test of its validity and the electrical conductivity characteristics of glioma. 2018 , 28, 348-355	45
1110	Glioblastoma in elderly patients: solid conclusions built on shifting sand?. 2018 , 20, 174-183	24
1109	Pediatric cancer pathology review from a single institution: Neuropathology expert opinion is essential for accurate diagnosis of pediatric brain tumors. 2018 , 65, e26709	4
1108	Prognostic relevance of genetic alterations in diffuse lower-grade gliomas. 2018 , 20, 66-77	128
1107	Undifferentiated sarcoma of the sphenoid sinus. 2018 , 45, 388-391	1
1106	Differential Response of Glioma Stem Cells to Arsenic Trioxide Therapy Is Regulated by MNK1 and mRNA Translation. 2018 , 16, 32-46	25
1105	Adolescents and young adults with brain tumors in the context of molecular advances in neuro-oncology. 2018 , 65, e26861	19
1104	Opposing roles of PGD in GBM. 2018 , 134, 66-76	8
1103	Multiparametric Imaging Improves Confidence in the Diagnosis of Multinodular and Vacuolating Neuronal Tumor of the Cerebrum. 2018 , 39, E32-E33	4
1102	Low FoxG1 and high Olig-2 labelling indices define a prognostically favourable subset in isocitrate dehydrogenase (IDH)-mutant gliomas. 2018 , 44, 207-223	7

1101	Clinical Features, Treatment, and Long-term Outcomes of Central Neurocytoma: A 20-Year Experience at a Single Center. 2018 , 109, e59-e66	15
1100	Multicenter pilot study of radiochemotherapy as first-line treatment for adults with medulloblastoma (NOA-07). 2018 , 20, 400-410	36
1099	Glioma CpG island methylator phenotype (G-CIMP): biological and clinical implications. 2018 , 20, 608-620	97
1098	Radiomic subtyping improves disease stratification beyond key molecular, clinical, and standard imaging characteristics in patients with glioblastoma. 2018 , 20, 848-857	111
1097	Identification of time-to-peak on dynamic 18F-FET-PET as a prognostic marker specifically in IDH1/2 mutant diffuse astrocytoma. 2018 , 20, 279-288	52
1096	The impact of surgery in molecularly defined low-grade glioma: an integrated clinical, radiological, and molecular analysis. 2018 , 20, 103-112	142
1095	Comprehensive molecular characterisation of epilepsy-associated glioneuronal tumours. <i>Acta Neuropathologica</i> , 2018 , 135, 115-129	143 36
1094	Combating malignant astrocytes: Strategies mitigating tumor invasion. 2018 , 126, 22-30	7
1093	Visual and semiquantitative 11C-methionine PET: an independent prognostic factor for survival of newly diagnosed and treatment-naïve gliomas. 2018 , 20, 411-419	10
1092	Vaccination in the immunotherapy of glioblastoma. 2018 , 14, 255-268	24
1091	Differentiation of grade II/III and grade IV glioma by combining "T1 contrast-enhanced brain perfusion imaging" and susceptibility-weighted quantitative imaging. 2018 , 60, 43-50	18
1090	Survival patterns of oligoastrocytoma patients: A surveillance, epidemiology and end results (SEER) based analysis. 2018 , 11, 70-75	0
1089	SEOM clinical guidelines for anaplastic gliomas (2017). 2018 , 20, 16-21	7
1088	Genomic analysis of the origins and evolution of multicentric diffuse lower-grade gliomas. 2018 , 20, 632-641	17
1087	Brain tumor research in the United Kingdom: current perspective and future challenges. A strategy document from the NCRI Brain Tumor CSG. 2018 , 5, 10-17	4
1086	Diffusion Tensor Imaging Shows Corpus Callosum Differences between High-Grade Gliomas and Metastases. 2018 , 28, 199-205	5
1085	Radiomics in paediatric neuro-oncology: A multicentre study on MRI texture analysis. 2018 , 31, e3781	33
1084	Overexpression of COX7A2 is associated with a good prognosis in patients with glioma. 2018 , 136, 41-50	5

1083	A microRNA signature from serum exosomes of patients with glioma as complementary diagnostic biomarker. 2018 , 136, 51-62	85
1082	Diffusion-weighted MRI combined with susceptibility-weighted MRI: added diagnostic value for four common lateral ventricular tumors. 2018 , 59, 980-987	4
1081	Rapid identification and validation of novel targeted approaches for Glioblastoma: A combined ex vivo-in vivo pharmaco-omic model. 2018 , 299, 281-288	14
1080	Identification of MEK162 as a Radiosensitizer for the Treatment of Glioblastoma. 2018 , 17, 347-354	11
1079	Brainstem pilocytic astrocytoma with H3 K27M mutation: case report. 2018 , 129, 593-597	17
1078	Primary Intraosseous Lymphoplasmacyte-Rich Meningioma. 2018 , 109, 291-293	3
1077	Advanced and amplified BOLD fluctuations in high-grade gliomas. 2018 , 47, 1616-1625	5
1076	Loco-regional extensions of central nervous system germ cell tumors: a retrospective radiological analysis of 100 patients. 2018 , 60, 27-34	11
1075	Supratentorial hemangioblastomas in von Hippel-Lindau wild-type patients: case series and literature review. 2018 , 128, 295-303	5
1074	Morphologic patterns of noncontrast-enhancing tumor in glioblastoma correlate with IDH1 mutation status and patient survival. 2018 , 47, 168-173	10
1073	Prognostic importance of temozolomide-induced neutropenia in glioblastoma, IDH-wildtype patients. 2018 , 41, 621-628	11
1072	Cellular and molecular characterization of IDH1-mutated diffuse low grade gliomas reveals tumor heterogeneity and absence of EGFR/PDGFR activation. 2018 , 66, 239-255	10
1071	The case for DNA methylation based molecular profiling to improve diagnostic accuracy for central nervous system embryonal tumors (not otherwise specified) in adults. 2018 , 47, 163-167	5
1070	The role of three-dimensional pseudo-continuous arterial spin labelling in grading and differentiating histological subgroups of meningiomas. 2018 , 73, 176-184	11
1069	Imaging Genetic Heterogeneity in Glioblastoma and Other Glial Tumors: Review of Current Methods and Future Directions. 2018 , 210, 30-38	35
1068	Clinical responses of patients with diffuse leptomeningeal glioneuronal tumors to chemotherapy. 2018 , 34, 329-334	19
1067	Taxonomy of CNS tumours; a series of three short reviews on the WHO 2016 classification and beyond. 2018 , 44, 137-138	4
1066	CNS embryonal tumours: WHO 2016 and beyond. 2018 , 44, 151-162	24

1065	In vivo assessment of tumor heterogeneity in WHO 2016 glioma grades using diffusion kurtosis imaging: Diagnostic performance and improvement of feasibility in routine clinical practice. 2018 , 45, 32-40	25
1064	Differentiation of grade II and III oligodendrogliomas from grade II and III astrocytomas: a histogram analysis of perfusion parameters derived from dynamic contrast-enhanced (DCE) and dynamic susceptibility contrast (DSC) MRI. 2018 , 59, 723-731	11
1063	Textural features of dynamic contrast-enhanced MRI derived model-free and model-based parameter maps in glioma grading. 2018 , 47, 1099-1111	34
1062	Molecular differences in IDH wildtype glioblastoma according to MGMT promoter methylation. 2018 , 20, 367-379	35
1061	Molecular pathogenesis and therapeutic implications in pediatric high-grade gliomas. 2018 , 182, 70-79	16
1060	Multinodular and vacuolating neuronal tumors in epilepsy: dysplasia or neoplasia?. 2018 , 28, 155-171	37
1059	Multiregional Tumor Drug-Uptake Imaging by PET and Microvascular Morphology in End-Stage Diffuse Intrinsic Pontine Glioma. 2018 , 59, 612-615	12
1058	Adaptive Global Innovative Learning Environment for Glioblastoma: GBM AGILE. 2018 , 24, 737-743	97
1057	Improving Diagnostic and Therapeutic Outcomes in Pediatric Brain Tumors. 2018 , 22, 25-39	5
1056	Spatial discrimination of glioblastoma and treatment effect with histologically-validated perfusion and diffusion magnetic resonance imaging metrics. 2018 , 136, 13-21	25
1055	Diffuse midline gliomas with histone H3-K27M mutation: A rare case with PNET-like appearance and neuropil-like islands. 2018 , 38, 165-170	9
1054	Surgical Management of Giant Intracranial Meningioma: Operative Nuances, Challenges, and Outcome. 2018 , 110, e32-e41	10
1053	Neurological update: gliomas and other primary brain tumours in adults. 2018 , 265, 717-727	18
1052	Repair gene O ⁶ -methylguanine-DNA methyltransferase is controlled by SP1 and up-regulated by glucocorticoids, but not by temozolomide and radiation. 2018 , 144, 139-151	26
1051	An immune-related lncRNA signature for patients with anaplastic gliomas. 2018 , 136, 263-271	85
1050	Residual Convolutional Neural Network for the Determination of Status in Low- and High-Grade Gliomas from MR Imaging. 2018 , 24, 1073-1081	189
1049	Prognostic Value of Tumor Volume in Glioblastoma Patients: Size Also Matters for Patients with Incomplete Resection. 2018 , 25, 558-564	16
1048	Extracellular vesicles compartment in liquid biopsies: Clinical application. 2018 , 60, 27-37	50

1047	Significance of systemic immune-inflammation index in the differential diagnosis of high- and low-grade gliomas. 2018 , 164, 50-52	14
1046	Sparse Representation-Based Radiomics for the Diagnosis of Brain Tumors. 2018 , 37, 893-905	45
1045	Farewell to monomodality treatment in patients with WHO lower grade glioma?. 2018 , 88, 109-114	1
1044	MRI Characteristics of Spinal Ependymoma in WHO Grade II: A Review of 59 Cases. 2018 , 43, E525-E530	20
1043	SEOM clinical guideline of diagnosis and management of low-grade glioma (2017). 2018 , 20, 3-15	17
1042	Treatment-related changes in glioblastoma: a review on the controversies in response assessment criteria and the concepts of true progression, pseudoprogression, pseudoresponse and radionecrosis. 2018 , 20, 939-953	44
1041	p53 and miR-210 regulated NeuroD2, a neuronal basic helix-loop-helix transcription factor, is downregulated in glioblastoma patients and functions as a tumor suppressor under hypoxic microenvironment. 2018 , 142, 1817-1828	23
1040	Double somatic SMARCB1 and NF2 mutations in sporadic spinal schwannoma. 2018 , 137, 33-38	5
1039	Neuropathology Patterns and Introduction. 2018 , 1-17	
1038	Ependymomas and Choroid Plexus Tumors. 2018 , 145-169	
1037	Embryonal Neoplasms of the Central Nervous System. 2018 , 233-258	1
1036	Role of extracellular vesicles in glioma progression. 2018 , 60, 38-51	43
1035	Contemporary management of high-grade gliomas. 2018 , 7, 51-65	18
1034	Management and outcome of children and adolescents with non-medulloblastoma CNS embryonal tumors in Spain: room for improvement in standards of care. 2018 , 137, 205-213	4
1033	Multinodular and vacuolating neuronal tumor of the cerebrum. A rare entity. New case and review of the literature. 2018 , 29, 44-55	13
1032	Predictors of clinical outcome in pediatric oligodendroglioma: meta-analysis of individual patient data and multiple imputation. 2018 , 21, 153-163	5
1031	SEOM clinical guidelines for diagnosis and treatment of glioblastoma (2017). 2018 , 20, 22-28	29
1030	Histopathological proof of the pathogenicity of a rare GFAP mutation in a patient with flaccid paraparesis. 2018 , 40, 330-333	1

1029	Treatment of a glioblastoma multiforme dural metastasis with stereotactic radiosurgery: A case report and select review of the literature. 2018 , 48, 118-121	3
1028	Determinants for Effective ALECSAT Immunotherapy Treatment on Autologous Patient-Derived Glioblastoma Stem Cells. 2018 , 20, 25-31	7
1027	Review of molecular classification and treatment implications of pediatric brain tumors. 2018 , 30, 3-9	30
1026	Histone Mutations in Cancer. 2018 , 2, 337-351	13
1025	Diffuse intrinsic pontine gliomas (DIPG) at recurrence: is there a window to test new therapies in some patients?. 2018 , 137, 111-118	13
1024	Prognostic value of a microRNA signature as a novel biomarker in patients with lower-grade gliomas. 2018 , 137, 127-137	34
1023	Introduction to Neuroimaging. 2018 , 131, 346-356	2
1022	Precision Medicine in Pediatric Neurooncology: A Review. 2018 , 9, 11-28	7
1021	Novel and shared neoantigen derived from histone 3 variant H3.3K27M mutation for glioma T cell therapy. 2018 , 215, 141-157	118
1020	Imaging in low-grade glioma: a guide for neurologists. 2018 , 18, 27-34	5
1019	Nanoparticle/siRNA-based therapy strategies in glioma: which nanoparticles, which siRNAs?. 2018 , 13, 89-103	17
1018	Sustained Response to Targeted Therapy in a Patient With Disseminated Anaplastic Pleomorphic Xanthoastrocytoma. 2018 , 40, 478-482	14
1017	Establishing cut-off points with clinical relevance for bcl-2, cyclin D1, p16, p21, p27, p53, Sox11 and WT1 expression in glioblastoma - a short report. 2018 , 41, 213-221	8
1016	Tumour stem cells in meningioma: A review. 2018 , 47, 66-71	15
1015	Increased signal intensity within glioblastoma resection cavities on fluid-attenuated inversion recovery imaging to detect early progressive disease in patients receiving radiotherapy with concomitant temozolomide therapy. 2018 , 60, 35-42	0
1014	Atypical meningioma: progression-free survival in 161 cases treated at our institution with surgery versus surgery and radiotherapy. 2018 , 136, 147-154	31
1013	Rapid Intraoperative Diagnosis of Pediatric Brain Tumors Using Stimulated Raman Histology. 2018 , 78, 278-289	58
1012	Glutathione reductase mediates drug resistance in glioblastoma cells by regulating redox homeostasis. 2018 , 144, 93-104	69

1011	Magnetic resonance imaging features of canine gliomatosis cerebri. 2018 , 59, 180-187	5
1010	RELA fusion-positive anaplastic ependymoma: molecular characterization and advanced MR imaging. 2018 , 35, 41-45	12
1009	Static and dynamic F-FET PET for the characterization of gliomas defined by IDH and 1p/19q status. 2018 , 45, 443-451	73
1008	Suppression of glioblastoma growth and angiogenesis through molecular targeting of methionine aminopeptidase-2. 2018 , 136, 243-254	6
1007	Histogram analysis of diffusion kurtosis imaging derived maps may distinguish between low and high grade gliomas before surgery. 2018 , 28, 1748-1755	33
1006	Imaging features of rosette-forming glioneuronal tumours. 2018 , 73, 275-282	17
1005	Impact of WHO 2016 update of brain tumor classification, molecular markers and clinical outcomes in pleomorphic xanthoastrocytoma. 2018 , 136, 343-350	18
1004	Clinical features, surgical management, and prognostic factors of secretory meningiomas: a single-center case series of 149 patients. 2018 , 136, 515-522	5
1003	Prognostic relevance of programmed cell death ligand 1 expression in glioblastoma. 2018 , 136, 453-461	20
1002	Histogram analysis of T2*-based pharmacokinetic imaging in cerebral glioma grading. 2018 , 155, 19-27	2
1001	Modeling phenotypes of malignant gliomas. 2018 , 109, 6-14	8
1000	CDK4, CDK6, cyclin D1, p16(INK4a) and EGFR expression in glioblastoma with a primitive neuronal component. 2018 , 136, 445-452	10
999	Secretion-mediated STAT3 activation promotes self-renewal of glioma stem-like cells during hypoxia. 2018 , 37, 1107-1118	44
998	Quality of Randomized Controlled Trials Reporting in the Treatment of Adult Patients with High-Grade Gliomas. 2018 , 23, 337-345	6
997	Impact of concurrent versus adjuvant chemotherapy on the severity and duration of lymphopenia in glioma patients treated with radiation therapy. 2018 , 136, 403-411	21
996	Pediatric Brain Tumors: A Different Ball Game. 2018 , 53, 77-100	0
995	Toxic effects of phytol and retinol on human glioblastoma cells are associated with modulation of cholesterol and fatty acid biosynthetic pathways. 2018 , 136, 435-443	9
994	Case of the Season: Multinodular and Vacuolating Neuronal Tumor. 2018 , 53, 3-5	4

993	Prediction of -Mutation and 1p/19q-Codeletion Status Using Preoperative MR Imaging Phenotypes in Lower Grade Gliomas. 2018 , 39, 37-42	69
992	Glioblastoma and chemoresistance to alkylating agents: Involvement of apoptosis, autophagy, and unfolded protein response. 2018 , 184, 13-41	161
991	Surgical management of spinal solitary fibrous tumor/hemangiopericytoma: a case series of 20 patients. 2018 , 27, 891-901	27
990	Clinical neuropathology of brain tumors. 2017 , 145, 477-534	3
989	GBP3 promotes glioma cell proliferation via SQSTM1/p62-ERK1/2 axis. 2018 , 495, 446-453	16
988	Outcomes and Prognostic Factors in Pediatric Oligodendroglioma: A Population-Based Study. 2018 , 53, 24-35	13
987	MR textural analysis on T FLAIR images for the prediction of true oligodendroglioma by the 2016 WHO genetic classification. 2018 , 48, 74-83	9
986	Clinical features, radiologic findings, and treatment of pediatric germ cell tumors involving the basal ganglia and thalamus: a retrospective series of 15 cases at a single center. 2018 , 34, 423-430	5
985	Current and emerging biomarkers in tumors of the central nervous system: Possible diagnostic, prognostic and therapeutic applications. 2018 , 52, 85-102	19
984	Inability of positive phase II clinical trials of investigational treatments to subsequently predict positive phase III clinical trials in glioblastoma. 2018 , 20, 113-122	30
983	Pediatric low-grade gliomas: next biologically driven steps. 2018 , 20, 160-173	76
982	pDok2, caspase 3 dependent glioma cell growth arrest by nitidine chloride. 2018 , 70, 48-54	5
981	WHO 2016 Classification of gliomas. 2018 , 44, 139-150	331
980	Phosphorylated Histone H3 (PHH3) as a Novel Cell Proliferation Marker and Prognosticator for Meningeal Tumors: A Short Review. 2018 , 26, 627-631	17
979	Loss of Pericytes in Radiation Necrosis after Glioblastoma Treatments. 2018 , 55, 4918-4926	8
978	Bilateral lateral ventricular subependymoma with extensive multiplicity presenting with hemorrhage. 2018 , 31, 27-31	0
977	Female sex, good performance status, and bevacizumab-induced hypertension associated with survival benefit in Asian patients with recurrent glioblastoma treated with bevacizumab. 2018 , 14, e8-e14	3
976	A simple algorithmic approach using histology and immunohistochemistry for the current classification of adult diffuse glioma in a resource-limited set-up. 2018 , 71, 323-329	8

975	An evidence-based approach to assess the accuracy of diffusion kurtosis imaging in characterization of gliomas. 2018 , 97, e13068	2
974	Characterization of Diffuse Gliomas With Histone H3-G34 Mutation by MRI and Dynamic 18F-FET PET. 2018 , 43, 895-898	14
973	Mismatch repair deficiency in high-grade meningioma: a rare but recurrent event associated with dramatic immune activation and clinical response to PD-1 blockade. 2018 , 2018,	22
972	Year 1 in the Molecular Era of Pediatric Brain Tumor Diagnosis: Application of Universal Clinical Targeted Sequencing in an Unselected Cohort of Children.. 2018 , 2, 1-13	0
971	High-Grade Gliomas: A Multidisciplinary Approach. 2018 , 40, 6-6	
970	Role of amino-tracer PET for decision-making in neuro-oncology. 2018 , 31, 720-726	7
969	Immunohistochemical characterization of lymphangiogenesis-related biomarkers in primary and recurrent gliomas: A STROBE compliant article. 2018 , 97, e12458	2
968	Whole genome duplication is an early event leading to aneuploidy in -wild type glioblastoma. 2018 , 9, 36017-36028	10
967	Zielsetzungen palliativmedizinischer Maßnahmen bei Patienten mit malignen Hirntumoren. 2018 , 19, 312-321	
966	Epidemiología y caracterización general de los tumores cerebrales primarios en el adulto. 2018 , 60,	1
965	Conventional and advanced magnetic resonance imaging in patients with high-grade glioma. 2018 , 62, 239-253	37
964	Modified fractal analysis of methionine positron emission tomography images for predicting prognosis in newly diagnosed patients with glioma. 2018 , 39, 1165-1173	1
963	Improved differentiation between high- and low-grade gliomas by combining dual-energy CT analysis and perfusion CT. 2018 , 97, e11670	8
962	Integrating Genomics Into Neuro-Oncology Clinical Trials and Practice. 2018 , 38, 148-157	2
961	Dynamic Susceptibility Contrast (DSC) Perfusion MR in the Prediction of Long-Term Survival of Glioblastomas (GBM): Correlation with MGMT Promoter Methylation and 1p/19q Deletions. 2018 , 22, 158	5
960	Einfluss der Resektion bei molekular definierten niedriggradigen Gliomen. 2018 , 21, 27-29	
959	Allicin induces apoptosis through activation of both intrinsic and extrinsic pathways in glioma cells. 2018 , 17, 5976-5981	15
958	Extensive Molecular and Clinical Heterogeneity in Patients With Histologically Diagnosed CNS-PNET Treated as a Single Entity: A Report From the Children's Oncology Group Randomized ACNS0332 Trial. 2018 , JCO2017764720	34

957	Recurrent Pituicytoma in a Pediatric Patient: A Case Report. 2018 , 37, 119-122	
956	Rotating Gamma System Irradiation: A Promising Treatment for Low-grade Brainstem Gliomas. 2017 , 31, 957-960	2
955	Rosette-forming glioneuronal tumour of the fourth ventricle. Not always a foreseeable development. 2018 , 22, 270-274	1
954	The effects of 2-hydroxyglutarate on the tumorigenesis of gliomas. 2018 , 22, 215-222	15
953	Introduction to the Special Issue on Pediatric Neuro-Oncology. 2018 , 5,	
952	Anaplastic Pleomorphic Xanthoastrocytoma Presenting with Musical Hallucination. 2018 , 2018, 6428492	2
951	Current and future tools for determination and monitoring of isocitrate dehydrogenase status in gliomas. 2018 , 31, 727-732	6
950	The Diagnosis and Treatment of Primary CNS Lymphoma. 2018 , 115, 419-426	31
949	G2/M inhibitors as pharmacotherapeutic opportunities for glioblastoma: the old, the new, and the future. 2018 , 15, 354-374	10
948	Are molecular subgroups of medulloblastomas really prognostic?. 2018 , 31, 747-751	2
947	Clinical significance of prognostic nutritional index in patients with glioblastomas. 2018 , 97, e13218	16
946	Current insights into matrix metalloproteinases and glioma progression: transcending the degradation boundary. 2018 , Volume 5, 13-30	7
945	Pathological features of paraganglioma in the lumbar spinal canal: A case report. 2018 , 97, e12586	3
944	PET imaging in glioma: techniques and current evidence. 2018 , 39, 1064-1080	7
943	CNN-LSTM: Cascaded Framework For Brain Tumour Classification. 2018 ,	24
942	Decoding Somatic Driver Gene Mutations and Affected Signaling Pathways in Human Medulloblastoma Subgroups. 2018 , 9, 4596-4610	9
941	[Brain tumors in children: about 136 cases]. 2018 , 30, 291	1
940	Ca-Dependent Transcriptional Repressors KCNIP and Regulation of Prognosis Genes in Glioblastoma. 2018 , 11, 472	7

939	Deubiquitinating enzyme 4 facilitates chemoresistance in glioblastoma by inhibiting P53 activity. 2019 , 17, 958-964	10
938	TLR-4/Wnt modulation as new therapeutic strategy in the treatment of glioblastomas. 2018 , 9, 37564-37580	6
937	Radiotherapy of Glioblastoma 15 Years after the Landmark Stupp's Trial: More Controversies than Standards?. 2018 , 52, 121-128	31
936	Multimodal treatment for local recurrent malignant gliomas: Resurgery and/or reirradiation followed by chemotherapy. 2019 , 10, 49-57	3
935	20 Posterior Fossa Tumors. 2018 ,	
934	21 Brainstem Gliomas. 2018 ,	
933	Significance of TERT and ATRX mutations in glioma. 2019 , 17, 95-102	16
932	Intracranial haemangiopericytoma: a rare case presenting with haemorrhage. 2018 , 2018,	
931	Perspectives of immunotherapy in isocitrate dehydrogenase-mutant gliomas. 2018 , 30, 368-374	10
930	Long-term side effects of radiotherapy, with or without chemotherapy, for glioma. 2018 ,	1
929	Interval brain imaging for adults with cerebral glioma. 2018 ,	1
928	Treatment outcomes for pediatric pineoblastoma: a single institute experience in Taiwan. 2018 , 2, 27-27	2
927	Pediatric Glioma at the Optic Pathway and Thalamus. 2018 , 61, 352-362	3
926	Pilomyxoid Astrocytoma: Case Report. 2018 , 37, 54-57	
925	Diffuse Intrinsic Pontine Glioma : Clinical Features, Molecular Genetics, and Novel Targeted Therapeutics. 2018 , 61, 343-351	29
924	miR-24 regulates angiogenesis in gliomas. 2018 , 18, 358-368	7
923	Unusual Case of Metastatic Intracranial Hemangiopericytoma and Emphasis on Role of 68Ga-PSMA PET in Imaging. 2018 , 43, e331-e333	5
922	A case of failed awake craniotomy due to progressive intraoperative hyponatremia. 2018 , 4, 40	1

921	Bilaterales hippocampales primäres ZNS-Lymphom: Ungewöhnliche Differentialdiagnose eines rasch progredienten dementiellen Syndroms. 2018 , 39, 248-251	
920	Bildgebung und Progressionsdiagnostik maligner Gliome. 2018 , 39, 648-652	
919	Moderne Verfahren für die Strahlentherapie von Hirntumoren und Tumoren der Schädelbasis. 2018 , 45, 445-456	
918	Current Trends in Glioblastoma Treatment. 2018 ,	4
917	Multiparametric Magnetic Resonance Imaging in the Assessment of Primary Brain Tumors Through Radiomic Features: A Metric for Guided Radiation Treatment Planning. 2018 , 10, e3426	9
916	Voxel-wise analysis of dynamic F-FET PET: a novel approach for non-invasive glioma characterisation. 2018 , 8, 91	12
915	Full Issue PDF Volume 33, Issue 3. 2018 , 33, 1-64	
914	Expanding Our Reach. 2018 , 33, 34-43	
913	The effect of marital status on glioma patient survival: analysis of 617 cases: A SEER-based study. 2018 , 97, e13900	5
912	Polo-Like Kinase 4 (PLK4) Is Overexpressed in Central Nervous System Neuroblastoma (CNS-NB). 2018 , 5,	13
911	High expression of GALNT7 promotes invasion and proliferation of glioma cells. 2018 , 16, 6307-6314	7
910	expression is influenced by astrocytoma grade and polymorphism. 2018 , 9, 4496-4502	6
909	Dysregulated circular RNAs in medulloblastoma regulate proliferation and growth of tumor cells via host genes. 2018 , 7, 6147-6157	25
908	Surgery and Evidence-based Treatments in Patients with Newly Diagnosed High-grade Glioma. 2018 , 34, 443-453	10
907	Aberrant neuronal differentiation is common in glioma but is associated neither with epileptic seizures nor with better survival. 2018 , 8, 14965	3
906	Corilagin Induces High Levels of Apoptosis in the Temozolomide-Resistant T98G Glioma Cell Line. 2018 , 26, 1307-1315	12
905	Toward Precision Medicine: Promising Areas of Research in Glioma. 2018 , 34, 569-572	2
904	Tropism of mesenchymal stem cell toward CD133 stem cell of glioblastoma in vitro and promote tumor proliferation in vivo. 2018 , 9, 310	37

903	Introduction to CNS Intraoperative Cytopathology. 2018 , 3-14	
902	Intersection of Brain Development and Paediatric Diffuse Midline Gliomas: Potential Role of Microenvironment in Tumour Growth. 2018 , 8,	10
901	Accumulation of protoporphyrin IX in medulloblastoma cell lines and sensitivity to subsequent photodynamic treatment. 2018 , 189, 298-305	11
900	Feature Optimization and Classification of Tumor Grades Using MR Images. 2018 ,	0
899	Hypermethylation of Secreted Frizzled Related Protein 1 gene promoter in different astrocytoma grades. 2018 , 59, 213-223	9
898	Integrative Molecular Tumor Classification: A Pathologist's View. 2018 , 279-279	
897	Efficacy and safety analysis on dendritic cell-based vaccine-treated high-grade glioma patients: a systematic review and meta-analysis. 2018 , 11, 7277-7293	2
896	Association analysis of RTEL1 variants with risk of adult gliomas in a Korean population. 2018 , 13, e0207660	4
895	Molecular Mechanisms Governing the Stem Cell's Fate in Brain Cancer: Factors of Stemness and Quiescence. 2018 , 12, 388	18
894	Compliance with patient-reported outcome assessment in glioma patients: predictors for drop out. 2018 , 5, 129-138	9
893	Human Glioma Migration and Infiltration Properties as a Target for Personalized Radiation Medicine. 2018 , 10,	25
892	EIF4A3-induced circular RNA MMP9 (circMMP9) acts as a sponge of miR-124 and promotes glioblastoma multiforme cell tumorigenesis. 2018 , 17, 166	172
891	Brain Tumor Characterization Using Multibiometric Evaluation of MRI. 2018 , 4, 14-25	6
890	A malignant astrocytoma with uncommon angiocentric features and dot-like EMA expression. 2018 , 22, 205-208	
889	Antiepileptic and psychiatric medication in a nationwide cohort of patients with glioma WHO grade II-IV. 2018 , 140, 739-748	7
888	Clinical evaluation of a dedicated next generation sequencing panel for routine glioma diagnostics. 2018 , 6, 126	19
887	Radiation-Induced Alterations in the Recurrent Glioblastoma Microenvironment: Therapeutic Implications. 2018 , 8, 503	35
886	Hypoxia increases chemoresistance in human medulloblastoma DAOY cells via hypoxia-inducible factor 1-mediated downregulation of the CYP2B6, CYP3A4 and CYP3A5 enzymes and inhibition of cell proliferation. 2019 , 41, 178-190	14

885	Sulforaphane from Cruciferous Vegetables: Recent Advances to Improve Glioblastoma Treatment. 2018 , 10,	17
884	Low-Grade Gliomas. 2018 , 573-579.e1	1
883	The 2016 World Health Organization classification of tumours of the central nervous system. 2018 , 47, e187-e200	37
882	An unusual case of a grade I meningioma with perineural spread. 2018 , 1-4	
881	The clinical use of IDH1 and IDH2 mutations in gliomas. 2018 , 18, 1041-1051	15
880	Parallel K-Means Clustering for Brain Cancer Detection Using Hyperspectral Images. 2018 , 7, 283	13
879	PI3K inhibitor AZD6482 exerts antiproliferative activity and induces apoptosis in human glioblastoma cells. 2019 , 41, 125-132	12
878	Management of meningioma. 2018 , 47, e245-e252	17
877	Pilot Study to Describe the Trajectory of Symptoms and Adaptive Strategies of Adults Living with Low-grade Glioma. 2018 , 34, 472-485	1
876	Tumor Treating Fields: Adjuvant Treatment for High-grade Gliomas. 2018 , 34, 454-464	6
875	Pediatric Brain Tumor Genetics: What Radiologists Need to Know. 2018 , 38, 2102-2122	32
874	Interrogating molecular data for medulloblastoma risk stratification. 2018 , 19, 1548-1549	3
873	Multiregional radiomics profiling from multiparametric MRI: Identifying an imaging predictor of IDH1 mutation status in glioblastoma. 2018 , 7, 5999-6009	44
872	SETD2 mutations in primary central nervous system tumors. 2018 , 6, 123	19
871	The role of amino-acid PET in the light of the new WHO classification 2016 for brain tumors. 2018 , 62, 267-271	6
870	Epidemiology and Overview of Gliomas. 2018 , 34, 420-429	57
869	Evidence-based Treatment for Low-grade Glioma. 2018 , 34, 465-471	4
868	Apparent diffusion coefficient reproducibility in brain tumors measured on 1.5 and 3 T clinical scanners: A pilot study. 2018 , 108, 249-253	7

867	Transcriptomic and epigenetic profiling of 'diffuse midline gliomas, H3 K27M-mutant' discriminate two subgroups based on the type of histone H3 mutated and not supratentorial or infratentorial location. 2018 , 6, 117	48
866	Grading and proliferation assessment of diffuse astrocytic tumors with monoexponential, biexponential, and stretched-exponential diffusion-weighted imaging and diffusion kurtosis imaging. 2018 , 109, 188-195	20
865	A comprehensive review of available omics data resources and molecular profiling for precision glioma studies. 2019 , 10, 3-9	5
864	Identification of neoepitopes recognized by tumor-infiltrating lymphocytes (TILs) from patients with glioma. 2018 , 9, 19469-19480	8
863	Distribution of cancer stem cells in two human brain gliomas. 2019 , 17, 2123-2130	9
862	The evolutionary pattern of mutations in glioblastoma reveals therapy-mediated selection. 2018 , 9, 7844-7858	23
861	Cancer Stem Cells and Immunosuppressive Microenvironment in Glioma. 2018 , 9, 2924	89
860	De novo and secondary anaplastic meningiomas: natural history, prognosis, and the TERT promoter. 2018 , 20, 1009-1010	2
859	Update on amino acid PET of brain tumours. 2018 , 31, 354-361	22
858	Expression of activating transcription factor 5 (ATF5) is increased in astrocytomas of different WHO grades and correlates with survival of glioblastoma patients. 2018 , 11, 8673-8684	13
857	Liquid biopsy for pediatric central nervous system tumors. 2018 , 2, 29	15
856	ADAR3 expression is an independent prognostic factor in lower-grade diffuse gliomas and positively correlated with the editing level of GRIA2. 2018 , 18, 196	8
855	NK Cell-Based Glioblastoma Immunotherapy. 2018 , 10,	36
854	Recent Advancement of the Molecular Diagnosis in Pediatric Brain Tumor. 2018 , 61, 376-385	1
853	Targeting cellular metabolism using rapamycin and/or doxycycline enhances anti-tumour effects in human glioma cells. 2018 , 18, 211	10
852	Identification of a multidimensional transcriptome signature for survival prediction of postoperative glioblastoma multiforme patients. 2018 , 16, 368	30
851	Extracellular matrix differences in glioblastoma patients with different prognoses. 2019 , 17, 797-806	12
850	Imagerie des tumeurs cérébrales de l'enfant. 2018 , 1, 229-234	

849	The Emerging Role of Amino Acid PET in Neuro-Oncology. 2018 , 5,	16
848	[Photodynamic therapy for the treatment of glioblastoma in neurosurgery]. 2018 , 34, 901-903	1
847	Application of atomic force microscopy in cancer research. 2018 , 16, 102	65
846	MiR-16-5p is frequently down-regulated in astrocytic gliomas and modulates glioma cell proliferation, apoptosis and response to cytotoxic therapy. 2019 , 45, 441-458	15
845	The STAT3/Slug Axis Enhances Radiation-Induced Tumor Invasion and Cancer Stem-like Properties in Radioresistant Glioblastoma. 2018 , 10,	36
844	Surgical strategy for temporal lobe epilepsy with dual pathology and incomplete evidence from EEG and neuroimaging. 2018 , 16, 4886-4892	1
843	SVM Optimization for Brain Tumor Identification Using Infrared Spectroscopic Samples. 2018 , 18,	6
842	Neuro-Immune Hemostasis: Homeostasis and Diseases in the Central Nervous System. 2018 , 12, 459	56
841	The Impacts of Tumor and Tumor Associated Epilepsy on Subcortical Brain Structures and Long Distance Connectivity in Patients With Low Grade Glioma. 2018 , 9, 1004	4
840	Mobile phone use and incidence of brain tumour histological types, grading or anatomical location: a population-based ecological study. 2018 , 8, e024489	15
839	A Systematic Review of Atypical Teratoid Rhabdoid Tumor in Adults. 2018 , 8, 567	27
838	Bromodomain PHD-finger transcription factor promotes glioma progression and indicates poor prognosis. 2019 , 41, 246-256	12
837	Childhood Medulloblastoma Revisited. 2018 , 27, 479-502	5
836	Solitary Fibrous Tumor/Hemangiopericytoma: A Companion Case Discussion of a Spectrum of Rare CNS Mesenchymal Tumors and Their Evolving WHO Classification. 2018 , 8, 188-192	
835	Peiminine Inhibits Glioblastoma in Vitro and in Vivo Through Cell Cycle Arrest and Autophagic Flux Blocking. 2018 , 51, 1566-1583	19
834	Use of Mendelian randomization for identifying risk factors for brain tumors. 2018 , 9, 525	12
833	Low Expression of miR-466f-3p Sustains Epithelial to Mesenchymal Transition in Sonic Hedgehog Medulloblastoma Stem Cells Through Vegfa-Nrp2 Signaling Pathway. 2018 , 9, 1281	16
832	Clinical course of the untreated calcified big cerebellar liponeurocytoma. 2018 , 2018, rjy316	2

831	Classification of the glioma grading using radiomics analysis. 2018 , 6, e5982	74
830	The Expressional Pattern of Invasion-Related Extracellular Matrix Molecules in CNS Tumors. 2018 , 36, 492-503	1
829	IDH1 mutation is associated with lower expression of VEGF but not microvessel formation in glioblastoma multiforme. 2018 , 9, 16462-16476	14
828	MGMT promoter methylation in Peruvian patients with glioblastoma. 2018 , 12, 812	
827	Application of Small Epigenetic Modulators in Pediatric Medulloblastoma. 2018 , 6, 370	8
826	Intranasal Perillyl Alcohol for Glioma Therapy: Molecular Mechanisms and Clinical Development. 2018 , 19,	40
825	Immunogenetics of glioblastoma: the future of personalized patient management. 2018 , 2, 27	16
824	Rare Embryonal Brain Tumours. 2018 , 289-316	4
823	Imaging Children with CNS Tumors. 2018 , 65-90	
822	Medulloblastoma. 2018 , 131-175	
821	Ultrarapid Evaluation of Meningioma Malignancy by Intraoperative Flow Cytometry. 2018 , 120, 320-327	3
820	Non-linear Approach for MRI to intra-operative US Registration Using Structural Skeleton. 2018 , 138-145	4
819	Introduction to Brain Tumors. 2018 , 131-134	
818	Conventional Imaging in the Diagnosis of Brain Tumors. 2018 , 135-150	1
817	The potential for remodelling the tumour vasculature in glioblastoma. 2018 , 136-137, 49-61	9
816	Proceedings of the International Cancer Imaging Society (ICIS) 18th Annual Teaching Course. 2018 , 18,	0
815	Embryonal Tumors of the Central Nervous System in Children: The Era of Targeted Therapeutics. 2018 , 5,	12
814	Diffuse Low Grade Glioma NMR Assessment for Better Intra-operative Targeting Using Fuzzy Logic. 2018 , 200-210	

813	Contribution of the Wnt Pathway to Defining Biology of Glioblastoma. 2018 , 20, 437-451	22
812	Verteporfin selectively kills hypoxic glioma cells through iron-binding and increased production of reactive oxygen species. 2018 , 8, 14358	17
811	Long-Term Outcomes Following Conventionally Fractionated Stereotactic Boost for High-Grade Gliomas in Close Proximity to Critical Organs at Risk. 2018 , 8, 373	1
810	ACTB and SDHA Are Suitable Endogenous Reference Genes for Gene Expression Studies in Human Astrocytomas Using Quantitative RT-PCR. 2018 , 17, 1533033818802318	11
809	Thioredoxin Confers Intrinsic Resistance to Cytostatic Drugs in Human Glioma Cells. 2018 , 19,	11
808	Identification of a Prognostic Hypoxia-Associated Gene Set in IDH-Mutant Glioma. 2018 , 19,	21
807	Bioinformatics analyses of significant genes, related pathways and candidate prognostic biomarkers in glioblastoma. 2018 , 18, 4185-4196	21
806	HOXA10-AS: A novel oncogenic long non-coding RNA in glioma. 2018 , 40, 2573-2583	15
805	Characterization of Intraoperative Motor Evoked Potential Monitoring for Surgery of the Pediatric Population with Brain Tumors. 2018 , 119, e1052-e1059	3
804	Comprehensive evaluation of treatment and outcomes of low-grade diffuse gliomas. 2018 , 13, e0203639	13
803	Improving the estimation of prognosis for glioblastoma patients by MR based hemodynamic tissue signatures. 2018 , 31, e4006	9
802	Biopsying a spinal cord lesion: A diagnostic dilemma. Case report and review of literature. 2018 , 64, 425-430	6
801	The subventricular zone concept: ready for therapeutic implications?. 2018 , 20, 1423-1424	1
800	A trend towards a more intense adjuvant treatment of low-grade-gliomas in tertiary centers in Germany after RTOG 9802 - results from a multi-center survey. 2018 , 18, 907	4
799	Long-term outcomes of surgical resection with or without adjuvant therapy for treatment of primary spinal peripheral primitive neuroectodermal tumors. 2018 , 175, 25-33	3
798	Blockade of Na/H exchanger stimulates glioma tumor immunogenicity and enhances combinatorial TMZ and anti-PD-1 therapy. 2018 , 9, 1010	28
797	Focused review on seizures caused by meningiomas. 2018 , 88, 146-151	10
796	Patterns of care and outcomes of postoperative radiation for low-grade gliomas in United States hospitals. 2018 , 58, 124-129	2

795	TERT, the target?. 2018 , 20, 1561-1562	
794	Expression of the Annexin A1 and its correlation with matrix metalloproteinases and the receptor for formylated peptide-2 in diffuse astrocytic tumors. 2018 , 37, 62-66	7
793	Prediction of Isocitrate Dehydrogenase Genotype in Brain Gliomas with MRI: Single-Shell versus Multishell Diffusion Models. 2018 , 289, 788-796	16
792	Preoperative and postoperative prediction of long-term meningioma outcomes. 2018 , 13, e0204161	19
791	Diffuse low grade glioma after the 2016 WHO update, seizure characteristics, imaging correlates and outcomes. 2018 , 175, 9-15	7
790	Effects of tumor grade and dexamethasone on myeloid cells in patients with glioma. 2018 , 7, e1507668	8
789	Spinal cord anaplastic meningioma with extra-neural metastasis in a cat. 2018 , 48,	1
788	Grada histolgica e aspectos clnico-patolgicos relacionados em 22 meningiomas de cs. 2018 , 38, 751-761	3
787	Epidemiology of Pediatric Central Nervous System Tumors. 2018 , 1-15	
786	High-Grade Glioma, Including Diffuse Intrinsic Pontine Glioma. 2018 , 193-221	
785	Investigation of Gene Polymorphism and Serum Survivin Levels in Patients with Brain Tumors. 2018 , 38, 5991-5998	2
784	Pleomorphic xanthoastrocytomas of adults: MRI features, molecular markers, and clinical outcomes. 2018 , 8, 14275	3
783	Gliosarcoma arising from oligodendroglioma (Oligosarcoma): A case report with genetic analyses. 2018 , 68, 567-573	5
782	Intra-operative cerebrospinal fluid sampling versus post-operative lumbar puncture for detection of leptomeningeal disease in malignant paediatric brain tumours. 2018 , 13, e0196696	
781	ATRX loss induces multiple hallmarks of the alternative lengthening of telomeres (ALT) phenotype in human glioma cell lines in a cell line-specific manner. 2018 , 13, e0204159	23
780	Bridging Cancer Biology with the Clinic: Comprehending and Exploiting IDH Gene Mutations in Gliomas. 2018 , 15, 421-436	6
779	The clinicopathological significance of CD133 and Sox2 in astrocytic glioma. 2018 , 23, 391-403	5
778	Advances in the classification of pediatric brain tumors through DNA methylation profiling: From research tool to frontline diagnostic. 2018 , 124, 4168-4180	30

777	cIMPACT-NOW update 3: recommended diagnostic criteria for "Diffuse astrocytic glioma, IDH-wildtype, with molecular features of glioblastoma, WHO grade IV". <i>Acta Neuropathologica</i> , 2018 , 136, 805-810	14.3	367
776	Association of MicroRNAs with the Clinicopathologic Characteristics of Ependymoma. 2018 , 66, 307-313		2
775	Loperamide, pimozone, and STF-62247 trigger autophagy-dependent cell death in glioblastoma cells. 2018 , 9, 994		33
774	Post-treatment maturation of medulloblastoma in children: two cases and a literature review. 2018 , 46, 4781-4790		2
773	Long-Term Electroclinical and Employment Follow up in Temporal Lobe Epilepsy Surgery. A Cuban Comprehensive Epilepsy Surgery Program. 2018 , 8,		0
772	Targeted Theranostic Nanoparticles for Brain Tumor Treatment. 2018 , 10,		59
771	Liponeurocytoma: Systematic Review of a Rare Entity. 2018 , 120, 214-233		18
770	Biomaterials Developments for Brain Tissue Engineering. 2018 , 1078, 323-346		6
769	Molecular diagnostic testing of diffuse gliomas in the real-life setting: A practical approach. 2018 , 37, 166-177		4
768	Anaplastic Glioma: Treatment Approaches in the Era of Molecular Diagnostics. 2018 , 19, 61		4
767	Neuroimaging in patients with high-grade gliomas. 2018 , 62, 221-224		
766	Receptor-Targeted Glial Brain Tumor Therapies. 2018 , 19,		23
765	Over-expressed lncRNA HOTAIRM1 promotes tumor growth and invasion through up-regulating HOXA1 and sequestering G9a/EZH2/Dnmts away from the HOXA1 gene in glioblastoma multiforme. 2018 , 37, 265		81
764	Microglia Induce PDGFRB Expression in Glioma Cells to Enhance Their Migratory Capacity. 2018 , 9, 71-83		23
763	Current Radiopharmaceuticals for Positron Emission Tomography of Brain Tumors. 2018 , 6, 47-53		18
762	Surgical Outcomes of Thalamic Tumors in Children: The Importance of Diffusion Tensor Imaging, Neuro-Navigation and Intraoperative Neurophysiological Monitoring. 2018 , 6, 60-67		6
761	Targeting Long Noncoding RNA in Glioma: A Pathway Perspective. 2018 , 13, 431-441		36
760	Methylation dependent down-regulation of G0S2 leads to suppression of invasion and improved prognosis of IDH1-mutant glioma. 2018 , 13, e0206552		5

759	Intracranial clear cell meningioma: Clinical study with long-term follow-up in 24 patients. 2018 , 175, 74-83	7
758	Integrating in vitro experiments with in silico approaches for Glioblastoma invasion: the role of cell-to-cell adhesion heterogeneity. 2018 , 8, 16200	15
757	Angiotensinogen rs5050 germline genetic variant as potential biomarker of poor prognosis in astrocytoma. 2018 , 13, e0206590	8
756	Gliosarcoma of Cerebello-Pontine Angle: A Case Report and Review of the Literature. 2018 , 6, 78-81	
755	Harnessing the immune system in glioblastoma. 2018 , 119, 1171-1181	79
754	Hypofractionated Stereotactic Radiotherapy as a Salvage Therapy for Recurrent High-Grade Gliomas: Single-Center Experience. 2018 , 17, 1533033818806498	6
753	The Evolving Role of the Oncologic Neurosurgeon: Looking Beyond Extent of Resection in the Modern Era. 2018 , 8, 406	1
752	Intra-tumoral treatment with oxygen-ozone in glioblastoma: A systematic literature search and results of a case series. 2018 , 16, 5813-5822	1
751	Regulating glioma stem cells by hypoxia through the Notch1 and Oct3/4 signaling pathway. 2018 , 16, 6315-6322	6
750	Pathology of Pediatric Hydrocephalus. 2018 , 1-25	
749	miR-29s function as tumor suppressors in gliomas by targeting TRAF4 and predict patient prognosis. 2018 , 9, 1078	12
748	Tumours of the central nervous system. 2018 , 36, 630-636	
747	Clinical applications of in vivo magnetic resonance spectroscopy in oncology. 2018 , 63, 21TR02	3
746	Evaluation of the most commonly used (semi-)quantitative parameters of 18F-FDG PET/CT to detect malignant transformation of neurofibromas in neurofibromatosis type 1. 2018 , 39, 961-968	8
745	Primary cilium and glioblastoma. 2018 , 10, 1758835918801169	18
744	Contralesional macrostructural plasticity of the insular cortex in patients with glioma: A VBM study. 2018 , 91, e1902-e1908	36
743	Nonmeasurable Speckled Contrast-Enhancing Lesions Appearing During Course of Disease Are Associated With IDH Mutation in High-Grade Astrocytoma Patients. 2018 , 102, 1472-1480	4
742	Posterior fossa recurrence of WHO grade II and III supratentorial gliomas. 2018 , 174, 705-710	0

741	Integration of Diffusion Magnetic Resonance Tractography into tomotherapy radiation treatment planning for high-grade gliomas. 2018 , 55, 127-134	8
740	Prognostic Factors and Survival of Gliomatosis Cerebri: A Systematic Review and Meta-Analysis. 2018 , 120, e818-e854	7
739	BRAF V600E, TERT, and IDH2 Mutations in Pleomorphic Xanthoastrocytoma: Observations from a Large Case-Series Study. 2018 , 120, e1225-e1233	12
738	Analysis of point mutations and copy number variation in Grade II and III meningioma. 2018 , 105, 328-333	12
737	High-Grade Gliomas: A Multidisciplinary Approach. 2018 , 40, 1-5	
736	Clinically Relevant and Minimally Invasive Tumor Surveillance of Pediatric Diffuse Midline Gliomas Using Patient-Derived Liquid Biopsy. 2018 , 24, 5850-5859	62
735	In vitro Influence of Different Fatty Acids on the Pharmacological Effect of Temozolomide. 2018 , 03,	
734	Glioma Shapes BloodBrain Barrier Integrity and Remodels the Tumor Microenvironment: Links with Clinical Features and Prognosis. 2022 , 11, 5863	0
733	2-Methoxyestradiol Damages DNA in Glioblastoma Cells by Regulating nNOS and Heat Shock Proteins. 2022 , 11, 2013	0
732	Glioma radiogenomics and artificial intelligence: road to precision cancer medicine. 2022 ,	0
731	Advances in Preclinical/Clinical Glioblastoma Treatment: Can Nanoparticles Be of Help?. 2022 , 14, 4960	2
730	Effect of nursing home care on the quality of life of patients with major depressive in Iranian patients: A randomized controlled trial. 2022 ,	0
729	Frameless robotic-assisted biopsy of pediatric brainstem lesions: A systematic review and meta-analysis of efficacy and safety.. 2022 ,	0
728	Clinical Management of Embryonal Tumor with Multilayered Rosettes: The CCMC Experience. 2022 , 9, 1560	0
727	A novel model based on necroptosis-related genes for predicting immune status and prognosis in glioma. 13,	0
726	The Oncogenesis of Glial Cells in Diffuse Gliomas and Clinical Opportunities.	0
725	The Significance of MGMT Promoter Methylation Status in Diffuse Glioma. 2022 , 23, 13034	1
724	A Mass Spectrometry Imaging and Lipidomic Investigation Reveals Aberrant Lipid Metabolism in the Orthotopic Mouse Glioma. 2022 , 100304	0

- 723 How Genetics and Genomics Advances Are Rewriting Pediatric Cancer Research and Clinical Care. **2022**, 58, 1386 ○
- 722 Adult's Medulloblastoma. **2022**, 4, 44-47 ○
- 721 Endoscopic endonasal resection of two rare cases of hemangiopericytomas invading the cavernous sinus and literature review. 9, ○
- 720 Targeting integrin α as potential strategy for radiochemosensitization of glioblastoma. ○
- 719 A Head-to-Head Comparison of 18F-Fluorocholine PET/CT and Conventional MRI as Predictors of Outcome in IDH Wild-Type High-Grade Gliomas. **2022**, 11, 6065 ○
- 718 Radiotherapy for meningiomas. ○
- 717 Primary Extracranial Meningioma Mimicking Musculoskeletal Malignancy: A Case Report. **2022**, 8, 98-102 ○
- 716 Distinct expression and function of breast cancer metastasis suppressor 1 in mutant P53 glioblastoma. ○
- 715 METTL3 regulates m6A methylation of PTCH1 and GLI2 in Sonic hedgehog signaling to promote tumor progression in SHH-medulloblastoma. **2022**, 41, 111530 ○
- 714 Pharmacological Landscape of FDA-approved Anticancer Drugs Reveals Sensitivities to Ixabepilone, Romidepsin, Omacetaxine, and Carfilzomib in Aggressive Meningiomas. ○
- 713 Molecular Engines, Therapeutic Targets, and Challenges in Pediatric Brain Tumors: A Special Emphasis on Hydrogen Sulfide and RNA-Based Nano-Delivery. **2022**, 14, 5244 1
- 712 A Single-Center Retrospective Analysis of Intracranial and Spinal Solitary Fibrous Tumor/Hemangiopericytoma Clinical Outcomes: Gender Association with Aggressiveness.. **2022**, ○
- 711 Conventional MRI-Derived Biomarkers of Adult-Type Diffuse Glioma Molecular Subtypes: A Comprehensive Review. **2022**, 10, 2490 ○
- 710 Primary Neoplasms of the Brain in Adults. 1-13 ○
- 709 Association of homotopic areas in the right hemisphere with language deficits in the short term after tumor resection. **2022**, 1-10 ○
- 708 Allergic airway inflammation delays glioblastoma progression and reinvigorates systemic and local immunity in mice. ○
- 707 FFCAEs : An efficient feature fusion framework using cascaded autoencoders for the identification of gliomas. 1
- 706 The trends and significance of SSTR PET/CT added to MRI in follow-up imaging of low-grade meningioma treated with fractionated proton therapy. ○

705	Language reorganization in patients with left-hemispheric gliomas is associated with increased cortical volume in language-related areas and in the default mode network. 2022,	2
704	SLC43A3 Promotes Oncogenesis and Predicts Poor Prognosis in Glioma.	0
703	Dual EGFR- and TfR-targeted Gene Transfer Improves Efficacy of Sodium Iodide Symporter (NIS) Gene Therapy of Glioblastoma. 2022,	0
702	Loss of CD99L2 contributed to temozolomide resistance and glioblastoma tumorigenesis based on Genome-scale CRISPR/Cas9 screening.	0
701	Olfactory Groove Meningiomas: Comprehensive assessment between the different microsurgical transcranial approaches and the Endoscopic Endonasal Approaches, systematic review and metanalysis on behalf of the EANS skull base section. 2022, 101661	0
700	Molecular and clinical characterization of H3 K27M-mutant Non-midline Glioblastoma: A case report and literature review. 2022, 33, 356-360	0
699	Integration of molecular pathology with histopathology to accurately evaluate the biological behaviour of WHO grade 2 meningiomas and patient prognosis.	0
698	Grading of gliomas using transfer learning on MRI images.	0
697	Pre-surgical evaluation challenges and long-term outcome in children operated on for Low Grade Epilepsy Associated brain Tumors. 2022, 41, 55-62	0
696	CRISPR/Cas9-induced knockout reveals the role of ABCB1 in the response to temozolomide, carmustine and lomustine in glioblastoma multiforme. 2022, 185, 106510	0
695	Smart Nanoformulations for Brain Cancer Theranostics: Challenges and Promises. 2022, 14, 5389	1
694	Meningeosis Neoplastica in Patients with Glioblastoma: Analysis of 36 Cases. 2022,	0
693	A rare cause of adult's epileptic crisis: Infratentorial multinodular and vacuolating neuronal tumor. 2022, 17, 4847-4849	0
692	CSNK1D is associated with stemness and invasiveness in glioblastoma. 2022, 240, 154187	0
691	Glioma diagnosis and therapy: Current challenges and nanomaterial-based solutions. 2022, 352, 338-370	1
690	Application of biomaterials for glioblastoma treatment: Promises, advances, and challenges. 2022, 33, 104562	0
689	LINC01711 promotes transforming growth factor-beta (TGF- β) induced invasion in glioblastoma multiforme (GBM) by acting as a competing endogenous RNA for miR-34a and promoting ZEB1 expression. 2023, 792, 136937	0
688	Signaling pathways governing glioma cancer stem cells behavior. 2023, 101, 110493	0

- 687 Embryonaler Tumor mit mehrschichtigen Rosetten. **2023**, 301-305 ○
- 686 Pilomyxoides Astrozytom. **2023**, 256-260 ○
- 685 Anaplastisches Astrozytom. **2023**, 261-265 ○
- 684 Comparative analysis of somatostatin analog uptake between successfully irradiated and non-irradiated meningiomas. **2022**, 20, ○
- 683 Brain Tumour Image Segmentation Using Deep Networks. 7-12 ○
- 682 Central nervous system germ cell tumor, an archetypal AYA tumor and a model for pediatric and neuro-oncology collaboration, review from the EURACAN domain 10 group. 12, ○
- 681 High dose craniospinal irradiation as independent risk factor of permanent alopecia in childhood medulloblastoma survivors: cohort study and literature review. ○
- 680 Fluorescein sodium in the surgical treatment of pleomorphic xanthoastrocytomas: Results from a retrospective study. 12, ○
- 679 Factors Involved in Preoperative Edema in High-Grade Gliomas. **2022**, ○
- 678 Influence of measurement mode on the results of glioblastoma multiforme analysis with the FTIR microspectroscopy. **2022**, 122086 ○
- 677 Single-nucleus transcriptomics of IDH1- and TP53-mutant glioma stem cells displays diversified commitment on invasive cancer progenitors. **2022**, 12, 1
- 676 Re-irradiation of Pediatric Medulloblastoma: A Case Report and Systematic Review. **2022**, ○
- 675 A three-component multi-b-value diffusion-weighted imaging might be a useful biomarker for detecting microstructural features in gliomas with differences in malignancy and IDH-1 mutation status. ○
- 674 Outcome and characteristics of patients with adult grade 4 diffuse gliomas changing sites of treatment. ○
- 673 Whole-genome sequencing of extrachromosomal circular DNA of cerebrospinal fluid of medulloblastoma. 12, ○
- 672 Global survival trends for brain tumors, by histology: analysis of individual records for 556,237 adults diagnosed in 59 countries during 2000-2014 (CONCORD-3). ○
- 671 Noninvasive approaches to detect methylation-based markers to monitor gliomas. **2022**, 4, ii22-ii32 1
- 670 LncRNA as potential biomarker and therapeutic target in glioma. ○

669	Siglec10A ⁿ an immunosuppressor and negative predictor of survival prognosis in gliomas. 13,	0
668	Changes to pediatric brain tumors in 2021 World Health Organization classification of tumors of the central nervous system.	1
667	Predicting survival of glioblastoma from automatic whole-brain and tumor segmentation of MR images. 2022, 12,	1
666	Evaluation of DNA Methylation Array for Glioma Tumor Profiling and Description of a Novel Epi-Signature to Distinguish IDH1/IDH2 Mutant and Wild-Type Tumors. 2022, 13, 2075	0
665	Towards a single-assay approach: a combined DNA/RNA sequencing panel eliminates diagnostic redundancy and detects clinically-relevant fusions in neuropathology. 2022, 10,	0
664	Single-voxel MR spectroscopy of gliomas with s-LASER at 7T.	0
663	A Novel Insight into Paraptosis-Related Classification and Signature in Lower-Grade Gliomas. 2022, 2022, 1-32	0
662	Alterations in white matter fiber density associated with structural MRI and metabolic PET lesions following multimodal therapy in glioma patients. 12,	0
661	Application of Artificial Intelligence in Pathology: Trends and Challenges. 2022, 12, 2794	1
660	Three-dimensional visualization of human brain tumors using the CUBIC technique.	1
659	UBD is a potential diagnostic and prognostic biomarker in glioma.	0
658	Registration of molecular markers in population-based cancer registries; Hopes & hurdles.	0
657	Proteomic landscape of primary and metastatic brain tumors for heterogeneity discovery.	0
656	Overexpression of Pleckstrin Homology Domain-Containing Family A Member 4 Is Correlated with Poor Prognostic Outcomes and Immune Infiltration in Lower-Grade Glioma. 2022, 2022, 1-15	0
655	TSPO PET signal using [18F]GE180 is associated with survival in recurrent gliomas.	1
654	HSP90 facilitates stemness and enhances glycolysis in glioma cells. 2022, 22,	0
653	Leptomeningeal metastases in glioma revisited: incidence and molecular predictors based on postcontrast fluid-attenuated inversion recovery imaging. 2022, 1-11	0
652	Multidisciplinary Treatment of Liver Metastases from Intracranial SFTs/HPCs: A Report of Three Consecutive Cases. 2022, 29, 8720-8741	0

- 651 Particulate Matters Affecting lncRNA Dysregulation and Glioblastoma Invasiveness: In Silico Applications and Current Insights. 1
- 650 CLINICAL INSIGHT ON PATTERNS OF CARE AND PROGNOSTIC FACTORS IN ADULT HIGH GRADE GLIOMA: EXPERIENCE FROM A TERTIARY CANCER HOSPITAL FROM EASTERN INDIA. 32-36 0
- 649 The tRNA-Cys-GCA Derived tsRNAs Suppress Tumor Progression of Gliomas via Regulating VAV2. 2022, 2022, 1-16 0
- 648 Progesterone receptor expression and prediction of benefits of adjuvant radiotherapy in de novo atypical meningiomas after gross-total resection. 2022, 1-10 0
- 647 Standard or extended STUPP? Optimal duration of temozolomide for patients with high-grade gliomas: a retrospective analysis. 1
- 646 Research on application of tumor treating fields in glioblastoma: A bibliometric and visual analysis. 12, 0
- 645 Strategies to overcome/penetrate the BBB for systemic nanoparticle delivery to the brain/brain tumor. 2022, 114619 1
- 644 Imaging features associated with H3 K27-altered and H3 G34-mutant gliomas: a narrative systematic review. 2022, 22, 0
- 643 Clinical and Molecular Features in Medulloblastomas Subtypes in Children in a Cohort in Taiwan. 2022, 14, 5419 0
- 642 Tumor-derived Biomarkers in Liquid Biopsy of Glioblastoma. 2022, 0
- 641 Drug Delivery to the Brain: Targeting Technologies to Deliver Therapeutics to Brain Lesions. 2022, 389-424 0
- 640 Intranasal delivery of nanoliposomal SN-38 for treatment of diffuse midline glioma. 2022, 1-10 0
- 639 Current perspectives on diffuse midline glioma and a different role for the immune microenvironment compared to glioblastoma. 2022, 19, 0
- 638 Image-localized Biopsy Mapping of Brain Tumor Heterogeneity: A Single-Center Study Protocol. 0
- 637 Hybrid tumors with perineurioma components: a systematic review of the literature and illustrative case. 0
- 636 MUC16 mutation is associated with tumor grade, clinical features, and prognosis in glioma patients. 2022, 0
- 635 A comparative study of quantitative metrics in chemical exchange saturation transfer imaging for grading gliomas in adults. 2022, 0
- 634 Long-term postoperative health-related quality of life in patients with subfrontal meningiomas. 2022, 1-10 0

- 633 Effect of intraoperative goal-directed fluid therapy on the postoperative brain edema in patients undergoing high-grade glioma resections: a study protocol of randomized control trial. **2022**, 23, 0
- 632 Glioma Stem Cells: Novel Data Obtained by Single-Cell Sequencing. **2022**, 23, 14224 0
- 631 Radiological Differentiation Between Intracranial Meningioma and Solitary Fibrous Tumor/Hemangiopericytoma: A Systematic Literature Review. **2022**, 0
- 630 Rare embryonal and sarcomatous central nervous system tumours: State-of-the art and future directions. **2023**, 66, 104660 0
- 629 Histone H3 K27 alterations in central nervous system tumours: Challenges and alternative diagnostic approaches. **2022**, 101876 0
- 628 MR-guided non-invasive typing of brain gliomas using machine learning. **2022**, 86, 36 0
- 627 Association of CT and MRI Manifestations with Pathology in Dysembryoplastic Neuroepithelial Tumors. **2022**, 106, 0
- 626 Treatment of Adult Gliomas: A Current Update. **2022**, 15, 0
- 625 Construction of a prognostic classifier and prediction of the immune landscape and immunosuppressive molecules in gliomas based on combination of inflammatory response-related genes and angiogenesis-associated genes. **2022**, 20, 1721727X2211337 0
- 624 Immunotherapy for a patient with high-grade glioblastoma. **2022**, 11, 37 0
- 623 Resective surgery for patients with frontal lobe diffuse low-grade glioma-related epilepsy: predictors of seizure outcomes. **2022**, 13, 204062232211418 0
- 622 Implication of lncRNA ZBED3-AS1 downregulation in acquired resistance to Temozolomide and glycolysis in glioblastoma. **2023**, 938, 175444 0
- 621 RAAGR2-Net: A brain tumor segmentation network using parallel processing of multiple spatial frames. **2023**, 152, 106426 0
- 620 Immunological profiles of human oligodendrogliomas define two distinct molecular subtypes. **2023**, 87, 104410 0
- 619 Terahertz technology in intraoperative neurodiagnostics: A review. **2023**, 220071-220071 1
- 618 Substrate stiffness regulates the recurrent glioblastoma cell morphology and aggressiveness. **2023**, 115, 107-127 1
- 617 Current studies and future directions for medulloblastoma: A review from the pacific pediatric neuro-oncology consortium (PNOC) disease working group. **2023**, 35, 100861 0
- 616 Increased relative biological effectiveness and periventricular radiosensitivity in proton therapy of glioma patients. **2023**, 178, 109422 1

- 615 Impact of EGFR289T/V mutation on relapse pattern in glioblastoma. **2023**, 8, 100740 ○
- 614 Mitosis domain generalization in histopathology images □The MIDOG challenge. **2023**, 84, 102699 ○
- 613 Multiparametric study for glioma grading with FLAIR, ADC map, eADC map, T1 map, and SWI images. **2023**, 96, 93-101 ○
- 612 AI-assisted clinical decision making (CDM) for dose prescription in radiosurgery of brain metastases using three-path three-dimensional CNN. **2023**, 39, 100565 ○
- 611 Imaging characterization of an adult H3 K27M-altered diffuse midline glioma of the medulla oblongata with a confounding steroid response. **2023**, 18, 788-793 ○
- 610 Pineocytoma with malignant transformation to pineal parenchymal tumor with intermediate differentiation and leptomeningeal dissemination after subtotal tumor resection and adjuvant radiotherapy. **2022**, 0 ○
- 609 Surgical treatment of giant tumors of the cerebral hemispheres in children. **2022**, 122, 24 ○
- 608 Cancer immune profiling unveils biomarkers, immunological pathways, and cell type score associated with glioblastoma patients' survival. **2022**, 14, 175883592211276 ○
- 607 Interdisciplinary Approach in Neurological Cancers. **2022**, ○
- 606 A rare lymphoplasmacyte-rich meningioma involving the dura of the skull base and cervical spinal cord: A case report. **2022**, 13, 470-475 ○
- 605 Molecular Neuropathology versus Histopathology in the Diagnosis of Central Nervous System Tumors: Review Article about Novel Diagnostic and Investigative Technologies. **2022**, 10, 55-72 ○
- 604 Intracranial Tumor Presenting as Raymond Syndrome in a Pediatric Patient. **2021**, 2, 18-21 ○
- 603 A Comprehensive Non-invasive System for Early Grading of Gliomas. **2022**, ○
- 602 Efficient Net Transfer Learning based Early Prediction of Monkey Pox Lesion. **2022**, ○
- 601 The role of angiogenic factors eNOS / VEGF in the treatment of anaplastic glioma. **2022**, 883-892 ○
- 600 A Model for Predicting Clinical Prognosis in Patients with WHO Grade 2 Glioma. **2022**, 2022, 1-9 ○
- 599 Comprehensive Analysis of the Prognostic Value and Molecular Function of CRNDE in Glioma at Bulk and Single-Cell Levels. **2022**, 11, 3669 1
- 598 Overview on Common Genes Involved in the Onset of Glioma and on the Role of Migraine as Risk Factor: Predictive Biomarkers or Therapeutic Targets?. **2022**, 12, 1969 ○

597	Clinical Profiles and Mutation Landscapes of Meningiomas with Different Growth Rate.	o
596	Cell-free DNA-based liquid biopsies in neurology.	o
595	Low grade gliomas guide-lines elaborated by the tumor section of Spanish Society of Neurosurgery. 2022,	o
594	Neuronal and tumourigenic boundaries of glioblastoma plasticity. 2022,	1
593	Multiprotein GLI Transcriptional Complexes as Therapeutic Targets in Cancer. 2022, 12, 1967	o
592	The Autologous Hematopoietic Stem Cells Transplantation Combination-Based Chimeric Antigen Receptor T-Cell Therapy Improves Outcomes of Relapsed/Refractory Central Nervous System B-Cell Lymphoma. 2022, 2022, 1-20	o
591	Predicting IDH Mutation Status in Low-Grade Gliomas Based on Optimal Radiomic Features Combined with Multi-Sequence Magnetic Resonance Imaging. 2022, 12, 2995	o
590	Liquid biopsy with multiplex ligation-dependent probe amplification targeting cell-free tumor DNA in cerebrospinal fluid from patients with adult diffuse glioma.	o
589	Qualitative descriptive study during the COVID-19 pandemic on the needs of informal caregivers of Chinese minors who underwent craniopharyngioma surgery. 2022,	o
588	Cognitive Rehabilitation in Patients with Cerebral Pathology. 2022, 7, 219-224	o
587	Clinical Management of Supratentorial Non-Skull Base Meningiomas. 2022, 14, 5887	o
586	Challenging Cases in Neuro-Oncology.	o
585	Plasma IL13R α 2 as a novel liquid biopsy biomarker for glioblastoma. 2022, 160, 743-752	o
584	Identification of VASH1 as a Potential Prognostic Biomarker of Lower-Grade Glioma by Quantitative Proteomics and Experimental Verification. 2022, 2022, 1-25	o
583	Diagnostic performance of perfusion-weighted imaging combined with serum MMP -2 and -9 levels in tumor recurrence after postoperative concomitant chemoradiotherapy of glioblastoma.	1
582	Implementing the Point Spread Function Deconvolution for Better Molecular Characterization of Newly Diagnosed Gliomas: A Dynamic 18F-FDOPA PET Radiomics Study. 2022, 14, 5765	o
581	Efficient Knowledge Distillation for Brain Tumor Segmentation. 2022, 12, 11980	o
580	Cost Matrix of Molecular Pathology in Glioma¶owards AI-Driven Rational Molecular Testing and Precision Care for the Future. 2022, 10, 3029	o

579	Anoctamins and Calcium Signalling: An Obstacle to EGFR Targeted Therapy in Glioblastoma?. 2022 , 14, 5932	0
578	Malignant meningioma. 2022 , 130, 1-58	0
577	Review of Intraoperative Adjuncts for Maximal Safe Resection of Gliomas and Its Impact on Outcomes. 2022 , 14, 5705	0
576	Establishing a glutamine metabolism-based model for predicting the prognosis of low-grade glioma. 13,	0
575	Molecular subgrouping of medulloblastoma in pediatric population using the NanoString assay and comparison with immunohistochemistry methods. 2022 , 22,	0
574	Machine learning-based identification of SOX10 as an immune regulator of macrophage in gliomas. 13,	0
573	Extended adjuvant temozolomide in newly diagnosed glioblastoma: A single-center retrospective study. 12,	0
572	Methylation Profiling in Diffuse Gliomas: Diagnostic Value and Considerations. 2022 , 14, 5679	0
571	Quality indicators for evaluating the 30-day postoperative outcome in pediatric brain tumor surgery: a 10-year single-center study and systematic review of the literature. 2022 , 1-15	0
570	The pro-invasive factor COL6A2 serves as a novel prognostic marker of glioma. 12,	0
569	PDPN contributes to constructing immunosuppressive microenvironment in IDH wildtype glioma.	1
568	Assessment and prediction of glioblastoma therapy response: challenges and opportunities.	1
567	Phase 2 study of AV-GBM-1 (a tumor-initiating cell targeted dendritic cell vaccine) in newly diagnosed Glioblastoma patients: safety and efficacy assessment. 2022 , 41,	1
566	Joint learning sample similarity and correlation representation for cancer survival prediction. 2022 , 23,	1
565	Update nuklearmedizinische Bildgebung von Gehirntumoren und -metastasen. 2022 , 45, 351-359	0
564	Primary Intramedullary Spinal High-Grade Glioma: A Case Series with Review of Literature.	0
563	Efficacy and safety of peptide receptor radionuclide therapy with [177Lu]Lu-DOTA-TATE in 15 patients with progressive treatment-refractory meningioma.	1
562	The LUMIERE dataset: Longitudinal Glioblastoma MRI with expert RANO evaluation. 2022 , 9,	0

- 561 Progress of radiological-pathological workflows in the differential diagnosis between primary central nervous system lymphoma and high-grade glioma (Review). **2022**, 49, ○
- 560 An effective tumor detection in MR brain images based on deep CNN approach: i-YOLOV5. **2022**, 36, ○
- 559 The role of sodium fluorescein in pediatric supratentorial intra-axial tumor resection: new insights from a monocentric series of 33 consecutive patients. 1
- 558 CHRDL1 Regulates Stemness in Glioma Stem-like Cells. **2022**, 11, 3917 ○
- 557 Defining the cell of origin for diffuse midline gliomas. **2022**, 54, 1770-1771 ○
- 556 Profiling and Bioinformatics Analyses of Differential Circular RNA Expression in Glioblastoma Multiforme Cells Under Hypoxia. ○
- 555 Exploration of natural product database for the identification of potent inhibitor against IDH2 mutational variants for glioma therapy. **2023**, 29, ○
- 554 Feasibility of evaluating the histologic and genetic subtypes of WHO grade II-IV gliomas by diffusion-weighted imaging. **2022**, 23, ○
- 553 Current management in the treatment of intramedullary ependymomas in children. ○
- 552 FCGRT, a cancer-derived immunoglobulin G binding protein, mediates the malignant phenotype of glioma. ○
- 551 Morphologically, genetically and spatially mixed astrocytoma and oligodendroglioma; chronological acquisition of 1p/19q codeletion and CDKN2A deletion: a case report. ○
- 550 Radiomics-based machine learning models for prediction of medulloblastoma subgroups: a systematic review and meta-analysis of the diagnostic test performance. 028418512211434 ○
- 549 Multi-instance learning based on spatial continuous category representation for case-level meningioma grading in MRI images. ○
- 548 Kavain ablates the radio-resistance of IDH-wildtype glioblastoma by targeting LITAF/NF- κ B pathway. ○
- 547 Predicting glioblastoma molecular subtypes and prognosis with a multimodal model integrating convolutional neural network, radiomics, and semantics. **2022**, 1-10 ○
- 546 Synthesis and Biological Evaluation of tert-Butyl Ester and Ethyl Ester Prodrugs of L-Methyleneglutamic Acid Amides for Cancer. **2022**, 117137 ○
- 545 Preoperative prediction and histological stratification of intracranial solitary fibrous tumours by machine-learning models. **2022**, ○
- 544 The landscape of tumor cell states and spatial organization in H3-K27M mutant diffuse midline glioma across age and location. **2022**, 54, 1881-1894 ○

- 543 Molecular targeted therapy: A new avenue in glioblastoma treatment (Review). **2022**, 25, 0
- 542 Pineal anlage tumor: a case report and the literature review. 0
- 541 Importancia pronóstica de las mutaciones del gen promotor de la transcriptasa inversa de la telomerasa en los meningiomas de alto grado. **2022**, 42, 574-590 0
- 540 Infiltrating gliomas with FGFR alterations: Histologic features, genetic alterations, and potential clinical implications. **2022**, 1-15 0
- 539 Prolonged survival in patients with local chronic infection after high-grade glioma treatment: Two case reports. 12, 0
- 538 Case report: Two unique cases of co-existing primary brain tumors of glial origin in opposite hemispheres. 12, 0
- 537 Health horizons: Future trends and technologies from the European Medicines Agency's horizon scanning collaborations. 9, 0
- 536 Roadmap toward subtype-specific vulnerabilities in adult glioma. **2022**, 1, 0
- 535 Impact of extent of resection on survival on Glioblastoma, IDH-wildtype, WHO grade 4 (WHO 2021). Systematic review and meta-analysis. **2022**, 0
- 534 Vision Transformer-based Weakly-Supervised Histopathological Image Analysis of Primary Brain Tumors. **2022**, 105872 0
- 533 Meningioma classification by immunohistochemistry: A replicability study. **2022**, 101711 0
- 532 Combination drug screen targeting glioblastoma core vulnerabilities reveals pharmacological synergisms. 0
- 531 Meningioma microstructure assessed by diffusion MRI: an investigation of the source of mean diffusivity and fractional anisotropy by quantitative histology. 0
- 530 Clinical and oncological outcomes in single-stage versus staged surgery for pediatric craniopharyngiomas: a multicenter retrospective study. 0
- 529 Cell signaling activation and extracellular matrix remodeling underpin glioma tumor microenvironment heterogeneity and organization. 0
- 528 Newly recognised Tumour Types in Glioneuronal tumours according to the 5th edition of the CNS WHO Classification. **2022**, 114, 447-454 1
- 527 A novel lncRNA MDHDH suppresses glioblastoma multiforme by acting as a scaffold for MDH2 and PSMA1 to regulate NAD⁺ metabolism and autophagy. **2022**, 41, 1
- 526 Predicting the grade of meningiomas by clinical-radiological features: A comparison of precontrast and postcontrast MRI. 12, 0

525	Tropomyosin receptor kinase B (TrkB) signalling: targeted therapy in neurogenic tumours.	o
524	SARS-CoV-2 Pattern Provides a New Scoring System and Predicts the Prognosis and Immune Therapeutic Response in Glioma. 2022 , 11, 3997	o
523	Expression analysis and regulation of GLI and its correlation with stemness and metabolic alteration in human brain tumor. 2023 , 13,	o
522	Brain Tumor Classification Using Machine Learning and Deep Learning Algorithms. 2022 , 10, 999-1004	o
521	Inter and intra-tumor heterogeneity of paediatric type diffuse high-grade gliomas revealed by single-cell mass cytometry. 12,	1
520	The Mediating Effect of Uncertainty in Illness on Cancer Coping in Patients With Primary Malignant Brain Tumors. Publish Ahead of Print,	o
519	Two Cases of Primary Spinal Glioblastoma in Adults Treated With Multimodality Therapy. 2022 ,	o
518	Glioblastoma Molecular Classification Tool Based on mRNA Analysis: From Wet-Lab to Subtype. 2022 , 23, 15875	o
517	Epigenetic programming of pediatric high-grade glioma: Pushing beyond proof of concept to clinical benefit. 10,	o
516	Experience in the use of dendritic vaccines in the treatment of patients with recurrent gliomas. 2022 , 9, 18-29	o
515	Deep learning based on preoperative MR images improves the predictive power of survival models in primary spinal cord astrocytomas.	o
514	An intelligent brain tumor segmentation using improved Deep Learning Model Based on Cascade Regression method.	o
513	A Novel Approach to Detect IDH Point Mutations in Gliomas Using Nanopore Sequencing, Test Validation for the Clinical Laboratory. 2022 ,	o
512	Epigenetic reprogramming shapes the cellular landscape of schwannoma.	o
511	Primary renal sporadic hemangioblastoma: A case report and literature review. 2,	o
510	Predictors of seizure outcomes in patients with diffuse low-grade glioma-related epilepsy after complete glioma removal.	o
509	Analyzing the role of reoperation in recurrent glioblastoma: a 15-year retrospective study in a single institution. 2022 , 20,	o
508	Preoperative Risk Stratification of Increased MIB-1 Labeling Index in Pituitary Adenoma: A Newly Proposed Prognostic Scoring System. 2022 , 11, 7151	o

- 507 Survival analysis in high-grade glioma: The role of salvage surgery. **2022**, ○
- 506 HOTAIR gene polymorphisms and risk of glioma in Chinese children. **2022**, 1, ○
- 505 NRP1 inhibition modulates radiosensitivity of medulloblastoma by targeting cancer stem cells. **2022**, 22, ○
- 504 Molecular profile and clinical features of patients with gliomas using a broad targeted next generation-sequencing panel. **2022**, 25, ○
- 503 Role of CDKN2A deletion in grade 2/3 IDH-mutant astrocytomas: need for selective approach in resource-constrained settings. **2022**, 53, E17 ○
- 502 Meta-topologies define distinct anatomical classes of brain tumors linked to histology and survival. ○
- 501 The impact of etiology in lesion-symptom mapping [A direct comparison between tumor and stroke. **2022**, 103305 ○
- 500 Fetal Brain Tumors, a Challenge in Prenatal Diagnosis, Counselling, and Therapy. **2023**, 12, 58 ○
- 499 Mitotic count is prognostic in IDH-mutant astrocytoma without homozygous deletion of CDKN2A/B. Results of consensus panel review of EORTC trials 26053 and EORTC 22033-26033. ○
- 498 Discovery of clinical and demographic determinants of symptom burden in primary brain tumor patients using network analysis and unsupervised clustering. ○
- 497 Age-Dependent Impact of Concomitant Radio-Chemotherapy and MGMT Promotor Methylation on PFS and OS in Patients with IDH Wild-Type Glioblastoma: The Real-Life Data. **2022**, 14, 6180 ○
- 496 Expression of IL-13R α and FUS in glioma: clinicopathological and prognostic correlation.. ○
- 495 Association between tumor mutations and meningioma recurrence in Grade I/II disease. **2022**, 9, 70-81 ○
- 494 Correlation of Diffusion Tensor Imaging Parameters with the Pathological Grade of Brain Glioma and Expression of Vascular Endothelial Growth Factor and Ki-67. **2022**, 19, ○
- 493 Toward digital histopathological assessment in surgery for central nervous system tumors using stimulated Raman histology. **2022**, 53, E12 ○
- 492 Systematic Analysis of a Pyroptosis-Related Signature to Predict the Prognosis and Immune Microenvironment of Lower-Grade Glioma. **2022**, 11, 3980 ○
- 491 The sinuous, wave-like intratumoral-wall sign is a sensitive and specific radiological biomarker for oligodendrogliomas. ○
- 490 Menadione Potentiates Auranofin-Induced Glioblastoma Cell Death. **2022**, 23, 15712 ○

- 489 Oligodendroglioma with ganglioglioma-like maturation: the histopathological diagnostic challenge of a brain neoplasm with aberrant neuronal component [A case report and review of the literature. 13, 587 ○
- 488 ADC histogram parameters differentiating atypical from transitional meningiomas: correlation with Ki-67 proliferation index. ○
- 487 A prognostic risk model for glioma patients by systematic evaluation of genomic variations. **2022**, 25, 105681 ○
- 486 Differentiation of pilocytic astrocytoma from glioblastoma using a machine-learning framework based upon quantitative T1 perfusion MRI. **2022**, ○
- 485 Mapping the functional expression of auxiliary subunits of KCa1.1 in glioblastoma. **2022**, 12, ○
- 484 Network topology in brain tumor patients with and without structural epilepsy- a prospective MEG-study. ○
- 483 The translome of Glioblastoma multiforme. ○
- 482 Radiomics and artificial intelligence. **2023**, 365-401 ○
- 481 Isocitrate-dehydrogenase-mutant lower grade glioma in elderly patients: treatment and outcome in a molecularly characterized contemporary cohort. ○
- 480 Temporal and spatial stability of the EM/PM molecular subtypes in adult diffuse glioma. ○
- 479 Effects of a monoclonal antibody against (pro)renin receptor on gliomagenesis. **2023**, 13, ○
- 478 The diagnostic value of ADC histogram and direct ADC measurements for coexisting isocitrate dehydrogenase mutation and O6-methylguanine-DNA methyltransferase promoter methylation in glioma. 16, ○
- 477 Central Nervous System Neoplasms in Microgravity. **2022**, 107-121 ○
- 476 Multiomic profiling of medulloblastoma reveals subtype-specific targetable alterations at the proteome and N-glycan level. ○
- 475 Raman spectroscopy: A prospective intraoperative visualization technique for gliomas. 12, 1
- 474 Case report: Bphotodynamics of Subependymal Giant Cell Astrocytoma with 5-Aminolevulinic acid [9, ○
- 473 Liquid biopsy in pediatric brain tumors. 13, ○
- 472 An RNA seq-based reference landscape of human normal and neoplastic brain. ○

- 471 Mutational signature of extracranial meningioma metastases and their respective primary tumors. **2023**, 11, ○
- 470 The Recurrent-Specific Regulation Network of Prognostic Stemness-Related Signatures in Low-Grade Glioma. **2023**, 2023, 1-29 ○
- 469 Imaging features of localized IDH wild-type histologically diffuse astrocytomas: a single-institution case series. **2023**, 13, ○
- 468 Signaling pathways in brain tumors and therapeutic interventions. **2023**, 8, ○
- 467 Risk factors, prognostic potency, and longitudinal variation of anxiety and depression in postoperative glioma patients. 9, ○
- 466 An RNA seq-based reference landscape of human normal and neoplastic brain. ○
- 465 Spatially controlled construction of assembloids using bioprinting. ○
- 464 Genomic analysis as a tool to infer disparate phylogenetic origins of dysembryoplastic neuroepithelial tumors and their satellite lesions. **2023**, 13, ○
- 463 DiPRO1 dependent transcriptional and epigenetic regulation distinctly controls the fate of muscle and mesenchymal cancer cells. ○
- 462 Hybrid Techniques of Analyzing MRI Images for Early Diagnosis of Brain Tumours Based on Hybrid Features. **2023**, 11, 212 3
- 461 Apparent Diffusion Coefficient as Imaging Biomarker for Identifying IDH Mutation, 1p19q Codeletion, and MGMT Promoter Methylation Status in Patients With Glioma. 1
- 460 Intravoxel incoherent motion (IVIM) for distinguishing glioma and solitary brain metastasis: A pilot multi-parameter magnetic resonance imaging histogram and texture analysis. ○
- 459 Novel genetically engineered H3.3G34R model reveals cooperation with ATRX loss in upregulation of Hoxa cluster genes and promotion of neuronal lineage. ○
- 458 Tacedinaline (CI-994), a class I HDAC inhibitor, targets intrinsic tumor growth and leptomeningeal dissemination in MYC-driven medulloblastoma while making them susceptible to anti-CD47-induced macrophage phagocytosis via NF- κ B-TGM2 driven tumor inflammation. **2023**, 11, e005871 ○
- 457 Events in CNS Tumor Pathology Post-2016 WHO CNS: cIMPACT-NOW Updates and Other Advancements: A Comprehensive Review Plus a Summary of the Salient Features of 2021 WHO CNS 5. Volume 16, 107-127 ○
- 456 Single-cell RNA sequencing reveals changes in glioma-associated macrophage polarization and cellular states of malignant gliomas with high AQP4 expression. ○
- 455 NCCN Guidelines[®] Insights: Central Nervous System Cancers, Version 2.2022. **2023**, 21, 12-20 ○
- 454 Development of an integrated predictive model for postoperative glioma-related epilepsy using gene-signature and clinical data. **2023**, 23, ○

- 453 Surgical Results of Using the Ommaya Reservoir System for the Management of Cystic Craniopharyngiomas; A Retrospective Single-Center Experience. ○
- 452 The efficacy of preoperative MRI features in the diagnosis of meningioma WHO grade and brain invasion. 12, ○
- 451 A magnetic resonance imaging based radiomics model to predict mitosis cycles in intracranial meningioma. **2023**, 13, ○
- 450 The Epidemiology of Brain and Spinal Cord Tumors. **2023**, 19-39 ○
- 449 Hierarchical multimodal fusion framework based on noisy label learning and attention mechanism for cancer classification with pathology and genomic features. **2023**, 102176 ○
- 448 An unusual indication of maxillectomy— case presentation of sphenoid wing meningioma. **2023**, 39, ○
- 447 Hybrid Optimization Algorithm Enabled Deep Learning Approach Brain Tumor Segmentation and Classification Using MRI. ○
- 446 Pediatric diffuse midline glioma H3K27- altered: A complex clinical and biological landscape behind a neatly defined tumor type. 12, ○
- 445 Non-operable glioblastoma: proposition of patient-specific forecasting by image-informed poromechanical model. ○
- 444 Deep Learning-Assisted Quantitative Susceptibility Mapping as a Tool for Grading and Molecular Subtyping of Gliomas. ○
- 443 Are Thalamic Intrinsic Lesions Operable? No-Man's Land Revisited by the Analysis of a Large Retrospective, Mono-Institutional, Cohort. **2023**, 15, 361 ○
- 442 Highly Multiplexed Spatially Resolved Proteomic and Transcriptional Profiling of the Glioblastoma Microenvironment Using Archived Formalin-Fixed Paraffin-Embedded Specimens. **2023**, 36, 100034 ○
- 441 Nucleic acid drug vectors for diagnosis and treatment of brain diseases. **2023**, 8, ○
- 440 Classification of central nervous system tumors histological diagnosed in a single center of Northwest China 2003-2019. ○
- 439 Functional genomic analysis of adult and pediatric brain tumor isolates. ○
- 438 Discrimination of the chemotherapy resistance status of human leukemia and glioblastoma cell lines by MALDI-TOF-MS profiling. ○
- 437 Association of RNA-modification Writers genes with prognosis and response to immunotherapy in patients with low-grade glioma. **2023**, 18, e0279119 ○
- 436 The clinical significance of radiological changes associated with gliadel implantation in patients with recurrent high grade glioma. **2023**, 13, ○

- 435 The impact of brain lesions on quality of life in patients with WHO CNS grade 3 or 4 glioma: A lesion-function and resting-state fMRI analysis. ○
- 434 Differentiating between adult intracranial medulloblastoma and ependymoma using MRI. **2023**, ○
- 433 Profiling of the genetic features of Chinese patients with gastric cancer with HRD germline mutations in a large-scale retrospective study. *jmg-2022-108816* ○
- 432 Emerging Perspectives on the Antiparasitic Mebendazole as a Repurposed Drug for the Treatment of Brain Cancers. **2023**, 24, 1334 ○
- 431 Overexpression of TPM4 is associated with worse prognosis and immune infiltration in patients with glioma. **2023**, 23, ○
- 430 Solitary fibrous tumor of the central nervous system invading and penetrating the skull: A case report. **2023**, 25, ○
- 429 HAT1 regulates the immune microenvironment and promotes the malignant pathology of lower-grade gliomas. ○
- 428 Is CD19-directed chimeric antigen receptor T cell therapy a smart strategy to combat central nervous system lymphoma?. 12, ○
- 427 Management of IDH-mutant astrocytoma based on WHO 2021 classification of central nervous system tumors: a single center retrospective study. ○
- 426 Sphingosine-1-Phosphate Recruits Macrophages and Microglia and Induces a Pro-Tumorigenic Phenotype That Favors Glioma Progression. **2023**, 15, 479 ○
- 425 Ferroptosis-related NFE2L2 and NOX4 Genes are Potential Risk Prognostic Biomarkers and Correlated with Immunogenic Features in Glioma. ○
- 424 The prognostic significance of tumor-associated neutrophils and circulating neutrophils in glioblastoma (WHO CNS5 classification). **2023**, 23, ○
- 423 A validated prognostic nomogram for patients with H3 K27M-mutant diffuse midline glioma. ○
- 422 Assessing the role of sodium fluorescein in peripheral nerve sheath tumors and mimicking lesions surgery: An update after 142 cases. 12, ○
- 421 Combining Multi-Shell Diffusion with Conventional MRI Improves Molecular Diagnosis of Diffuse Gliomas with Deep Learning. **2023**, 15, 482 ○
- 420 Low-grade epilepsy-associated neuroepithelial tumors: Tumor spectrum and diagnosis based on genetic alterations. 16, ○
- 419 Reciprocal expression of the immune response genes CXCR3 and IFI44L as module hubs are associated with patient survivals in primary central nervous system lymphoma. ○
- 418 Identification of a robust scoring system based on metabolic genes followed by in-depth validation of ATP1A3 in glioma. **2023**, 315, 121377 ○

- 417 Multiclass convolutional neural network based classification for the diagnosis of brain MRI images. **2023**, 82, 104542 ○
- 416 Brain Tumor Classification Using Deep Transfer Learning CNN Models. **2022**, ○
- 415 Deciphering the Clinical Trials of Immunotherapy in Glioblastoma: What a Neuroradiologist Needs to Know. **2022**, 12, 176-187 ○
- 414 High expression of NLRP12 predicts poor prognosis in patients with intracranial glioma. **2023**, 86, 88-97 ○
- 413 Meningioma or Mimic: Look Twice and Save a Life. **2022**, 12, 216-232 ○
- 412 Proton radiotherapy in the treatment of IDH-mutant diffuse gliomas: an early experience from shanghai proton and heavy ion center. ○
- 411 Hotspot on 18F-FET PET/CT to Predict Aggressive Tumor Areas for Radiotherapy Dose Escalation Guiding in High-Grade Glioma. **2023**, 15, 98 ○
- 410 Post Surgical Management of WHO Grade II Meningiomas: Our Experience, the Role of Gamma Knife and a Literature Review. **2023**, 13, 37 ○
- 409 Towards an Established Intraoperative Oncological Favorable Tool: Results of Fluorescein-Guided Resection from a Monocentric, Prospective Series of 93 Primary Glioblastoma Patients. **2023**, 12, 178 ○
- 408 Relative survival after meningioma surgery. A French nationwide population-based cohort study. 1-7 ○
- 407 Intracranial Subdural Fluid Accumulation Associated with a Choroid Plexus Carcinoma in a Dog. **2023**, 10, 24 ○
- 406 Differential Plasma Metabolites between High- and Low-Grade Meningioma Cases. **2023**, 24, 394 ○
- 405 Multiparametric Magnetic Resonance Imaging Correlates of Isocitrate Dehydrogenase Mutation in WHO high-Grade Astrocytomas. **2023**, 13, 72 ○
- 404 Surgical Principles for Spinal Meningiomas. ○
- 403 Preoperative surgical risk assessment of meningiomas: a narrative review based on MRI radiomics. **2023**, 46, ○
- 402 Clinical applications and prospects of PET imaging in patients with IDH-mutant gliomas. ○
- 401 Impact of COVID-19 Epidemic on Psycho-Oncological Distress in Neuro-Oncological Patients. **2023**, 30, 358-369 ○
- 400 A CNN-Based Strategy to Classify MRI-Based Brain Tumors Using Deep Convolutional Network. **2023**, 13, 312 ○

- 399 Clinicopathological and prognostic significance of COX-2 in glioma patients: a meta-analysis. **2022**, 80, 1254-1261 ○
- 398 Implications of deferred diagnosis of paediatric intracranial germ cell tumours. ○
- 397 Correlation of Surgical Outcomes of Petroclival Meningiomas with Clinicoradiologic Parameters and Molecular and Chromosomal Alterations. **2022**, ○
- 396 Apatinib combined with temozolomide treatment for pseudoprogression in glioblastoma: A case report. **2022**, 101, e32156 ○
- 395 Tumor sound, auditory cues, and tissue pathology in glioma surgery: a proof-of-concept study. **2022**, 1-9 ○
- 394 Hydrated C60 fullerene, glioblastoma h re hatt da parthanatosu artt  ve otofaji ile ilgili biyobelirteleleri ind ler. ○
- 393 Preclinical and Clinical Applications of Metabolomics and Proteomics in Glioblastoma Research. **2023**, 24, 348 ○
- 392 Contemporary Biological Insights and Clinical Management of Craniopharyngioma. ○
- 391 Myxopapillary ependymoma: A rare case presentation. **2022**, 2, 107 ○
- 390 Novel cell delivery systems: Intracranial and intrathecal. **2023**, 263-280 ○
- 389 MALDI Imaging Mass Spectrometry of High-Grade Gliomas: A Review of Recent Progress and Future Perspective. **2023**, 45, 838-851 ○
- 388 Apparent Diffusion Coefficient in the Differentiation of Common Pediatric Brain Tumors in the Posterior Fossa: Different Region-of-Interest Selection Methods for Time Efficiency, Measurement Reproducibility, and Diagnostic Utility. Publish Ahead of Print, ○
- 387 Observation of the delineation of the target volume of radiotherapy in adult-type diffuse gliomas after temozolomide-based chemoradiotherapy: analysis of recurrence patterns and predictive factors. **2023**, 18, ○
- 386 Meta-Analysis of Modulated Electro-Hyperthermia and Tumor Treating Fields in the Treatment of Glioblastomas. **2023**, 15, 880 ○
- 385 Molecular pathology and clinical implications of diffuse glioma. Publish Ahead of Print, ○
- 384 Deep Learning for Noninvasive Assessment of H3 K27M Mutation Status in Diffuse Midline Gliomas Using MR Imaging. ○
- 383 Emerging Recombinant Oncolytic Poliovirus Therapies Against Malignant Glioma: A Review. **2023**, ○
- 382 ¹¹C-methionine PET imaging characteristics in children with diffuse intrinsic pontine gliomas and relationship to survival and H3 K27M mutation status. ○

- 381 Effect of Dexmedetomidine versus Propofol on Intraoperative Seizure Onset During Awake Craniotomy: A Retrospective Study. **2023**, ○
- 380 Simpson's Grading Scale for WHO Grade I Meningioma Resection in the Modern Neurosurgical Era: Are We Really Asking the Right Question?. ○
- 379 Predictive model of language deficit after removing glioma involving language areas under general anesthesia. 12, ○
- 378 PIEZO1-Related Physiological and Pathological Processes in CNS: Focus on the Gliomas. **2023**, 15, 883 ○
- 377 Risk Stratification for Management of Solitary Fibrous Tumor/Hemangiopericytoma of the Central Nervous System. **2023**, 15, 876 ○
- 376 Tumor immunology. **2023**, 245-452 ○
- 375 Repeat resection for recurrent glioblastoma in the temozolomide era: a real-world multi-centre study. 1-9 ○
- 374 Prognostic Factors of Gliosarcoma in the Real World: A Retrospective Cohort Study. **2023**, 2023, 1-14 ○
- 373 Immunoreactivity against SLC3A2 in high grade gliomas displays positive correlation with glioblastoma patient survival: Potential target for glioma diagnosis and therapy. ○
- 372 Prognostic and predictive factors of secondary gliosarcoma: A single-institution series of 18 cases combined with 89 cases from literature. 12, ○
- 371 YAP nuclear translocation is regulated by EGFR activation through PTEN/AKT axis in glioblastomas. **2023**, 100053 ○
- 370 Metabolic rewiring in MYC-driven medulloblastoma by BET-bromodomain inhibition. **2023**, 13, ○
- 369 Usefulness of Serum Soluble Interleukin-2 Receptor Levels for Differentiating between PCNSL and SCNSL. **2023**, ○
- 368 Optic tract edema in craniopharyngioma as a predictor of BRAFV600E mutation presence. ○
- 367 Paths of Evolution of Progressive Anaplastic Meningiomas: A Clinical and Molecular Pathology Study. **2023**, 13, 206 ○
- 366 Diffusion Weighted Imaging in Neuro-Oncology: Diagnosis, Post-Treatment Changes, and Advanced Sequences—An Updated Review. **2023**, 15, 618 ○
- 365 Glioblastoma Combined With an Extracranial Bone Tumor in the Femur—A Case Report. **2023**, 39, 19-23 ○
- 364 Impact of peritumoral brain edema on pre- and postoperative clinical conditions and on long-term outcomes in patients with intracranial meningiomas. **2023**, 28, ○

- 363 Multimodal and Multiparametric Neuroimaging of Gliomas. **2023**, 3027-3054 ○
- 362 Raman Spectroscopy as a Tool to Study the Pathophysiology of Brain Diseases. **2023**, 24, 2384 ○
- 361 NMDA receptors expression activity in anaplastic astrocytomas. **2023**, 123, 97 ○
- 360 A novel cuproptosis-related LncRNA signature: Prognostic and therapeutic value for low grade glioma. 12, ○
- 359 Animal Models in Cancer Research. **2023**, 315-333 ○
- 358 Surgeon experience in glioblastoma surgery of the elderly: a multicenter, retrospective cohort study. ○
- 357 A Morphology Focused Diffusion Probabilistic Model for Synthesis of Histopathology Images. **2023**, 1 ○
- 356 Biomarkers and Corresponding Biosensors for Childhood Cancer Diagnostics. **2023**, 23, 1482 1
- 355 Natural killer cells in the treatment of glioblastoma: Diverse antitumor functions and potential clinical applications. **2023**, 335-367 ○
- 354 [18F]FET-PET in children and adolescents with central nervous system tumors: does it support difficult clinical decision-making?. ○
- 353 Immunodetection of Pyruvate Carboxylase Expression in Human Astrocytomas, Glioblastomas, Oligodendrogliomas, and Meningiomas. ○
- 352 The new oncogene transmembrane protein 60 is a potential therapeutic target in glioma. 13, ○
- 351 Free complement and complement containing extracellular vesicles as potential biomarkers for neuroinflammatory and neurodegenerative disorders. 13, 1
- 350 Brain Invasion and Trends in Molecular Research on Meningioma. **2023**, 11, 47 ○
- 349 Clinical, Imaging and Neurogenetic Features of Patients with Gliomatosis Cerebri Referred to a Tertiary Neuro-Oncology Centre. **2023**, 13, 222 ○
- 348 Role of Nanomedicine-Based Therapeutics in the Treatment of CNS Disorders. **2023**, 28, 1283 ○
- 347 Effectiveness of Antiseizure Medication Triple Therapy in Glioma Patients With Refractory Epilepsy: An Observational Cohort Study. 10.1212/WNL.000000000206852 ○
- 346 WHO grade and pathological markers of meningiomas: Clinical and prognostic role. **2023**, 243, 154340 ○

- 345 Comparison of multi-cycle and standard-cycle temozolomide chemotherapies in patients with glioblastoma undergoing surgery and successive radiotherapy. **2023**, 32, 101736 1
- 344 Detection of Isocitrate Dehydrogenase (IDH-1), Epidermal Growth Factor Receptor (EGFR), P53 and C-erbB2/HER2 Mutation in Glial Tumour. **2022**, 18, 111-119 0
- 343 An Automatic Brain Tumor Segmentation Using 3D Residual U-Net. **2022**, 0
- 342 Combination of Caffeic Acid Phenethyl Ester and Crocin Realign Potential Molecular Markers in U87-MG Glioma Cells. **2023**, 98, 100695 0
- 341 Meningioma microstructure assessed by diffusion MRI: An investigation of the source of mean diffusivity and fractional anisotropy by quantitative histology. **2023**, 37, 103365 0
- 340 Skull Base and Bone. **2023**, 167-211 0
- 339 LonP1 Drives Proneural Mesenchymal Transition in IDH1-R132H Diffuse Glioma. 0
- 338 Multi-classification of Brain Tumor MRI Images Using Deep CNN Features and ML Classifiers. **2023**, 139-151 0
- 337 A survival nomogram model constructed with common clinical characteristics to assist clinical decisions for diffuse low-grade gliomas: A population analysis based on SEER database. 13, 0
- 336 Radiomic features from dynamic susceptibility contrast perfusion-weighted imaging improve the three-class prediction of molecular subtypes in patients with adult diffuse gliomas. 0
- 335 Imaging and pathological diagnosis of primary intracranial malignant melanoma: A case report and literature review. **2023**, 102, e32767 0
- 334 Roles of STAT3 in the pathogenesis and treatment of glioblastoma. 11, 0
- 333 Identification and validation of a risk model and molecular subtypes based on tryptophan metabolism-related genes to predict the clinical prognosis and tumor immune microenvironment in lower-grade glioma. 17, 0
- 332 Cellular and molecular features related to exceptional therapy response and extreme long-term survival in glioblastoma. 0
- 331 Metabolomic profiles of human glioma inform patient survival. 0
- 330 A survey of deep learning for MRI brain tumor segmentation methods: Trends, challenges, and future directions. **2023**, 13, 181-201 0
- 329 An Integrated Monte Carlo Model for Heterogeneous Glioblastoma Treated with Boron Neutron Capture Therapy. **2023**, 15, 1550 0
- 328 MRI -based deep learning techniques for the prediction of isocitrate dehydrogenase and 1p/19q status in grade 2-4 adult gliomas. 0

- 327 Epigenetics and immune cells in medulloblastoma. 14,
- 326 Epithelial-mesenchymal transition is the main way in which glioma-associated microglia/macrophages promote glioma progression. 14,
- 325 TERT Immunohistochemistry as a Surrogate Marker for TERT Promoter Mutations in Infiltrating Gliomas. Publish Ahead of Print,
- 324 The Glioma-IRE project [Molecular profiling in patients with glioma: steps toward an individualized diagnostic and therapeutic approach. **2023**, 21,
- 323 Predictive role of magnetic resonance imaging in the distinction of isocitrate dehydrogenase (IDH) mutant grade 4 astrocytomas versus glioblastomas. 028418512311652
- 322 Can a bulky glycocalyx promote catch bonding in early integrin adhesion? Perhaps a bit.
- 321 A 53-year-old female with suprasellar mass.
- 320 A novel signature of cuproptosis-related lncRNAs predicts prognosis in glioma: Evidence from bioinformatic analysis and experiments. 14,
- 319 Impact of age and gender on glioblastoma onset, progression, and management. **2023**, 211, 111801
- 318 Prognostic evaluation of patients with glioblastoma using a new score prediction model. **2023**,
- 317 The Chromatin Remodeler ATRX: Role and Mechanism in Biology and Cancer. **2023**, 15, 2228
- 316 Macrophage cell membrane infused biomimetic liposomes for glioblastoma targeted therapy. **2023**, 49, 102663
- 315 Monocyte depletion enhances neutrophil influx and proneural to mesenchymal transition in glioblastoma. **2023**, 14,
- 314 Surgical strategies for intracranial meningioma in the molecular era.
- 313 Same but different. Incidental and symptomatic lower grade gliomas show differences in molecular features and survival.
- 312 PSMA Expression Correlates with Improved Overall Survival and VEGF Expression in Glioblastoma. **2023**, 11, 1148
- 311 Advanced Radio Frequency Applicators for Thermal Magnetic Resonance Theranostics of Brain Tumors. **2023**, 15, 2303
- 310 Intraoperative shear-wave elastography and superb microvascular imaging contribute to the glioma grading. **2023**, 110, 92-99

- 309 A review of deep learning-based multiple-lesion recognition from medical images: classification, detection and segmentation. **2023**, 157, 106726
- 308 CAR T-cells to treat brain tumors. **2023**, 196, 76-98
- 307 IKBIP might be a potential prognostic biomarker for glioblastoma multiforme. **2023**, 118, 110030
- 306 Primary suprasellar germinoma: A series of 15 cases. **2023**, 111, 71-77
- 305 The promise of metabolic imaging in diffuse midline glioma. **2023**, 39, 100896
- 304 Outcomes of Patients Treated in the UK Proton Overseas Programme: Central Nervous System Group. **2023**, 35, 283-291
- 303 GMetaNet: Multi-scale ghost convolutional neural network with auxiliary MetaFormer decoding path for brain tumor segmentation. **2023**, 83, 104694
- 302 The clinical progression of patients with glioblastoma. **2023**, 32, 101756
- 301 High-Grade Glioma Radiation Therapy and Reirradiation Treatment Planning Using Translocator Protein Positron Emission Tomography With 18F-GE-180. **2023**, 8, 101185
- 300 Prognosis prediction for glioblastoma multiforme patients using machine learning approaches: Development of the clinically applicable model. **2023**, 183, 109617
- 299 Is pre-radiotherapy metabolic heterogeneity of glioblastoma predictive of progression-free survival?. **2023**, 183, 109665
- 298 Predicting gene mutation status via artificial intelligence technologies based on multimodal integration (MMI) to advance precision oncology. **2023**, 91, 1-15
- 297 Diffuse intrinsic pontine glioma: Insights into oncogenesis and opportunities for targeted therapy. **2023**, 8, 73-79
- 296 Development, characterization and in vitro cytotoxicity of kaempferol-loaded nanostructured lipid carriers in glioblastoma multiforme cells. **2023**, 226, 113309
- 295 Expert knowledge guided manifold representation learning for magnetic resonance imaging-based glioma grading. **2023**, 85, 104876
- 294 WBM-DLNets: Wrapper-Based Metaheuristic Deep Learning Networks Feature Optimization for Enhancing Brain Tumor Detection. **2023**, 10, 475
- 293 Reasons for uncontrolled orbital tumors after Gamma Knife surgery.
- 292 From cells to organoids: The evolution of blood-brain barrier technology for modelling drug delivery in brain cancer. **2023**, 196, 114777

- 291 Therapeutic avenues for targeting treatment challenges of diffuse midline gliomas. **2023**, 40, 100899 ○
- 290 Insight into the transcription factors regulating Ischemic stroke and glioma in response to shared stimuli. **2023**, 92, 102-127 ○
- 289 Prediction of IDH mutation status of glioma based on terahertz spectral data. **2023**, 295, 122629 ○
- 288 Surgical approach to the treatment of pituitaryoma. Report of five cases and a literature review. **2023**, 19, 100186 ○
- 287 Possibilities of using navigational transcranial magnetic stimulation as an element of radiotherapy preparation of patients with brain tumors: a pilot study. **2023**, 13, 102-108 ○
- 286 Elevated ratio of C-type lectin-like receptor 2 level and platelet count (C2PAC) aids in the diagnosis of post-operative venous thromboembolism in IDH-wildtype gliomas. **2023**, 223, 36-43 ○
- 285 Breast cancer survival analysis agents for clinical decision support. **2023**, 231, 107373 ○
- 284 Osteopontin and Ki-67 expression in World Health Organization graded canine meningioma. **2023**, 201, 41-48 ○
- 283 Pseudo slicer on three dimensional brain tumor segmentation. **2022**, ○
- 282 Newly Diagnosed Adult Basal Ganglia Gliomas Treated With Laser Interstitial Thermal Therapy: A Comparative Cohort With Needle Biopsy. **2023**, 24, 383-390 ○
- 281 Frequency and burden of potentially treatable symptoms in glioma patients with stable disease. **2023**, 9, e13278 ○
- 280 Intra-operative brain tumor detection with deep learning-optimized hyperspectral imaging. **2023**, 1 ○
- 279 Brain Tumor Detection and Localization: An Inception V3 - Based Classification Followed By RESUNET-Based Segmentation Approach. **2023**, 8, 336-352 ○
- 278 Ca²⁺-Dependent Effects of the Selenium-Sorafenib Nanocomplex on Glioblastoma Cells and Astrocytes of the Cerebral Cortex: Anticancer Agent and Cytoprotector. **2023**, 24, 2411 ○
- 277 Provocative non-canonical roles of p53 and AKT signaling: A role for Thymosin β 4 in medulloblastoma. **2023**, 116, 109785 ○
- 276 Developing H3K27M mutant selective radiosensitization strategies in diffuse intrinsic pontine glioma. **2023**, 37, 100881 ○
- 275 Editorial: Molecular biology of biomarkers in diagnosis and treatment of glioblastoma multiforme. **2023**, 13, ○
- 274 Multiple Brain Tumor Classification with Dense CNN Architecture Using Brain MRI Images. **2023**, 13, 349 ○

- 273 Postoperative peritumoral edema can predict the prognosis in intracranial meningioma with preoperative peritumoral edema. ○
- 272 Antiepileptic drugs for treating seizures in people with brain tumours. **2023**, 2023, ○
- 271 Synthesis, Characterization, Molecular Docking and in vitro Anticancer Screening of Some Novel Thiophene Derivatives. **2023**, 8, ○
- 270 Effective data augmentation for brain tumor segmentation. ○
- 269 Green sol-gel synthesis of hydroxyapatite nanoparticles using lemon extract as capping agent and investigation of its anticancer activity against human cancer cell lines (T98, and SHSY5). **2023**, 16, 104646 ○
- 268 Patterns of Extranural Metastases in Children With Ependymoma. **2023**, 45, e272-e278 ○
- 267 Improving Noninvasive Classification of Molecular Subtypes of Adult Gliomas With Diffusion-Weighted MR Imaging: An Externally Validated Machine Learning Algorithm. ○
- 266 ONC201 for Glioma Treatment: Adding an Important Weapon to Our Arsenal. **2023**, 4, 28-33 ○
- 265 T1-Weighted Contrast Enhancement, Apparent Diffusion Coefficient, and Cerebral-Blood-Volume Changes after Glioblastoma Resection: MRI within 48 Hours vs. beyond 48 Hours. **2023**, 9, 342-351 ○
- 264 Survival in a consecutive series of 467 glioblastoma patients: Association with prognostic factors and treatment at recurrence at two independent institutions. **2023**, 18, e0281166 ○
- 263 MUC17 mutations are associated with poor prognosis in both adult low-grade glioma and glioblastoma patients. ○
- 262 Hypoglycemia From Metastatic Meningeal Solitary Fibrous Tumor Occurring Over Two Decades After Initial Diagnosis. **2022**, 1, ○
- 261 The relationship between connexin-43 expression and Ki67 in non-gliial central nervous system tumors. **2023**, 38, 46-52 ○
- 260 Hormone Receptor Expression in Meningiomas: A Systematic Review. **2023**, 15, 980 ○
- 259 MRI-Based Radiomics Combined with Deep Learning for Distinguishing IDH-Mutant WHO Grade 4 Astrocytomas from IDH-Wild-Type Glioblastomas. **2023**, 15, 951 ○
- 258 Valor pronóstico de la perfusión cerebral por RM en el estudio inicial de los gliomas de alto grado. **2023**, ○
- 257 Three-Dimensional Amide Proton Transfer-Weighted Imaging for Differentiating between Glioblastoma, IDH-Wildtype and Primary Central Nervous System Lymphoma. **2023**, 15, 952 ○
- 256 Sex-specific radiomic features of L-[S-methyl-11C] methionine PET in patients with newly-diagnosed gliomas in relation to IDH1 predictability. 13, ○

- 255 Code-free machine learning for classification of central nervous system histopathology images. **2023**, 82, 221-230 ○
- 254 Non-coding RNAs as Genetic Biomarkers for the Diagnosis, Prognosis, Radiosensitivity, and Histopathologic Grade of Meningioma. **2023**, ○
- 253 Longitudinal DNA methylation analysis of adult-type IDH-mutant gliomas. **2023**, 11, ○
- 252 Clinical case of primary multiple hemangioendothelioma in a child with CNS lesions. **2023**, 9, 88-95 ○
- 251 The emerging applications and advancements of Raman spectroscopy in pediatric cancers. 13, ○
- 250 Continuous Real-Time Neuropsychological Testing during Resection Phase in Left and Right Prefrontal Brain Tumors. **2023**, 30, 2007-2020 ○
- 249 Entering a new era of molecular classification of brain tumors: An update of 2021 World Health Organization classification in adult gliomas. **2023**, 56, 43-46 ○
- 248 Characterization of an IDH1 R132H Rabbit Monoclonal Antibody, MRQ-67, and Its Applications in the Identification of Diffuse Gliomas. **2023**, 12, 14 ○
- 247 Identification and validation of neurotrophic factor-related gene signatures in glioblastoma and Parkinson disease. 14, ○
- 246 Advancements and Technical Considerations for Extracellular Vesicle Isolation and Biomarker Identification in Glioblastoma. **2023**, Publish Ahead of Print, ○
- 245 Cytohesin-4 Upregulation in Glioma-Associated M2 Macrophages Is Correlated with Pyroptosis and Poor Prognosis. **2023**, 73, 143-158 ○
- 244 Tumor volume and calcifications as indicators for preoperative differentiation of grade II/III diffuse gliomas. **2023**, 161, 555-562 ○
- 243 A critical analysis of neuro-oncology clinical trials. ○
- 242 Multi-Parametric Radiomic Model to Predict 1p/19q Co-Deletion in Patients with IDH-1 Mutant Glioma: Added Value to the T2-FLAIR Mismatch Sign. **2023**, 15, 1037 ○
- 241 Case report: Intracranial lesions of cat-scratch disease mimicking an atypical meningioma. 14, ○
- 240 The impact of brain lesions on health-related quality of life in patients with WHO CNS grade 3 or 4 glioma: a lesion-function and resting-state fMRI analysis. **2023**, 161, 643-654 ○
- 239 Prognostic Prediction Model for Glioblastoma: A Ferroptosis-Related Gene Prediction Model and Independent External Validation. **2023**, 12, 1341 ○
- 238 A rare, giant, anaplastic oligodendroglioma. **2023**, 18, 1544-1548 ○

237	The molecular pathogenesis of craniopharyngiomas. 2023 ,	0
236	Medulloblastoma: From TP53 Mutations to Molecular Classification and Liquid Biopsy. 2023 , 12, 267	1
235	Astrocytoma (CNS WHO grade 4), IDH -mutant with co-occurrence of BRAF p. V600E mutation, and homozygous loss of CDKN2A .	0
234	Recent progress and novel approaches to treating atypical teratoid rhabdoid tumor. 2023 , 37, 100880	0
233	Outcomes following management of relapsed pediatric posterior fossa ependymoma in the molecular era. 2023 , 161, 573-582	0
232	Construction of a pyroptosis-related lncRNAs signature for predicting prognosis and immunotherapy response in glioma. 2023 , 102, e32793	0
231	Liquid biopsy-based identification of prognostic and immunotherapeutically relevant gene signatures in lower grade glioma. 2023 , 10,	0
230	Rational design of poly-L-glutamic acid-palboiclib conjugates for pediatric glioma treatment. 2023 , 355, 385-394	0
229	microRNAs (miRNAs) in Glioblastoma Multiforme (GBM)Recent Literature Review. 2023 , 24, 3521	0
228	Factors affecting cognitive functions of patients with high-grade gliomas: a systematic review.	0
227	An initial study on the predictive value using multiple MRI characteristics for Ki-67 labeling index in glioma. 2023 , 21,	0
226	Pyroptosis-Related Genes as Markers for Identifying Prognosis and Microenvironment in Low-Grade Glioma. 2023 , 2023, 1-20	0
225	Novel Cuproptosis-Related Gene Signature for Precise Identification of High-Risk Populations in Low-Grade Gliomas. 2023 , 2023, 1-12	0
224	Epithelial membrane antigen-reactive feline chordoid meningioma in a European wildcat (<i>Felis silvestris</i>). 2023 , 201, 114-117	0
223	Development and validation of a pyroptosis-related genes signature for risk stratification in gliomas. 14,	0
222	Stereotactic biopsy for multiple intra-axial brain lesions: impact on consequent treatment Regimen. 2023 , 38,	0
221	Lipid metabolism-related gene signature predicts prognosis and depicts tumor microenvironment immune landscape in gliomas. 14,	0
220	Individualized Multimodal Immunotherapy for Adults with IDH1 Wild-Type GBM: A Single Institute Experience. 2023 , 15, 1194	0

- 219 Emerging Therapeutic Strategies for Diffuse Intrinsic Pontine Glioma: A Systematic Review. **2023**, 11, 559 ○
- 218 Lessons learned from evolving frameworks in adult glioblastoma. **2023**, 131-140 ○
- 217 Hypoxic glioma cell-secreted exosomal circ101491 promotes the progression of glioma by regulating miR-125b-5p/EDN1. **2023**, 195, 55-65 ○
- 216 Central neurocytomas: research trends, most cited papers, and scientometrics analysis to date. **2023**, 46, ○
- 215 Long non-coding RNA in glioma: novel genetic players in temozolomide resistance. **2023**, 27, 19-28 ○
- 214 Understanding the Epitranscriptome for Avant-Garde Brain Tumour Diagnostics. **2023**, 15, 1232 ○
- 213 Nanoparticle-based drug delivery across the blood-brain barrier for treating malignant brain glioma. **2023**, 10, 100128 ○
- 212 Urinary 8-hydroxy-2'-deoxyguanosine levels are elevated in patients with IDH1-wildtype glioblastoma and are associated with tumor recurrence in gliomas. **2023**, 124, 103463 ○
- 211 Antitumor Potential of Antiepileptic Drugs in Human Glioblastoma: Pharmacological Targets and Clinical Benefits. **2023**, 11, 582 ○
- 210 Practice of the new supervised machine learning predictive analytics for glioma patient survival after tumor resection: Experiences in a high-volume Chinese center. 9, ○
- 209 Acetazolamide versus placebo for cerebral oedema requiring dexamethasone in recurrent and/or progressive high-grade glioma: phase II randomised placebo-controlled double-blind study. spcare-2022-004119 ○
- 208 Frailty as a predictor of neurosurgical outcomes in brain tumor patients: A systematic review and meta-analysis. 14, ○
- 207 Unusual manifestation of cerebellopontine angle medulloblastoma with tinnitus and sensorineural hearing loss. **2023**, 13, 22-31 ○
- 206 DNA Methylation and Histone Modification in Low-Grade Gliomas: Current Understanding and Potential Clinical Targets. **2023**, 15, 1342 ○
- 205 Flavin fluorescence lifetime and autofluorescence optical redox ratio for improved visualization and classification of brain tumors. 13, ○
- 204 Unchanged perfusion in normal-appearing white and grey matter of glioma patients nine months after proton beam irradiation. **2023**, 62, 141-149 ○
- 203 Le m dulloblastome   les derni res avanc es majeures. **2023**, 110, 412-423 ○
- 202 Improvement grading brain glioma using T2 relaxation times and susceptibility-weighted images in MRI. **2023**, 37, 101201 ○

- 201 National Brain Tumour Registry of China (NBTRC) statistical report of primary brain tumours diagnosed in China in years 2019-2020. **2023**, 100715 ○
- 200 Updating TCGA glioma classification through integration of molecular profiling data following the 2016 and 2021 WHO guidelines. ○
- 199 Assessing the added value of apparent diffusion coefficient, cerebral blood volume, and radiomic magnetic resonance features for differentiation of pseudoprogression versus true tumor progression in patients with glioblastoma. **2023**, 5, ○
- 198 A Novel Molecular Classification Method for Glioblastoma Based on Tumor Cell Differentiation Trajectories. **2023**, 2023, 1-27 ○
- 197 Delineation of recurrent glioblastoma by whole brain spectroscopic magnetic resonance imaging. **2023**, 18, ○
- 196 Type IV collagen-derived angiogenesis inhibitor: canstatin low expressing in brain-invasive meningiomas using liquid chromatography-mass spectrometry (LC-MS/MS). **2023**, 161, 415-423 ○
- 195 Glioblastomas: Hijacking Metabolism to Build a Flexible Shield for Therapy Resistance. ○
- 194 Salvage boron neutron capture therapy for pediatric patients with recurrent diffuse midline glioma. ○
- 193 Integrative analysis of a Novel six methylated pseudogene Prognostic signature in patients with glioma. ○
- 192 Brain tumor detection with mRMR-based multimodal fusion of deep learning from MR images using Grad-CAM. ○
- 191 Spatial transcriptomics reveals niche-specific enrichment and vulnerabilities of radial glial stem-like cells in malignant gliomas. **2023**, 14, ○
- 190 Vorasidenib and ivosidenib in IDH1-mutant low-grade glioma: a randomized, perioperative phase 1 trial. **2023**, 29, 615-622 ○
- 189 Artificial Intelligence in Brain Tumor Imaging: A Step toward Personalized Medicine. **2023**, 30, 2673-2701 ○
- 188 Update for astrocytomas: medical and surgical management considerations. 1-26 ○
- 187 Cystic lesions in giant intraventricular meningioma: Two case reports. **2023**, 102, e32494 ○
- 186 Primary Pediatric Brain Tumors of the Posterior Fossa: Part I. **2023**, 389-420 ○
- 185 The role of reoperation in paediatric cerebellar pilocytic astrocytoma. ○
- 184 EPITHELIOD GLIOBLASTOMA OF BRAIN: A RARE CASE REPORT WITH REVIEW OF LITERATURE. **2023**, 55-56 ○

- 183 Value of Cellular Components and Focal Dedifferentiation to Predict the Risk of Metastasis in a Benign-Appearing Extra-Meningeal Solitary Fibrous Tumor: An Original Series from a Tertiary Sarcoma Center. **2023**, 15, 1441 ○
- 182 Isolation of Cells from Glioblastoma Multiforme Grade 4 Tumors for Infection with Zika Virus prME and ME Pseudotyped HIV-1. **2023**, 24, 4467 ○
- 181 Repurposing chlorpromazine as add-on in the adjuvant phase of first-line glioblastoma therapeutic protocol in patients carrying hypo-/un-methylatedMGMTgene promoter: RACTAC, a Phase II multicenter single-arm clinical trial. ○
- 180 PDGF gene expression and p53 alterations contribute to the biology of diffuse astrocytic gliomas. **2023**, 8, ○
- 179 Cooperativity between H3.3K27M and PDGFRA poses multiple therapeutic vulnerabilities in human iPSC-derived diffuse midline glioma avatars. ○
- 178 Liquid biopsy and glioblastoma. **2023**, 4, 28-41 ○
- 177 A variational algorithm to detect the clonal copy number substructure of tumors from scRNA-seq data. **2023**, 14, ○
- 176 SP2G: an imaging and analysis pipeline revealing the inter and intra-patient migratory diversity of glioblastoma. ○
- 175 Revisiting prognostic factors in glioma with leptomeningeal metastases: a comprehensive analysis of clinical and molecular factors and treatment modalities. **2023**, 162, 59-68 ○
- 174 Radiogenomic classification for MGMT promoter methylation status using multi-omics fused feature space for least invasive diagnosis through mpMRI scans. **2023**, 13, ○
- 173 An enhanced deep learning method for multi-class brain tumor classification using deep transfer learning. ○
- 172 Quantitative analysis of magnetic resonance images for characterization of blood-brain barrier dysfunction in dogs with brain tumors. **2023**, 37, 606-617 ○
- 171 PET tracers in glioblastoma: Toward neurotheranostics as an individualized medicine approach. 3, ○
- 170 Regulatory networks driving expression of genes critical for glioblastoma are controlled by the transcription factor c-Jun and the pre-existing epigenetic modifications. **2023**, 15, ○
- 169 A neurodevelopmental epigenetic programme mediated by SMARCD3DAB1Beelin signalling is hijacked to promote medulloblastoma metastasis. **2023**, 25, 493-507 ○
- 168 A novel multi-class brain tumor classification method based on unsupervised PCANet features. ○
- 167 Single-cell RNA sequencing reveals tumor heterogeneity, microenvironment, and drug-resistance mechanisms of recurrent glioblastoma. ○
- 166 Analysis of Prognostic Factors and Surgical Management of Elderly Patients with Low-Grade Gliomas. **2023**, ○

- 165 Bioenergetic Profiling in Glioblastoma Multiforme Patients with Different Clinical Outcomes. **2023**, 13, 362 ○
- 164 Systems Medicine for Precise Targeting of Glioblastoma. ○
- 163 Manifestation of the malignant progression of glioma following initial intracerebral hemorrhage: A case report. 11, 1576-1585 ○
- 162 Amide Proton Transfer/Chemical Exchange Saturation Transfer Imaging of Intracranial Brain Tumors and Tumor-Like Lesions: Our Experience and a Review. **2023**, 13, 914 ○
- 161 Identification of a copper metabolism-related gene signature for predicting prognosis and immune response in glioma. ○
- 160 Research progress in molecular pathology markers in medulloblastoma. **2023**, 4, 139-156 ○
- 159 Brain tumor magnetic resonance images enhanced by hybrid method based on deep learning paradigm. ○
- 158 Proposed Novel Classification of Circumscribed Lower-Grade Gliomas (cLGG) vs. Infiltrating Lower-Grade Gliomas (iLGG): Correlations of radiological features and clinical outcomes. ○
- 157 Infantile ZFTA Fusion Positive Tumor of the Posterior Fossa: Molecular Tumor Board. **2023**, ○
- 156 A rare case of H3K27-altered diffuse midline glioma with multiple osseous and spinal metastases at the time of diagnosis. **2023**, 23, ○
- 155 Advanced MR Techniques for Preoperative Glioma Characterization: Part 1. ○
- 154 Exploring Novel Therapeutic Opportunities for Glioblastoma Using Patient-Derived Cell Cultures. **2023**, 15, 1562 ○
- 153 Construction and Verification of an RNA-Binding Protein-Associated Prognostic Model for Gliomas. **2023**, 43, 156-165 ○
- 152 Cerebellar Mutism Syndrome After Posterior Fossa Tumor Surgery in Children: A Retrospective Single-Center Study. **2023**, ○
- 151 Progress in phase III clinical trials of molecular targeted therapy and immunotherapy for glioblastoma. ○
- 150 Antisense lncRNA CHOMR is linked to glioma patient survival. 10, ○
- 149 ATRX, a guardian of chromatin. **2023**, ○
- 148 Nonconvulsive status epilepticus characteristics in glioma patients: a retrospective study. **2023**, 14, ○

- 147 Histone H3-wild type diffuse midline gliomas with H3K27me3 loss are a distinct entity with exclusive EGFR or ACVR1 mutation and differential methylation of homeobox genes. **2023**, 13, ○
- 146 Advances and trends in meningioma research over the last decade: A scientometric and visual analysis. 13, ○
- 145 MicroRNAs in the Diagnosis of Malignancy of Supratentorial Brain Gliomas and Prognosis of Disease Progression. **2023**, ○
- 144 An Effective and Novel Approach for Brain Tumor Classification Using AlexNet CNN Feature Extractor and Multiple Eminent Machine Learning Classifiers in MRIs. **2023**, 2023, 1-19 ○
- 143 Transcallosal and endoscopic hybrid approach to a rare entity of pediatric intraventricular tumors: Dibriform neuroepithelial tumor: a case report and literature review. ○
- 142 Prognostic value of microRNA-125a expression status in molecular groups of pediatric medulloblastoma. ○
- 141 Clinical, histopathological and molecular risk factors for recurrence of pilocytic astrocytomas: brainstem/spinal location, nestin expression and gain of 7q and 19 are associated with early tumor recurrence. **2023**, 40, 109-123 ○
- 140 Cavernous Sinus. **2023**, 279-307 ○
- 139 Functional state and rehabilitation of patients after primary brain tumor surgery for malignant and non-malignant tumors: a prospective observational study. ○
- 138 The oncogenic circular RNA circ_63706 is a potential therapeutic target in sonic hedgehog-subtype childhood medulloblastomas. **2023**, 11, ○
- 137 Leveraging Base Pair Mammalian Constraint to Understand Genetic Variation and Human Disease. ○
- 136 The role of sphingosine 1-phosphate metabolism in brain health and disease. **2023**, 244, 108381 ○
- 135 Functional and targeted proteomics characterization of a human primary endothelial cell model of the blood-brain barrier (BBB) for drug permeability studies. **2023**, 465, 116456 ○
- 134 Exploring Novel Innovation Strategies to Close a Technology Gap in Neurosurgery: The HORA○ Crowdsourcing Campaign (Preprint). ○
- 133 CEBPB upregulates P4HA2 to promote the malignant biological behavior in IDH1 wildtype glioma. **2023**, 37, ○
- 132 Identification of CD114 Membrane Receptors as a Molecular Target in Medulloblastomas. **2023**, 24, 5331 ○
- 131 SESN2 Could Be a Potential Marker for Diagnosis and Prognosis in Glioma. **2023**, 14, 701 ○
- 130 Refining the Intraoperative Identification of Suspected High-Grade Glioma Using a Surgical Fluorescence Biomarker: GALA BIDD Study Report. **2023**, 13, 514 ○

- 129 lncRNA TRHDE-AS1 correlated with genomic landscape and clinical outcome in glioma.
- 128 Aminobenzofuran-containing analogues of proximicins exhibit higher antiproliferative activity against human UG-87 glioblastoma cells compared to temozolomide. **2023**, 13, 8420-8426
- 127 Nucleolin promotes angiogenesis and endothelial metabolism along the onco-fetal axis in the human brain vasculature.
- 126 Clinical updates on gliomas and implications of the 5th edition of the WHO classification of central nervous system tumors. 13,
- 125 Visualizing genomic characteristics across an RNA-Seq based reference landscape of normal and neoplastic brain. **2023**, 13,
- 124 The Current State of Adult Glial Tumor Patients' Care in Kazakhstan: Challenges in Diagnosis and Patterns in Survival Outcomes. **2023**, 11, 886
- 123 BOLD fMRI and DTI fiber tracking for preoperative mapping of eloquent cerebral regions in brain tumor patients: impact on surgical approach and outcome.
- 122 Target-Based Anticancer Indole Derivatives for the Development of Anti-Glioblastoma Agents. **2023**, 28, 2587
- 121 A Handheld Visible Resonance Raman Analyzer Used in Intraoperative Detection of Human Glioma. **2023**, 15, 1752
- 120 Investigate the possibility of using phosphorescence in clinical oncology as an early prognostic test in detecting brain carcinogenesis.
- 119 MRI features of pediatric atypical teratoid rhabdoid tumors and medulloblastomas of the posterior fossa.
- 118 Transport of nanocarriers to brain for treatment of glioblastoma multiforme: Routes and challenges. **2023**, 1, 100005
- 117 Highlighted Advances in Therapies for Difficult-To-Treat Brain Tumours Such as Glioblastoma. **2023**, 15, 928
- 116 DNA methylation provides diagnostic value for meningioma recurrence in clinical practice.
- 115 Dimethylation of histone H3 lysine 36 (H3K36me2) as a potential biomarker for glioma diagnosis, grading, and prognosis. **2023**, 82, 412-418
- 114 Long-term survival in patients with IDH-wildtype glioblastoma: clinical and molecular characteristics. **2023**, 165, 1075-1085
- 113 Diagnostic accuracy of retinal optical coherence tomography in children with a newly diagnosed brain tumour.
- 112 Symptom networks in glioma patients: understanding the multidimensionality of symptoms and quality of life.

- 111 H3 G34-mutant high-grade gliomas: integrated clinical, imaging and pathological characterisation of a single-centre case series. ○
- 110 Immune microenvironment of medulloblastoma: The association between its molecular subgroups and potential targeted immunotherapeutic receptors. 14, 117-130 ○
- 109 Modeling thermal therapy of poroelastic brain tumor using magnetic nanoparticles. **2023**, 73-94 ○
- 108 Efficacy of radiotherapy and stereotactic radiosurgery as adjuvant or salvage treatment in atypical and anaplastic (WHO grade II and III) meningiomas: a systematic review and meta-analysis. **2023**, 46, ○
- 107 Can a bulky glycocalyx promote catch bonding in early integrin adhesion? Perhaps a bit. ○
- 106 Deep Learning-Based Radiomics for Prognostic Stratification of Low-Grade Gliomas Using a Multiple-Gene Signature. **2023**, 13, 3873 ○
- 105 Targeted gene expression profiling predicts meningioma outcomes and radiotherapy responses. ○
- 104 Correlations between intravoxel incoherent motion-derived fast diffusion and perfusion fraction parameters and VEGF- and MIB-1-positive rates in brain gliomas: an intraoperative MR-navigated, biopsy-based histopathologic study. ○
- 103 Annotation-free glioma grading from pathological images using ensemble deep learning. **2023**, 9, e14654 ○
- 102 The combination of radiomics features and VASARI standard to predict glioma grade. 13, ○
- 101 Dynamic Regulation Genes at Microtubule Plus Ends: A Novel Class of Glioma Biomarkers. **2023**, 12, 488 ○
- 100 Anti-tumor effects of miR -34a by regulating immune cells in the tumor microenvironment. ○
- 99 Pseudoprogression and pseudoresponse according to MRI data after radiosurgical treatment of glioblastoma using metronidazole. **2022**, 13, 7-18 ○
- 98 ChatGPT in glioma patient adjuvant therapy decision making: ready to assume the role of a doctor in the tumour board?. ○
- 97 Awake craniotomy for high-grade gliomas: a prospective cohort study in a UK tertiary- centre. ○
- 96 Influence of MMR, MGMT Promotor Methylation and Protein Expression on Overall and Progression-Free Survival in Primary Glioblastoma Patients Treated with Temozolomide. **2023**, 24, 6184 ○
- 95 Deep Neural Ideal Networks for Brain Tumour Image Segmentation. **2023**, 301-313 ○
- 94 Blockchain-Based Deep CNN for Brain Tumor Prediction Using MRI Scans. **2023**, 13, 1229 ○

- 93 Mutated Isocitrate Dehydrogenase (mIDH) as Target for PET Imaging in Gliomas. **2023**, 28, 2890 ○
- 92 New perspectives: glioma in adult patients. 030089162311597 ○
- 91 Radiosurgery outcomes in infratentorial juvenile pilocytic astrocytomas. **2023**, 162, 157-165 ○
- 90 Mortality trends in primary malignant brain and central nervous system tumors vary by histopathology, age, race, and sex. **2023**, 162, 167-177 ○
- 89 The Role of Radiotherapy in the Treatment of Higher-Grade Meningioma. **2023**, ○
- 88 Exploring Monocytes-Macrophages in Immune Microenvironment of Glioblastoma for the Design of Novel Therapeutic Strategies. **2023**, 13, 542 ○
- 87 Synergistic structural and functional alterations in the medial prefrontal cortex of patients with high-grade gliomas infiltrating the thalamus and the basal ganglia. 17, ○
- 86 Molecular subtypes based on centrosome-related genes can predict prognosis and therapeutic responsiveness in patients with low-grade gliomas. 13, ○
- 85 Glioma Cells Expressing High Levels of ALDH5A1 Exhibit Enhanced Migration Transcriptional Signature in Patient Tumors. ○
- 84 Recapitulating the Key Advances in the Diagnosis and Prognosis of High-Grade Gliomas: Second Half of 2021 Update. **2023**, 24, 6375 ○
- 83 Clinical characteristics and radiological features of glioblastoma, IDH-wildtype, grade 4 with histologically lower-grade gliomas. **2023**, 40, 48-55 ○
- 82 Association of an eight-gene signature prognosis model with tumor immunity in medulloblastoma. ○
- 81 Multimodal deep learning to predict prognosis in adult and pediatric brain tumors. **2023**, 3, ○
- 80 Brain tumor detection & segmentation using deep learning. **2022**, 10, 27 ○
- 79 Neural Stem Cells as Potential Glioblastoma Cells of Origin. **2023**, 13, 905 ○
- 78 Non-operable glioblastoma: Proposition of patient-specific forecasting by image-informed poromechanical model. **2023**, 4, 100067 ○
- 77 MAPK4 predicts poor prognosis and facilitates the proliferation and migration of glioma through the AKT / mTOR pathway. ○
- 76 Lutathera[®] Orphans: State of the Art and Future Application of Radioligand Therapy with ¹⁷⁷Lu-DOTATATE. **2023**, 15, 1110 ○

- 75 Glioblastoma imitating a cavernoma radiologically: A unique image report. 14, 112 ○
- 74 Molecular Imaging in Neurology. **2023**, 375-423 ○
- 73 The Performance of Different Machine Learning Algorithm and Regression Models in Predicting High-Grade Intracranial Meningioma. **2023**, 13, 594 ○
- 72 Predicting regrowth of low-grade gliomas after radiotherapy. **2023**, 19, e1011002 ○
- 71 Posterior fossa tumors in children: An update and new concepts. 14, 114 ○
- 70 Clinical Characteristics and Treatment Outcomes of Long-Level Intramedullary Spinal Cord Tumors: A Consecutive Series of 43 Cases. **2023**, 20, 231-239 ○
- 69 Leptomeningeal dissemination in pediatric brain tumors. **2023**, 39, 100898 ○
- 68 MRI techniques using image processing Brain Tumor Detection. **2023**, ○
- 67 Considerations for modelling diffuse high-grade gliomas and developing clinically relevant therapies. ○
- 66 Data augmentation method based on the Gaussian kernel density for glioma diagnosis with Raman spectroscopy. **2023**, 15, 1861-1869 ○
- 65 Concurrent IDH1 and IDH2 mutations in glioblastoma: A case report. 13, ○
- 64 Automated Classification of Brain Tumors from Magnetic Resonance Imaging Using Deep Learning. **2023**, 13, 602 ○
- 63 Functional characterization of acid-sensing ion channels in the cerebellum-originating medulloblastoma cell line DAOY and in cerebellar granule neurons “. ○
- 62 A2AR as a Prognostic Marker and a Potential Immunotherapy Target in Human Glioma. **2023**, 24, 6688 ○
- 61 BraDect: A Novel Brain Tumor Image Classification Algorithm. **2022**, ○
- 60 Emerging hallmark of gliomas microenvironment in evading immunity: a basic concept. **2023**, 59, ○
- 59 Integrative analysis of a novel super-enhancer-associated lncRNA prognostic signature and identifying LINC00945 in aggravating glioma progression. **2023**, 17, ○
- 58 Enhancing Brain Tumor Detection Classification by Computational Intelligence. **2023**, ○

- 57 Radiosensitisation by olaparib through focused ultrasound delivery in a diffuse midline glioma model. **2023**, 357, 287-298 ○
- 56 Discrimination of the chemotherapy resistance status of human leukemia and glioblastoma cell lines by MALDI-TOF-MS profiling. **2023**, 13, ○
- 55 Challenges in, and recommendations for, hyperspectral imaging in ex vivo malignant glioma biopsy measurements. **2023**, 13, ○
- 54 Thirty years of progress in the management of low-grade gliomas. **2023**, ○
- 53 GRN is a prognostic biomarker and correlated with immune infiltration in glioma: A study based on TCGA data. 13, ○
- 52 Dictionary learning LASSO for feature selection with application to hepatocellular carcinoma grading using contrast enhanced magnetic resonance imaging. 13, ○
- 51 Treating oligodendroglioma [An analysis of a homogeneous 1p/19q-codeleted and isocitrate dehydrogenase-mutant patient cohort. **2023**, 100626 ○
- 50 Multimodal data fusion for cancer biomarker discovery with deep learning. ○
- 49 DeepDixon synthetic CT for [18F]FET PET/MRI attenuation correction of post-surgery glioma patients with metal implants. 17, ○
- 48 Pediatric Brain Tumors: Role of Imaging. **2022**, 1-25 ○
- 47 Delineation of Grade II and III Gliomas Investigated by 7T MRI: An Inter-Observer Pilot Study. **2023**, 13, 1365 ○
- 46 Ancient ubiquitous protein 1 (AUP1) is a prognostic biomarker connected with TP53 mutation and the inflamed microenvironments in glioma. **2023**, 23, ○
- 45 Early Detection of ColoRectal Cancer Using Patch-Based Hybrid Model and Transfer Learning. **2023**, 87-97 ○
- 44 A pilot study: Metabolic profiling of plasma and saliva samples from newly diagnosed glioblastoma patients. ○
- 43 Intracranial Germinomas: Diagnosis, Pathogenesis, Clinical Presentation, and Management. ○
- 42 High VEGFA Expression Is Associated with Improved Progression-Free Survival after Bevacizumab Treatment in Recurrent Glioblastoma. **2023**, 15, 2196 ○
- 41 Effect of palliative care decisions making on hospital service use at end-of-life in patients with malignant brain tumors: a retrospective study. **2023**, 22, ○
- 40 Clustering of Pediatric Brain Tumors in Texas, 2000-2017. **2023**, 11, 351 ○

- 39 Bromodomain and Extraterminal Domain (BET) Protein Inhibition Hinders Glioblastoma Progression by Inducing Autophagy-Dependent Differentiation. **2023**, 24, 7017 ○
- 38 Preoperative prediction of sonic hedgehog and group 4 molecular subtypes of pediatric medulloblastoma based on radiomics of multiparametric MRI combined with clinical parameters. 17, ○
- 37 Potential Use of Thalidomide in Glioblastoma Treatment: An Updated Brief Overview. **2023**, 13, 543 ○
- 36 Clinically relevant glioblastoma patient-derived xenograft models to guide drug development and identify molecular signatures. 13, ○
- 35 Differences in intraoperative sampling during meningioma surgery regarding CNS invasion □ Results of a survey on behalf of the EANS skull base section. **2023**, 3, 101740 ○
- 34 Medical Management of Meningiomas. **2023**, ○
- 33 Regulative Roles of Metabolic Plasticity Caused by Mitochondrial Oxidative Phosphorylation and Glycolysis on the Initiation and Progression of Tumorigenesis. **2023**, 24, 7076 ○
- 32 Stalled oligodendrocyte differentiation in IDH-mutant gliomas. **2023**, 15, ○
- 31 Intelligent noninvasive meningioma grading with a fully automatic segmentation using interpretable multiparametric deep learning. ○
- 30 Flavopiridol suppresses cell proliferation and migration and induces apoptotic cell death by inhibiting oncogenic FOXM1 signaling in IDH-wild type and -mutant GBM cells. ○
- 29 BRAF-mediated brain tumors in adults and children: A review and the Australian and New Zealand experience. 13, ○
- 28 Review of meningioma diagnosis and management. **2023**, 38, ○
- 27 Role of Molecular Targeted Therapeutic Drugs in Treatment of Glioblastoma: A Review Article. **2023**, 10, 042-047 ○
- 26 Potassium Ion Channels in Glioma: From Basic Knowledge into Therapeutic Applications. **2023**, 13, 434 ○
- 25 LonP1 Drives Proneural Mesenchymal Transition in IDH1-R132H Diffuse Glioma. ○
- 24 Diffuse Isocitrate Dehydrogenase Mutant Gliomas With Histone H3 Alterations Are Distinguished by Unique Clinical Characteristics, Molecular Expression Profile, and Survival Prognosis. **2023**, Publish Ahead of Print, ○
- 23 The 2021 WHO Classification for Gliomas and Implications on Imaging Diagnosis: Part 2 □ Summary of Imaging Findings on Pediatric-Type Diffuse High-Grade Gliomas, Pediatric-Type Diffuse Low-Grade Gliomas, and Circumscribed Astrocytic Gliomas. ○
- 22 Association of Kinase-Insert-Domain-Containing Receptor Polymorphisms with Glioma Susceptibility in a Chinese Population: A Hospital-Based Case-Control Study. **2023**, 2023, 1-7 ○

- 21 Imaging the WHO 2021 Brain Tumor Classification: Fully Automated Analysis of Imaging Features of Newly Diagnosed Gliomas. **2023**, 15, 2355 ○
- 20 The 2021 WHO Classification for Gliomas and Implications on Imaging Diagnosis: Part 1 Key Points of the Fifth Edition and Summary of Imaging Findings on Adult-Type Diffuse Gliomas. ○
- 19 Predicting methylation class from diffusely infiltrating adult gliomas using multi-modality MRI data. ○
- 18 Afatinib in Pediatric Patients With Recurrent/Refractory ErbB-dysregulated Tumors: Results of a Phase I/Expansion Trial. **2023**, ○
- 17 Cell Cycle-Related FAM64A Could be Activated by TGF- β Signaling to Promote Glioma Progression. ○
- 16 Fractionated Stereotactic Re-Irradiation for recurrent glioblastoma: a systematic review and meta-analysis. **2023**, 107728 ○
- 15 Glioneuronal and Neuronal Tumors: Who? When? Where? An Update Based on the 2021 World Health Organization Classification. **2023**, 13, 1-14 ○
- 14 Low-coverage and cost-effective whole-genome sequencing assay for glioma risk stratification. ○
- 13 Intracerebral de novo arterio-venous malformations as a side effect of bevacizumab. 107815522311711 ○
- 12 Identifying G6PC3 as a potential key molecule in hypoxic glucose metabolism of glioblastoma derived from the depiction of 18F-fluoromisonidazole and 18F-fluorodeoxyglucose positron emission tomography. ○
- 11 Artificial Intelligence Applications in Glioma With 1p/19q Co-Deletion: A Systematic Review. ○
- 10 Comparative treatment results of children with atypical teratoid/rhabdoid tumor of the central nervous system in the younger age group. **2023**, 10, 11-24 ○
- 9 Necroptosis-related lncRNAs: establishment of a gene module and distinction between the cold and hot tumors in glioma. 13, ○
- 8 Mutation detection of urinary cell-free DNA via catch-and-release isolation on nanowires for liquid biopsy. **2023**, 115318 ○
- 7 Engineered extracellular vesicles (EVs): Promising diagnostic/therapeutic tools for pediatric high-grade glioma. **2023**, 163, 114630 ○
- 6 An overview of glioblastoma multiforme and temozolomide resistance: can LC-MS-based proteomics reveal the fundamental mechanism of temozolomide resistance?. 13, ○
- 5 Investigate the Possibility of Using Phosphorescence in Clinical Oncology as an Early Prognostic Test in Detecting Brain Carcinogenesis. ○
- 4 Computerized Classification Method for Molecular Subtypes in Glioma with Multi-Scale 3D-Attention Branch Networks Analyzing Multi-Sequence Brain MRI Images. **2023**, 143, 539-545 ○

- 3 Pediatric Spine, Spinal Cord, and Peripheral Nervous System Tumors. **2023**, 141-158 ○
- 2 Global trends, gaps, and future agenda in medulloblastoma research: a bibliometric analysis. ○
- 1 The clinical value of proneural, classical and mesenchymal protein signatures in WHO 2021 adult-type diffuse lower-grade gliomas. **2023**, 18, e0285732 ○